_MEMBER_AD Prioritization - 0.9-1.1%,_MEMBER_AD Prioritization - 4.5-5.5%,_MEMBER_AD Prioritization - 9.0-11.0%,_MEMBER_Data Prioritization - 0.9-1.1%,_MEMBER_Data Prioritization - 4.5-5.5%,_MEMBER_Data Prioritization - 9.0-11.0%,_MEMBER_M20337 - Micro - Data Prioritization,_MEMBER_M20337 - Micro - SCZ Prioritization,_MEMBER_M20337 - OPC - SCZ Prioritization,_MEMBER_M20337 - Oligo - AD Prioritization,_MEMBER_M20337 - Oligo - SCZ Prioritization,_MEMBER_M31969 - Micro - Data Prioritization,_MEMBER_M31969 - Micro - SCZ Prioritization,_MEMBER_M31969 - Oligo - AD Prioritization,_MEMBER_M31969 - Oligo - Data Prioritization,_MEMBER_M31969 - Oligo - SCZ Prioritization,_MEMBER_SCZ Prioritization - 0.9-1.1%,_MEMBER_SCZ Prioritization - 4.5-5.5%,_MEMBER_SCZ Prioritization - 9.0-11.0%,_LogP_AD Prioritization - 0.9-1.1%,_LogP_AD Prioritization - 4.5-5.5%,_LogP_AD Prioritization - 9.0-11.0%,_LogP_Data Prioritization - 0.9-1.1%,_LogP_Data Prioritization - 4.5-5.5%,_LogP_Data Prioritization - 9.0-11.0%,_LogP_M20337 - Micro - Data Prioritization,_LogP_M20337 - Micro - SCZ Prioritization,_LogP_M20337 - OPC - SCZ Prioritization,_LogP_M20337 - Oligo - AD Prioritization,_LogP_M20337 - Oligo - SCZ Prioritization,_LogP_M31969 - Micro - Data Prioritization,_LogP_M31969 - Micro - SCZ Prioritization,_LogP_M31969 - Oligo - AD Prioritization,_LogP_M31969 - Oligo - Data Prioritization,_LogP_M31969 - Oligo - SCZ Prioritization,_LogP_SCZ Prioritization - 0.9-1.1%,_LogP_SCZ Prioritization - 4.5-5.5%,_LogP_SCZ Prioritization - 9.0-11.0%,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,1,1,1,0,1,0,1,1,1,0,0,1,0,1,1,1,-6.9,-6.7,-4.6,-16,-10,-10,0,-2.8,0,-2.6,-2.1,-3.1,0,0,-2.9,0,-18,-7.9,-5.3,GO:0030097,hemopoiesis,M1111110101110010111,14,0
1,1,1,1,1,1,1,1,0,1,1,0,0,0,0,0,1,1,1,-8.3,-2.4,-4.8,-13,-7.8,-6.1,-2.6,-3.5,0,-2.7,-2.2,0,0,0,0,0,-12,-6.1,-6.7,GO:0050865,regulation of cell activation,M1111111101100000111,13,0
1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-4.6,-4,-3.1,-7.1,-4.9,-3.9,0,-4.6,0,-5.3,-2.1,0,0,0,0,0,-8.3,-3.9,-6.2,GO:0002697,regulation of immune effector process,M1111110101100000111,12,0
1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-9.7,-3.7,-5.3,-14,-7.9,-5.9,0,-4.9,0,-3.3,-2.3,0,0,0,0,0,-15,-5.1,-7.8,GO:0046649,lymphocyte activation,M1111110101100000111,12,0
1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-3.7,-3.5,-2.6,-4.8,-8,-5.1,0,-2.7,0,-7.5,-4.6,0,0,0,0,0,-5.6,-4.9,-5.5,GO:0002683,negative regulation of immune system process,M1111110101100000111,12,0
1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-9.8,-3.6,-7.2,-15,-8.2,-7.5,0,-3.9,0,-4.9,-4.4,0,0,0,0,0,-18,-5.9,-10,GO:0045321,leukocyte activation,M1111110101100000111,12,0
1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-3.5,-4.3,-3.5,-4.4,-2.4,-6.9,0,-2.2,0,-4.5,-6,0,0,0,0,0,-8.5,-2.7,-4.2,WP3945,TYROBP causal network in microglia,M1111110101100000111,12,0
1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-11,-3.6,-6.7,-17,-7.3,-6.1,0,-3.2,0,-5.1,-4.6,0,0,0,0,0,-18,-5.2,-9.8,GO:0001775,cell activation,M1111110101100000111,12,0
1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-6.7,-2.4,-5.1,-8.2,-4.4,-4.5,0,-5.1,0,-4.3,-2.4,0,0,0,0,0,-9.6,-3.6,-7.3,GO:0050863,regulation of T cell activation,M1111110101100000111,12,0
1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-5.5,-2.7,-4,-11,-5.2,-2.9,0,-4,0,-3.2,-2.2,0,0,0,0,0,-11,-2.6,-4.9,GO:0022407,regulation of cell-cell adhesion,M1111110101100000111,12,0
1,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-5.5,-2.8,-4.4,-9.1,-3.5,-4,0,-5.1,0,-4.3,-2.4,0,0,0,0,0,-9.1,-3.6,-6.6,GO:1903037,regulation of leukocyte cell-cell adhesion,M1111110101100000111,12,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-6.6,-2.2,-3.4,-11,-3.6,-4.2,0,-2.6,0,-3.3,0,0,0,0,0,0,-12,-3.2,-4.4,GO:0042110,T cell activation,M1111110101000000111,11,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-2.8,-3,-3.3,-3.5,-4.4,-3,0,-3.4,0,-2.2,0,0,0,0,0,0,-6.7,-2.6,-4.8,GO:0046637,regulation of alpha-beta T cell differentiation,M1111110101000000111,11,0
1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,-5.8,-3.7,-4.3,-12,-5.4,-4.2,0,0,0,-2.6,-4.3,0,0,0,0,0,-13,-4.9,-6.5,R-HSA-449147,Signaling by Interleukins,M1111110001100000111,11,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-5.4,-2.5,-3.1,-4.9,-3.4,-2.1,0,-4.7,0,-2.4,0,0,0,0,0,0,-11,-2.9,-4.6,GO:0046634,regulation of alpha-beta T cell activation,M1111110101000000111,11,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-7.7,-2.2,-4.8,-11,-3.6,-2.8,0,-3.5,0,-2.2,0,0,0,0,0,0,-13,-3.4,-5.6,GO:0050867,positive regulation of cell activation,M1111110101000000111,11,0
1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,-3.9,-4.2,-5.8,-9,-4.2,-4,0,0,0,-4.2,-2.3,0,0,0,0,0,-10,-8.4,-5.3,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M1111110001100000111,11,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-5.2,-2.8,-3.9,-10,-6.8,-4.5,0,-2.3,0,-2.9,0,0,0,0,0,0,-14,-5.2,-5.2,GO:1903131,mononuclear cell differentiation,M1111110101000000111,11,0
1,1,1,1,1,1,0,1,0,0,0,0,0,0,1,0,1,1,1,-3.3,-2.2,-3.8,-7.7,-4,-3.8,0,-2,0,0,0,0,0,0,-2.2,0,-4.6,-2.4,-4.6,GO:0009617,response to bacterium,M1111110100000010111,11,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-7.5,-2.5,-4.6,-11,-4.1,-3.1,0,-3.7,0,-2.4,0,0,0,0,0,0,-13,-3.7,-5.9,GO:0002696,positive regulation of leukocyte activation,M1111110101000000111,11,0
1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,-3.6,-4,-2.7,-7.4,-5.1,-3.5,0,0,0,-5.4,-3.5,0,0,0,0,0,-13,-4.7,-7.5,GO:0001819,positive regulation of cytokine production,M1111110001100000111,11,0
1,1,1,1,1,1,0,0,0,1,0,0,0,0,1,0,1,1,1,-4.3,-5.9,-3.3,-11,-5.6,-7.6,0,0,0,-2.4,0,0,0,0,-2.9,0,-11,-4.4,-3.7,GO:0030099,myeloid cell differentiation,M1111110001000010111,11,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-6.3,-2.7,-5,-11,-6.9,-5.5,0,-4.7,0,-3.2,0,0,0,0,0,0,-11,-6.4,-8.2,GO:0051249,regulation of lymphocyte activation,M1111110101000000111,11,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-4.6,-3.3,-2.4,-4.1,-3.6,-3.8,0,-3.4,0,-2.9,0,0,0,0,0,0,-8.9,-3.1,-4.5,GO:0002703,regulation of leukocyte mediated immunity,M1111110101000000111,11,0
0,1,0,1,1,1,0,1,0,1,1,0,0,0,1,0,1,1,1,0,-7.1,0,-8.5,-5.4,-4.6,0,-2,0,-3,-2.8,0,0,0,-4.6,0,-9.4,-5.4,-5.8,GO:0006954,inflammatory response,M0101110101100010111,11,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-7.5,-2.5,-5.2,-11,-7.8,-6.8,0,-4,0,-3.2,0,0,0,0,0,0,-12,-6.7,-7.7,GO:0002694,regulation of leukocyte activation,M1111110101000000111,11,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-4.5,-4.4,-3.9,-12,-6.9,-5.6,0,-2.9,0,-2.9,0,0,0,0,0,0,-16,-7.1,-5.3,GO:0002521,leukocyte differentiation,M1111110101000000111,11,0
1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,-6,-5.2,-6,-14,-4.8,-3.9,0,0,0,-3.6,-4,0,0,0,0,0,-13,-8.3,-8.3,R-HSA-1280215,Cytokine Signaling in Immune system,M1111110001100000111,11,0
0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,-4.7,-2,-7.5,-5,-3.2,0,-2.3,0,-2.4,-2,0,0,0,0,0,-2.4,-6.6,-4,GO:0002253,activation of immune response,M0111110101100000111,11,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-2.8,-2.5,-4.4,-4.3,-3.7,-2.5,0,-3.1,0,-2.7,0,0,0,0,0,0,-6.7,-2.2,-4.4,GO:0045582,positive regulation of T cell differentiation,M1111110101000000111,11,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-6.9,-2.6,-3.9,-11,-4,-2.7,0,-4,0,-2.7,0,0,0,0,0,0,-11,-2.7,-5.8,GO:0051251,positive regulation of lymphocyte activation,M1111110101000000111,11,0
0,1,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,-6.1,-3.7,-11,-6,-3.2,0,-2.3,0,-3.8,-2,0,0,0,0,0,-6.8,-7.9,-6.4,GO:0050778,positive regulation of immune response,M0111110101100000111,11,0
1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-2.5,0,-2.2,-5.2,-6.8,-3.5,0,-2.5,0,-3.4,-3.3,0,0,0,0,0,-4.4,-2.8,-4.2,GO:0050866,negative regulation of cell activation,M1011110101100000111,11,0
1,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,1,1,-3.7,-6.7,-3.2,-7.5,-5.4,-2.5,0,0,0,0,-2.3,0,0,0,0,0,-4,-4.6,-2.6,M183,PID IL6 7 PATHWAY,M1111110000100000111,10,0
1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,-4,-4.8,-6.1,-5.5,-7.8,-4.8,0,-5.3,0,0,0,0,0,0,0,0,-7,-6.1,-3.8,WP2849,Hematopoietic stem cell differentiation,M1111110100000000111,10,0
1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,-6.5,-2.4,-3.8,-7.9,-3,0,0,-4,0,-3.3,0,0,0,0,0,0,-9.2,-2.7,-4.8,GO:0050870,positive regulation of T cell activation,M1111100101000000111,10,0
1,0,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-6.3,0,-10,-6.2,-3.8,-3.2,0,-5.2,0,-4.4,0,0,0,0,0,0,-4.4,-2.2,-5.6,R-HSA-9012999,RHO GTPase cycle,M1011110101000000111,10,0
0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,-3.2,-4.7,-3.5,-3,0,-2.8,0,-2.4,-3.2,0,0,0,0,0,-4,-2.3,-3.4,GO:0022408,negative regulation of cell-cell adhesion,M0011110101100000111,10,0
1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,-2.1,-3,-4.2,-3.5,-2.4,-3.4,0,0,0,-4.1,-3,0,0,0,0,0,0,-2.6,-4.7,hsa04664,Fc epsilon RI signaling pathway,M1111110001100000011,10,0
0,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,-2.1,-4.1,-5.2,-5.1,-4.8,0,0,0,-3,-3.4,0,0,0,0,0,-6.4,-2.6,-6,GO:0002274,myeloid leukocyte activation,M0111110001100000111,10,0
1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,-5.7,-3.7,-2.9,-7.8,-3.5,0,0,-3.2,0,-3.7,0,0,0,0,0,0,-9.2,-2.5,-4.2,GO:0045785,positive regulation of cell adhesion,M1111100101000000111,10,0
0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,-2.7,-3.8,-5.9,-3.7,0,-2.9,0,-4,-3.3,0,0,0,0,0,-4.2,-2.9,-4.9,GO:0002695,negative regulation of leukocyte activation,M0011110101100000111,10,0
0,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,-3.4,-2.5,-7.9,-3,-2.6,0,0,0,-4.5,-2.1,0,0,0,0,0,-6.5,-3.1,-5.9,GO:0045087,innate immune response,M0111110001100000111,10,0
1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,-3.3,-2.7,-4.4,-4.2,-4.3,-3,0,-2.3,0,0,0,0,0,0,0,0,-8.1,-2.2,-3.8,GO:0045580,regulation of T cell differentiation,M1111110100000000111,10,0
1,1,1,1,1,1,0,0,0,1,1,0,0,0,0,0,0,1,1,-2.2,-3.1,-4.5,-4.5,-3.1,-3.6,0,0,0,-3.5,-2.4,0,0,0,0,0,0,-3.8,-3.9,WP286,IL 3 signaling pathway,M1111110001100000011,10,0
1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,-3.7,0,-2.6,-5.7,-3.5,-3.4,0,-3.2,0,-2.7,-2.1,0,0,0,0,0,-5.6,0,-6.4,GO:0050670,regulation of lymphocyte proliferation,M1011110101100000101,10,0
1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,-2.4,-2.6,0,-3.5,-4.7,-2.3,0,0,0,-2.6,-2.9,0,0,0,0,0,-4,-2.2,-3,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M1101110001100000111,10,0
1,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,-3.6,-2.6,-4.7,-6.5,-4.1,-2.7,0,-2.8,0,-2.5,0,0,0,0,0,0,-8,0,-3.9,GO:0045621,positive regulation of lymphocyte differentiation,M1111110101000000101,10,0
1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,-3.9,-2.2,-3.4,-8.3,-6,-4.2,0,-2.6,0,0,0,0,0,0,0,0,-11,-4.3,-3.8,GO:0030098,lymphocyte differentiation,M1111110100000000111,10,0
1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,-3.8,0,-2.6,-5.9,-3.4,-3.8,0,-3.1,0,-3.3,-2.6,0,0,0,0,0,-5.8,0,-6.3,GO:0032944,regulation of mononuclear cell proliferation,M1011110101100000101,10,0
0,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0,-5,-2.6,-7.4,-4.2,-3.6,0,-2.8,0,-2.3,0,0,0,0,0,0,-2.9,-6,-4.8,GO:0002757,immune response-activating signaling pathway,M0111110101000000111,10,0
0,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0,-2.5,-5.5,-3.3,-3.5,-2.1,0,-2.8,0,-4.1,0,0,0,0,0,0,-2.3,-3,-7.5,R-HSA-9658195,Leishmania infection,M0111110101000000111,10,0
1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,-3.8,-2.7,-3.9,-8.9,-3.1,-3,0,-2.1,0,0,0,0,0,0,0,0,-12,-2.4,-2.7,GO:1902107,positive regulation of leukocyte differentiation,M1111110100000000111,10,0
1,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,-5,-5.1,-2.1,-11,-5.1,-3,0,0,0,-2.2,0,0,0,0,0,0,-9.8,-2.9,-3.8,GO:0071345,cellular response to cytokine stimulus,M1111110001000000111,10,0
0,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0,-2.2,-4.5,-2.8,-3.4,-2.6,0,-4.3,0,-2.8,0,0,0,0,0,0,-4.7,-2.9,-5.2,GO:0046638,positive regulation of alpha-beta T cell differentiation,M0111110101000000111,10,0
1,0,1,0,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-3.1,0,-5.6,0,-3.4,-3.2,0,-3.8,0,-4.9,-2.2,0,0,0,0,0,-3.6,-5.7,-4.3,GO:0043087,regulation of GTPase activity,M1010110101100000111,10,0
1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,-3.8,-2.7,-3.9,-8.9,-3.1,-3,0,-2.1,0,0,0,0,0,0,0,0,-12,-2.4,-2.7,GO:1903708,positive regulation of hemopoiesis,M1111110100000000111,10,0
0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,-3.2,-3.6,-4.7,-3.2,0,-3.3,0,-3.6,-3.2,0,0,0,0,0,-3.8,-3.6,-5.7,GO:0051250,negative regulation of lymphocyte activation,M0011110101100000111,10,0
1,1,1,1,1,0,1,0,0,0,0,1,1,0,0,0,1,1,0,-4.2,-2.7,-2.4,-3.4,-3,0,-2.5,0,0,0,0,-2.1,-2.1,0,0,0,-3,-2.8,0,WP2882,Nuclear receptors meta pathway,M1111101000011000110,10,0
1,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,-6.7,-5.8,-3.1,-8.8,-6,-3.9,0,0,0,-3.2,0,0,0,0,0,0,-9.2,-11,-4.7,hsa04380,Osteoclast differentiation,M1111110001000000111,10,0
0,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0,-2.5,-5.5,-3.3,-3.5,-2.1,0,-2.8,0,-4.1,0,0,0,0,0,0,-2.3,-3,-7.5,R-HSA-9824443,Parasitic Infection Pathways,M0111110101000000111,10,0
0,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0,-6,-2.3,-7,-5,-4.2,0,-2.6,0,-2.1,0,0,0,0,0,0,-3.5,-6.7,-4.4,GO:0002764,immune response-regulating signaling pathway,M0111110101000000111,10,0
0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,-3.3,-2.5,-2.6,-4.2,0,-3.9,0,-3.4,-3.3,0,0,0,0,0,-3.5,-3.2,-4.9,GO:1903038,negative regulation of leukocyte cell-cell adhesion,M0011110101100000111,10,0
0,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,0,0,-3.4,-2.1,-2.9,-4.4,0,-4,0,-3.5,-3.4,0,0,0,0,0,-3.8,-3.3,-5.1,GO:0050868,negative regulation of T cell activation,M0011110101100000111,10,0
1,1,0,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-2.9,-3.2,0,-2,-2.1,-2.8,0,-2,0,-2.5,0,0,0,0,0,0,-3.9,-3.1,-2.4,GO:0002698,negative regulation of immune effector process,M1101110101000000111,10,0
1,0,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-4.9,0,-4.6,-4.8,-3.1,-2,0,-4.9,0,-3.3,0,0,0,0,0,0,-9.1,-2.3,-5.3,GO:0046635,positive regulation of alpha-beta T cell activation,M1011110101000000111,10,0
1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,-5.8,-3.7,-4.5,-8,-3.2,0,0,-3.6,0,-3.7,0,0,0,0,0,0,-10,-3.3,-4.3,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M1111100101000000111,10,0
1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,-2.1,-2.6,0,-2.6,-3.2,-2,0,0,0,-2.8,-2.9,0,0,0,0,0,-3.3,-2.3,-2.8,GO:1903557,positive regulation of tumor necrosis factor superfamily cytokine production,M1101110001100000111,10,0
1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,-6.1,-3.4,-3.9,-7.3,-3.2,0,0,-3.2,0,-3.3,0,0,0,0,0,0,-12,-2.7,-3.8,GO:0022409,positive regulation of cell-cell adhesion,M1111100101000000111,10,0
1,1,1,0,1,1,0,1,0,1,1,0,0,0,0,0,0,1,1,-5.7,-2.5,-2.8,0,-4.8,-3.1,0,-4,0,-5,-2.8,0,0,0,0,0,0,-3.8,-3.5,GO:0051336,regulation of hydrolase activity,M1110110101100000011,10,0
1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,-6.2,-4.3,-2.5,-5.8,-4,-3.3,0,-2.1,0,0,0,0,0,0,0,0,-3.2,-5.5,-4,hsa04662,B cell receptor signaling pathway,M1111110100000000111,10,0
1,0,1,1,1,1,0,1,0,1,1,0,0,0,0,0,1,0,1,-3.2,0,-2.3,-6,-4.1,-3.9,0,-2.9,0,-3.7,-2.3,0,0,0,0,0,-5.6,0,-6.6,GO:0070663,regulation of leukocyte proliferation,M1011110101100000101,10,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-6,-4.6,-3.5,-11,-5.3,-4.8,0,0,0,0,0,0,0,0,0,0,-15,-6.1,-3.6,GO:1903706,regulation of hemopoiesis,M1111110000000000111,9,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-7.7,-6,-3.3,-6.5,-6.7,-4.5,0,0,0,0,0,0,0,0,0,0,-5.3,-4.9,-5.8,WP23,B cell receptor signaling pathway,M1111110000000000111,9,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-4.4,-2.2,-2.7,-4.2,-5.1,-2.7,0,0,0,0,0,0,0,0,0,0,-2.9,-3.8,-2.2,M10,PID BCR 5PATHWAY,M1111110000000000111,9,0
1,1,0,1,1,0,0,1,0,1,0,0,0,0,0,0,1,1,1,-2.1,-4,0,-2.8,-3.9,0,0,-3,0,-4.1,0,0,0,0,0,0,-4.6,-4.3,-2.9,GO:0050777,negative regulation of immune response,M1101100101000000111,9,0
1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,-2.5,-2.7,-2,-2.1,-2.4,-2.6,0,-2.7,0,0,0,0,0,0,0,0,-5.6,-2.9,0,GO:0031341,regulation of cell killing,M1111110100000000110,9,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-2.8,-3.5,-2.5,-3.7,-2.6,-4.2,0,0,0,0,0,0,0,0,0,0,-3.2,-8.8,-2.1,WP69,T cell receptor signaling pathway,M1111110000000000111,9,0
0,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,-4.7,-2,-5.4,-4,-4.1,0,-3.6,0,0,0,0,0,0,0,0,-2.4,-6.7,-4,GO:0002429,immune response-activating cell surface receptor signaling pathway,M0111110100000000111,9,0
1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,1,0,-3.1,-4,0,-6,-4.6,-4,0,0,0,-5.9,-2.7,0,0,0,0,0,-4,-3.4,0,GO:0031348,negative regulation of defense response,M1101110001100000110,9,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-4.2,-2.4,-2.2,-2.7,-4.1,-2.2,0,0,0,0,0,0,0,0,0,0,-3,-4.9,-5.6,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M1111110000000000111,9,0
1,0,1,1,0,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-3.7,0,-5.9,-4.5,0,-2.9,0,-5.5,0,-3.9,0,0,0,0,0,0,-3.9,-2.1,-3.5,R-HSA-9013149,RAC1 GTPase cycle,M1011010101000000111,9,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-3.6,-2.4,-4.3,-6.6,-4.2,-3.3,0,0,0,0,0,0,0,0,0,0,-8.6,-3.2,-3.9,GO:0045619,regulation of lymphocyte differentiation,M1111110000000000111,9,0
0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,0,-5.1,-5.3,-4.1,-2.5,-4.1,0,0,0,-3.8,0,0,0,0,0,0,-4.3,-3.5,-3,hsa04650,Natural killer cell mediated cytotoxicity,M0111110001000000111,9,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-5.8,-2.2,-4.1,-11,-4.6,-3.8,0,0,0,0,0,0,0,0,0,0,-9.2,-3.6,-3.8,GO:0010720,positive regulation of cell development,M1111110000000000111,9,0
0,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,-3.3,-4.8,-2.9,-2.6,-2.9,0,-2.7,0,-2.5,0,0,0,0,0,0,0,-2.2,-4.1,R-HSA-9664407,Parasite infection,M0111110101000000011,9,0
1,0,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,-3.2,0,-2.5,-6.1,-2.5,-2.6,0,-2.4,0,-4.4,0,0,0,0,0,0,-6.1,0,-6.5,GO:0070665,positive regulation of leukocyte proliferation,M1011110101000000101,9,0
1,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,1,0,-4.5,-2.8,-2.4,-9.7,-5.6,-4.3,0,0,-2.2,0,0,0,0,0,0,0,-6.3,-3.9,0,M167,PID AP1 PATHWAY,M1111110010000000110,9,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-5.1,-3.8,-3.5,-10,-4.6,-4.1,0,0,0,0,0,0,0,0,0,0,-14,-4.8,-3.4,GO:1902105,regulation of leukocyte differentiation,M1111110000000000111,9,0
1,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,-2.6,0,-3.3,0,-3.7,-2.8,0,-2.9,0,-4.3,0,0,0,0,0,0,-4.5,-3.8,-4.9,GO:0043547,positive regulation of GTPase activity,M1010110101000000111,9,0
0,1,1,0,1,1,0,0,0,1,1,0,0,0,0,0,1,1,1,0,-2.4,-4.6,0,-3.7,-5.1,0,0,0,-3,-2.2,0,0,0,0,0,-2.4,-4,-3.7,R-HSA-2871796,FCERI mediated MAPK activation,M0110110001100000111,9,0
1,0,1,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,-2.4,0,-2.7,-4.6,-4,-4.5,0,0,0,-2.7,-2.1,0,0,0,0,0,-6.7,0,-3.5,hsa05202,Transcriptional misregulation in cancer,M1011110001100000101,9,0
1,0,0,0,1,1,0,1,0,1,1,0,0,0,0,0,1,1,1,-5.1,0,0,0,-6.2,-3.2,0,-2.8,0,-5.5,-3.1,0,0,0,0,0,-3.2,-2.9,-4.2,GO:0051345,positive regulation of hydrolase activity,M1000110101100000111,9,0
0,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,-3.3,-4.8,-2.9,-2.6,-2.9,0,-2.7,0,-2.5,0,0,0,0,0,0,0,-2.2,-4.1,R-HSA-9664417,Leishmania phagocytosis,M0111110101000000011,9,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-2.3,-4.9,-4.8,-4.8,-3.8,-5.7,0,0,0,0,0,0,0,0,0,0,-3.2,-5,-3.3,M7,PID FCER1 PATHWAY,M1111110000000000111,9,0
1,1,1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,-3.8,-2.3,-2.5,-2.6,-2.4,-2.8,0,-2.6,0,0,0,0,0,0,0,0,0,-3,-4,M8626,SIG BCR SIGNALING PATHWAY,M1111110100000000011,9,0
1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,-2.3,-2.5,-2.4,-3,-3.6,0,0,-4,0,0,0,0,0,0,0,0,-7,-3.4,-3.8,GO:0043370,"regulation of CD4-positive, alpha-beta T cell differentiation",M1111100100000000111,9,0
1,0,1,1,1,1,0,1,0,1,0,0,0,0,0,0,1,0,1,-3.3,0,-2.7,-5.5,-2.4,-2.2,0,-2.5,0,-2.9,0,0,0,0,0,0,-6.2,0,-5,GO:0032946,positive regulation of mononuclear cell proliferation,M1011110101000000101,9,0
0,1,1,1,1,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,-3.3,-4.8,-2.9,-2.6,-2.9,0,-2.7,0,-2.5,0,0,0,0,0,0,0,-2.2,-4.1,R-HSA-9664422,FCGR3A-mediated phagocytosis,M0111110101000000011,9,0
1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,-3.1,0,-2.8,-5.3,-2.5,0,0,-2.6,0,-2.2,0,0,0,0,0,0,-6,0,-5.1,GO:0050671,positive regulation of lymphocyte proliferation,M1011100101000000101,8,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-4.1,-2.6,-3.9,-4.3,-3.6,-2.2,0,0,0,0,0,0,0,0,0,0,-4.3,-3,0,WP366,TGF beta signaling pathway,M1111110000000000110,8,0
0,0,1,0,1,1,0,1,0,1,0,0,0,0,0,0,1,1,1,0,0,-3.3,0,-2.2,-2.6,0,-2.5,0,-3.4,0,0,0,0,0,0,-2.7,-2.8,-3.8,GO:0090630,activation of GTPase activity,M0010110101000000111,8,0
1,1,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,1,1,-2.6,-2.6,0,0,-2.6,-2.3,0,0,0,-2.1,0,0,0,0,0,0,-2.9,-2.5,-2.5,GO:0043300,regulation of leukocyte degranulation,M1100110001000000111,8,0
1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,-2.5,0,0,-4.8,-4.7,-3.2,0,-2.4,0,0,0,0,0,0,0,0,-6.8,-2.4,-4,GO:0042113,B cell activation,M1001110100000000111,8,0
1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,1,-3.2,0,-2.7,-3.1,-3.4,0,0,-3.6,0,0,0,0,0,0,0,0,-6.6,-2.8,-5.1,GO:2000514,"regulation of CD4-positive, alpha-beta T cell activation",M1011100100000000111,8,0
1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,1,0,-2.7,0,0,-4.1,-4.1,-2.5,0,0,0,0,0,-4.5,-3.3,0,0,0,-3.3,-3.5,0,M255,PID HIF1 TFPATHWAY,M1001110000011000110,8,0
1,1,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,-3.9,-2.4,0,-4.3,-2.6,-3,0,0,0,0,0,-2.1,-2.1,0,0,0,-5.5,0,0,M195,PID CMYB PATHWAY,M1101110000011000100,8,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-3,-2.7,-2.8,-2.1,-3.8,-3.1,0,0,0,0,0,0,0,0,0,0,-3,-4.4,0,WP2526,PDGF pathway,M1111110000000000110,8,0
1,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,-2.8,0,-2.7,-4.5,0,-2.9,0,0,0,-3.5,-2,0,0,0,0,0,-3.2,0,-5,GO:0002718,regulation of cytokine production involved in immune response,M1011010001100000101,8,0
0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,-4.8,0,-4.2,-2.6,-2.8,0,-2.3,0,0,0,0,0,0,0,0,-5.3,-2.6,-3.7,GO:0050900,leukocyte migration,M0101110100000000111,8,0
1,0,1,1,1,1,0,0,0,0,0,1,0,0,0,0,1,0,1,-5.5,0,-3.1,-9.5,-4.7,-3.3,0,0,0,0,0,-2.6,0,0,0,0,-11,0,-2.3,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M1011110000010000101,8,0
0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,-6,0,-5.3,-4.9,-4.8,0,-3.4,0,0,0,0,0,0,0,0,-3.1,-7.6,-3.7,GO:0002768,immune response-regulating cell surface receptor signaling pathway,M0101110100000000111,8,0
1,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,-2.2,-2.6,-2.6,-4.1,-3,-3,0,0,-2.3,0,0,0,0,0,0,0,-4.3,0,0,GO:0051216,cartilage development,M1111110010000000100,8,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-4.4,-2.5,-2.2,-5.6,-4.5,-3.3,0,0,0,0,0,0,0,0,0,0,-6.7,-2.6,0,GO:0071559,response to transforming growth factor beta,M1111110000000000110,8,0
0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,-4.9,-3,-4.1,-4.8,-2.5,0,0,0,0,0,0,0,0,0,0,-6,-9.1,-3,R-HSA-1280218,Adaptive Immune System,M0111110000000000111,8,0
0,1,1,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,-2.2,-3.3,-2.5,-2.2,-3.5,0,0,0,0,-2.6,0,0,0,0,0,-2.2,0,-2.5,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M0111110000100000101,8,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-5.2,-3.7,-3.1,-8.7,-6.5,-2.5,0,0,0,0,0,0,0,0,0,0,-5.1,-4.3,0,hsa05200,Pathways in cancer,M1111110000000000110,8,0
1,1,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,0,-4.9,-2.9,-3.8,-5.9,-3.5,0,0,-4,0,-4.2,0,0,0,0,0,0,-7.2,0,0,GO:0051056,regulation of small GTPase mediated signal transduction,M1111100101000000100,8,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.1,-3.1,-2.7,-2.4,-2.6,-3.5,0,0,0,0,0,0,0,0,0,0,-2.6,-2.4,0,R-HSA-8951430,RUNX3 regulates WNT signaling,M1111110000000000110,8,0
1,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,-3.3,-2.3,0,-9.8,-6.9,-2.9,0,0,0,-2.5,0,0,0,0,0,0,-5.5,0,-3,GO:0050727,regulation of inflammatory response,M1101110001000000101,8,0
1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,-2.2,0,-3,-5.2,-2.2,0,0,-2.3,0,-2.8,0,0,0,0,0,0,-3.9,0,-4.5,GO:0002702,positive regulation of production of molecular mediator of immune response,M1011100101000000101,8,0
1,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,-2.2,-2.7,0,-3.4,-4.9,-2.4,0,0,0,0,-2.4,0,0,0,0,0,-3.7,0,-2.4,GO:0032680,regulation of tumor necrosis factor production,M1101110000100000101,8,0
1,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,0,-3.3,-3.1,0,-7.4,-4.8,-4.1,0,0,0,-5.8,-2.7,0,0,0,0,0,-3.5,0,0,GO:0032102,negative regulation of response to external stimulus,M1101110001100000100,8,0
1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,-2.4,0,-3.2,-7.2,-2.7,0,0,-3.7,0,-3.1,0,0,0,0,0,0,-7.1,0,-3.4,GO:0002699,positive regulation of immune effector process,M1011100101000000101,8,0
0,1,1,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,-5.1,-2.9,-5.5,-2.3,-2.9,0,0,0,-2.8,0,0,0,0,0,0,-7.2,0,-6,GO:0019221,cytokine-mediated signaling pathway,M0111110001000000101,8,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.3,-2.5,-2.6,-4.5,-2.6,-2.9,0,0,0,0,0,0,0,0,0,0,-3.3,-6.5,0,WP3863,T cell antigen receptor TCR pathway during Staphylococcus aureus infection,M1111110000000000110,8,0
1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-3.2,0,-4.1,-8,-3.7,-3.7,0,0,0,0,0,0,0,0,0,0,-3.5,-5.7,-4.8,M186,PID PDGFRB PATHWAY,M1011110000000000111,8,0
0,1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,-3.5,-3.1,-2.3,0,-3.2,0,0,0,0,-2.2,0,0,0,0,0,-2.4,-2.6,-3.6,WP3937,Microglia pathogen phagocytosis pathway,M0111010000100000111,8,0
1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-3.3,-3.1,-3.7,-4.5,0,-3.7,0,0,0,0,0,0,0,0,0,0,-3,-7,-2.3,hsa04660,T cell receptor signaling pathway,M1111010000000000111,8,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2,-5.2,-2.2,-5.4,-3.1,-3.2,0,0,0,0,0,0,0,0,0,0,-7.4,-6.8,0,GO:0045639,positive regulation of myeloid cell differentiation,M1111110000000000110,8,0
1,1,0,1,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,-3.3,-4.8,0,-3.8,0,-3.7,0,-2.2,0,-2.9,0,0,0,0,0,0,0,-2.3,-5.4,GO:0032655,regulation of interleukin-12 production,M1101010101000000011,8,0
1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,-3.5,-2.1,-2.2,0,0,0,0,0,0,-3.2,-2.2,0,0,0,0,0,-2.6,-3,-6.4,GO:0060627,regulation of vesicle-mediated transport,M1110000001100000111,8,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.1,-2,-2.9,-3,-2.1,-2.6,0,0,0,0,0,0,0,0,0,0,-3.8,-2.3,0,hsa05215,Prostate cancer,M1111110000000000110,8,0
0,1,1,1,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,-3.1,-3.4,-3,0,-2.7,0,0,0,-2.3,-2.4,0,0,0,0,0,0,-2.9,-2.8,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M0111010001100000011,8,0
1,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,-4.9,0,0,-6.5,-3,-2.9,0,-2.2,0,0,0,0,0,0,0,0,-3.2,-2.3,-2.4,R-HSA-9616222,Transcriptional regulation of granulopoiesis,M1001110100000000111,8,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,-2,-4.1,-2.8,-4.6,-4.3,-5,0,0,0,0,0,0,0,0,0,0,-3.6,0,-3.3,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M1111110000000000101,8,0
0,1,1,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,-3.4,-2.3,-12,-5.8,0,0,0,0,-2.6,0,0,0,0,0,0,-10,-3.6,-2.6,GO:0002250,adaptive immune response,M0111100001000000111,8,0
1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,-3.7,-3.1,-2.9,-2.5,-2.5,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2.2,-2.7,WP437,EGF EGFR signaling pathway,M1111100000000000111,8,0
1,0,1,1,0,1,0,0,0,0,0,1,0,0,0,0,1,1,1,-5.3,0,-2.8,-3.8,0,-2.8,0,0,0,0,0,-2.4,0,0,0,0,-4.2,-3.2,-2.1,WP5083,Neuroinflammation and glutamatergic signaling,M1011010000010000111,8,0
1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,-4.8,0,-7.7,-5.4,-2.5,0,0,-4,0,-3.2,0,0,0,0,0,0,-3.6,0,-4,R-HSA-194315,Signaling by Rho GTPases,M1011100101000000101,8,0
0,1,0,1,1,1,0,0,0,1,1,0,0,0,0,0,1,0,1,0,-2.6,0,-5.8,-4,-2.3,0,0,0,-2.1,-2.3,0,0,0,0,0,-3.8,0,-2.1,GO:0007162,negative regulation of cell adhesion,M0101110001100000101,8,0
0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,-4.1,0,-4.5,-4.5,-2.9,0,-3,0,0,0,0,0,0,0,0,-2.3,-6.4,-2.5,GO:0050851,antigen receptor-mediated signaling pathway,M0101110100000000111,8,0
1,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,-9.3,-2.3,-2.1,-5.9,-3.8,-2.4,0,0,-3,0,0,0,0,0,0,0,-3.6,0,0,GO:0048568,embryonic organ development,M1111110010000000100,8,0
1,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,-2.5,-2.2,-2.4,-2.7,-3.5,-3.5,0,0,-2.2,0,0,0,0,0,0,0,-3.2,0,0,GO:0002062,chondrocyte differentiation,M1111110010000000100,8,0
1,0,1,1,1,0,0,1,0,1,0,0,0,0,0,0,1,0,1,-4.4,0,-7.5,-5.3,-2.7,0,0,-3.9,0,-3.1,0,0,0,0,0,0,-3.4,0,-3.9,R-HSA-9716542,"Signaling by Rho GTPases, Miro GTPases and RHOBTB3",M1011100101000000101,8,0
1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-2.6,-3.5,-3.7,0,-5.2,-2.7,0,0,0,0,0,0,0,0,0,0,-3.8,-5.5,-4.3,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M1110110000000000111,8,0
1,1,1,1,1,1,0,0,1,0,0,0,0,0,0,0,1,0,0,-8.6,-2.5,-2,-9.1,-5.4,-3.4,0,0,-2.1,0,0,0,0,0,0,0,-11,0,0,GO:0008283,cell population proliferation,M1111110010000000100,8,0
1,0,1,1,0,1,0,0,0,1,1,0,0,0,0,0,1,0,1,-3.3,0,-3.4,-4.5,0,-2.2,0,0,0,-3.8,-2.1,0,0,0,0,0,-3.6,0,-5.9,GO:0002700,regulation of production of molecular mediator of immune response,M1011010001100000101,8,0
0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,-3,0,-4.2,-4.3,-2.7,0,-3.2,0,0,0,0,0,0,0,0,0,-3,-3.2,GO:0050853,B cell receptor signaling pathway,M0101110100000000011,7,0
1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,-2.2,0,-3.3,-3.9,-3.7,0,0,0,0,0,0,0,0,0,0,0,-8,-2.4,-4.2,GO:0002819,regulation of adaptive immune response,M1011100000000000111,7,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.8,-3.6,0,-4.8,-2.3,-2,0,0,0,0,0,0,0,0,0,0,-8.8,-4.2,0,GO:0002761,regulation of myeloid leukocyte differentiation,M1101110000000000110,7,0
1,1,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,-3.3,-2.1,-2.3,-2.4,0,0,0,0,0,-3.3,0,0,0,0,0,0,-2.3,0,-3,GO:0120031,plasma membrane bounded cell projection assembly,M1111000001000000101,7,0
1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,-2.4,0,-2.5,-3,-2.1,-2,0,0,0,-2,0,0,0,0,0,0,0,0,-3.2,GO:0071222,cellular response to lipopolysaccharide,M1011110001000000001,7,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.9,-3.2,-3.8,-8.4,-2.4,-3.1,0,0,0,0,0,0,0,0,0,0,-6.5,0,0,GO:0001501,skeletal system development,M1111110000000000100,7,0
1,1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,1,0,-5.7,-2.8,0,-7.2,-3.8,0,0,-2.1,0,0,0,0,0,0,0,0,-5.8,-4.6,0,hsa04659,Th17 cell differentiation,M1101100100000000110,7,0
1,1,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,0,-2.3,-3.2,-2.1,0,-2.5,-3.6,0,0,0,0,-2.1,0,0,0,0,0,0,-2.7,0,M17200,SA B CELL RECEPTOR COMPLEXES,M1110110000100000010,7,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,1,-2.7,0,0,-4.3,-3.5,-3.4,0,0,0,0,0,0,0,0,-3,0,-5.7,0,-2.3,GO:0048872,homeostasis of number of cells,M1001110000000010101,7,0
1,0,1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,-3,0,-2.6,-3.2,-2.6,-3,0,0,0,-2.4,0,0,0,0,0,0,0,0,-4.8,GO:0071216,cellular response to biotic stimulus,M1011110001000000001,7,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.4,-3.2,0,-3.3,-4.1,-2.8,0,0,0,0,0,0,0,0,0,0,-5.7,-3,0,GO:0140467,integrated stress response signaling,M1101110000000000110,7,0
1,0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,1,0,0,-3.4,0,-2,-4.9,-3.6,-2.6,-3.2,0,0,0,0,0,0,0,0,0,-4.2,0,0,GO:1902075,cellular response to salt,M1011111000000000100,7,0
0,1,0,1,1,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,-2.6,0,-2.3,-3.3,-2.1,0,0,0,0,-2.3,0,0,0,0,0,-2.9,0,-2.1,GO:0032760,positive regulation of tumor necrosis factor production,M0101110000100000101,7,0
0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.5,-3.2,-5.5,-2.9,-3.9,0,0,0,0,0,0,0,0,0,0,-5.4,-3.4,0,WP5293,Acute myeloid leukemia,M0111110000000000110,7,0
1,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,-3.8,0,-2.4,-4.3,-2,0,0,-2.4,0,0,0,0,0,0,0,0,-5.3,0,-6.3,GO:0042129,regulation of T cell proliferation,M1011100100000000101,7,0
0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.6,-3.3,-5.9,-3,-4,0,0,0,0,0,0,0,0,0,0,-5.6,-3.4,0,hsa05221,Acute myeloid leukemia,M0111110000000000110,7,0
1,1,1,0,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,-4.5,-3.2,-2.4,0,-2.4,0,0,0,0,-4.3,0,0,0,0,0,0,0,-2.8,-5.9,R-HSA-109582,Hemostasis,M1110100001000000011,7,0
0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,-3.9,-8,-4.8,-3.1,0,0,0,0,0,0,0,0,0,0,-8,-2.7,-5,GO:0002252,immune effector process,M0011110000000000111,7,0
1,1,1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,-4,-3.1,-2.4,-2.1,0,-2.7,0,-3.7,0,0,0,0,0,0,0,0,0,-4.4,0,hsa05130,Pathogenic Escherichia coli infection,M1111010100000000010,7,0
1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,-4,0,-2.2,-6.8,0,-2.8,0,0,0,0,-2.2,0,0,0,0,0,-4.7,-3.1,0,WP4816,TGF beta receptor signaling in skeletal dysplasias,M1011010000100000110,7,0
0,1,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,-3,0,-4.1,-3.1,-4.5,0,-2.5,0,0,0,0,0,0,0,0,-4.7,0,-2.3,GO:0030595,leukocyte chemotaxis,M0101110100000000101,7,0
0,1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,-2.6,-3.8,0,-2.7,-3,0,-2.8,0,0,0,0,0,0,0,0,0,-2.3,-2,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,M0110110100000000011,7,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.4,-2.5,-3.2,-2.1,-2.9,-2.3,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,hsa05210,Colorectal cancer,M1111110000000000100,7,0
0,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,-3.3,0,0,-2.3,-4,0,-2.6,0,0,0,0,0,0,0,0,-3.5,-3.6,-2.4,GO:0097529,myeloid leukocyte migration,M0100110100000000111,7,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-4.2,-2.4,0,-4.1,-4.6,-2.1,0,0,0,0,0,0,0,0,0,0,-4.6,-7.2,0,GO:0045646,regulation of erythrocyte differentiation,M1101110000000000110,7,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.8,-4.7,0,-6.1,-3.8,-3.1,0,0,0,0,0,0,0,0,0,0,-10,-6,0,GO:0045637,regulation of myeloid cell differentiation,M1101110000000000110,7,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,-3,-2.7,0,-2.8,-2.9,-2.2,0,0,0,0,0,0,0,0,0,0,0,-3.3,-4.4,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M1101110000000000011,7,0
0,1,1,0,0,1,0,0,0,1,1,0,0,0,0,0,0,1,1,0,-3.4,-4.6,0,0,-3.8,0,0,0,-3,-3.3,0,0,0,0,0,0,-4,-3.7,R-HSA-912631,Regulation of signaling by CBL,M0110010001100000011,7,0
1,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,1,-2.6,0,0,-3.8,0,0,0,0,0,-4.6,-3,0,0,0,0,0,-2.2,-2.7,-7.1,R-HSA-76002,"Platelet activation, signaling and aggregation",M1001000001100000111,7,0
1,0,0,1,1,1,0,0,0,0,0,1,1,0,0,0,1,0,0,-2.4,0,0,-2.4,-2.5,-2.3,0,0,0,0,0,-3.4,-2.5,0,0,0,-2.2,0,0,GO:0001890,placenta development,M1001110000011000100,7,0
1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.4,-2.2,-2.9,0,-2.9,-2.5,0,0,0,0,0,0,0,0,0,0,-2.9,-2.6,0,GO:2001187,"positive regulation of CD8-positive, alpha-beta T cell activation",M1110110000000000110,7,0
0,1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,1,0,-2.5,-3.6,0,-2.6,-2.9,0,0,0,-2.5,0,0,0,0,0,0,0,-3.1,-5.4,R-HSA-2871809,FCERI mediated Ca+2 mobilization,M0110110001000000011,7,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.5,-2.5,0,-6,-3.9,-3,0,0,0,0,0,0,0,0,0,0,-4.1,-2.4,0,M60,PID NFAT TFPATHWAY,M1101110000000000110,7,0
1,1,1,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,-2.8,-3.2,-2.7,0,0,0,0,0,0,-4,-2.1,0,0,0,0,0,-2.2,0,-4.2,GO:0030031,cell projection assembly,M1110000001100000101,7,0
0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,-2.9,-4.5,-2.3,-3.4,0,0,-2.1,0,0,0,0,0,0,0,0,0,-2.1,-6.3,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M0111100100000000011,7,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.7,-3.3,0,-5.2,-3.2,-3.9,0,0,0,0,0,0,0,0,0,0,-4.1,-7.4,0,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M1101110000000000110,7,0
1,0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,1,1,0,-2.8,0,-2.2,0,-2.7,-3.2,0,0,0,0,0,-2.9,0,0,0,0,-2.4,-4.4,0,hsa05211,Renal cell carcinoma,M1010110000010000110,7,0
1,0,1,1,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,-3.7,0,-2.3,-4.3,0,0,0,-2.3,0,-2,0,0,0,0,0,0,-5.3,0,-3.7,GO:0042102,positive regulation of T cell proliferation,M1011000101000000101,7,0
1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,-2.6,-3.4,0,0,-3.4,-4,0,0,0,0,0,0,0,0,0,0,-3.1,-2.5,-4.5,GO:0001818,negative regulation of cytokine production,M1100110000000000111,7,0
0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,1,1,0,-2.6,0,-4.9,-4.5,0,0,0,0,-2.8,-2.3,0,0,0,0,0,0,-2.5,-4.3,GO:0031349,positive regulation of defense response,M0101100001100000011,7,0
0,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,1,0,0,-3.4,-2.5,0,-3.4,0,0,0,0,-2.1,0,0,0,0,0,-2.4,-2,-2.7,R-HSA-168898,Toll-like Receptor Cascades,M0011010000100000111,7,0
1,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,1,0,-3,-3.8,0,-2.7,0,0,0,0,0,-2.5,-3.9,0,0,0,0,0,-3,-4,0,hsa05142,Chagas disease,M1101000001100000110,7,0
1,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.5,-2.6,-2.4,-2.2,-3,-2.4,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M1111110000000000100,7,0
1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,-2.5,-2.3,-3.6,-2.6,0,-2.4,0,0,0,0,0,0,0,0,0,0,-3.1,0,-4.4,GO:0006909,phagocytosis,M1111010000000000101,7,0
1,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-6,-3.3,-2.3,-4.3,0,-2.1,0,0,0,0,0,0,0,0,0,0,-3,-2.4,0,R-HSA-8878159,Transcriptional regulation by RUNX3,M1111010000000000110,7,0
1,1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,1,1,0,-2.4,-2.9,0,0,-2.6,-2.2,0,-2.8,0,0,0,0,0,0,0,0,-4.1,-2.4,0,GO:0002704,negative regulation of leukocyte mediated immunity,M1100110100000000110,7,0
1,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,-6.3,0,-2.1,-5,0,0,0,0,0,-2.9,-2.1,0,0,0,0,0,-4.9,0,-3.6,GO:0046641,positive regulation of alpha-beta T cell proliferation,M1011000001100000101,7,0
1,1,0,0,0,0,0,0,0,1,1,0,0,1,0,1,0,0,1,-2.4,-2.8,0,0,0,0,0,0,0,-2.2,-2.3,0,0,-3,0,-2.8,0,0,-3.7,GO:0045185,maintenance of protein location,M1100000001100101001,7,0
0,1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-3.1,-2.1,-3.5,-2.8,-3.3,0,0,0,0,0,0,0,0,0,0,-3.1,-5.1,0,hsa05132,Salmonella infection,M0111110000000000110,7,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-5.1,-3.7,0,-6.8,-3.8,-2.4,0,0,0,0,0,0,0,0,0,0,-6.2,-4.1,0,hsa04658,Th1 and Th2 cell differentiation,M1101110000000000110,7,0
0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,-3.1,0,-6,-2.8,-2.8,0,0,0,-2.2,0,0,0,0,0,0,-8.1,-3.1,0,GO:0002573,myeloid leukocyte differentiation,M0101110001000000110,7,0
0,1,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,-5.6,0,-4.3,-4.3,-2.7,0,0,0,-2.1,0,0,0,0,0,0,-2.3,0,-3.4,GO:0032675,regulation of interleukin-6 production,M0101110001000000101,7,0
1,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,-2.8,0,0,-2.1,-2.6,0,0,0,0,-3.8,-2.5,0,0,0,0,0,-4.5,0,-3,GO:0002886,regulation of myeloid leukocyte mediated immunity,M1001100001100000101,7,0
1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-3,0,-2.2,-3.2,-4.1,-2.2,0,0,0,0,0,0,0,0,0,0,-3.6,-2.4,0,GO:0071277,cellular response to calcium ion,M1011110000000000110,7,0
0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,1,1,1,0,-4.4,0,-7.6,-5.1,0,0,0,0,-4,0,0,0,0,0,0,-3.7,-2.9,-4.9,GO:0032103,positive regulation of response to external stimulus,M0101100001000000111,7,0
0,0,1,0,1,0,0,0,0,0,0,1,0,0,0,0,1,1,1,0,0,-4.1,0,-2,0,0,0,0,0,0,-2.7,0,0,0,0,-3.4,-5.4,-5.4,R-HSA-6798695,Neutrophil degranulation,M0010100000010000111,6,0
0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,-3.8,-3.2,-2.7,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.3,-4.3,R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,M0011100000000000111,6,0
0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,-3.1,0,0,0,-2.8,0,-2.2,0,0,0,0,0,0,0,0,-2.4,-3.9,-3.2,GO:0097530,granulocyte migration,M0100010100000000111,6,0
1,0,0,1,1,1,0,0,0,0,0,0,0,1,0,0,1,0,0,-3.7,0,0,-5.5,-2.6,-2.3,0,0,0,0,0,0,0,-2.2,0,0,-7,0,0,GO:0071695,anatomical structure maturation,M1001110000000100100,6,0
1,1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,-4.3,-3.1,0,-2.9,-3.2,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,-3.3,GO:0043254,regulation of protein-containing complex assembly,M1101101000000000001,6,0
1,1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,-7,-2.6,0,-5.7,-2.4,0,0,0,-2.4,0,0,0,0,0,0,0,-4.4,0,0,GO:0007423,sensory organ development,M1101100010000000100,6,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,-5.3,0,0,-6.7,-6,-2.7,0,0,0,0,0,0,0,0,-2.4,0,-5.3,0,0,GO:0050678,regulation of epithelial cell proliferation,M1001110000000010100,6,0
0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,-3.7,0,-4.1,-2.7,0,0,0,0,-3.6,0,0,0,0,0,0,0,-5,-2.1,GO:0002831,regulation of response to biotic stimulus,M0101100001000000011,6,0
1,0,0,0,1,1,0,0,0,0,0,1,0,0,1,0,1,0,0,-4.7,0,0,0,-2.7,-2.6,0,0,0,0,0,-3,0,0,-2.1,0,-4.2,0,0,GO:0048871,multicellular organismal-level homeostasis,M1000110000010010100,6,0
1,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,0,-2.4,0,-2.3,0,-2.1,0,0,0,0,-2.2,-2.3,0,0,0,0,0,-4,0,0,GO:0032673,regulation of interleukin-4 production,M1010100001100000100,6,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,-3.2,0,0,-3.5,-2,0,0,0,0,0,0,0,0,0,0,0,-3,-2.6,-2.3,hsa04921,Oxytocin signaling pathway,M1001100000000000111,6,0
1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.8,-3,-2.5,-2.2,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,GO:0030832,regulation of actin filament length,M1111100000000000001,6,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.2,-3.4,0,-6,-5.2,-3.5,0,0,0,0,0,0,0,0,0,0,-6.4,0,0,GO:0061448,connective tissue development,M1101110000000000100,6,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-7.6,-2.3,0,-7.2,-4.8,-3.3,0,0,0,0,0,0,0,0,0,0,-5.8,0,0,GO:0045165,cell fate commitment,M1101110000000000100,6,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-7.6,0,0,-6.8,-4.5,-2.3,0,0,0,0,0,0,0,0,0,0,-4.7,-2.6,0,GO:2000628,regulation of miRNA metabolic process,M1001110000000000110,6,0
0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,-2.3,-4.7,-2.7,0,0,0,0,0,0,0,0,0,0,0,-2.9,-3,-3.6,WP3929,Chemokine signaling pathway,M0011100000000000111,6,0
1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-7.2,0,-4,-9.4,-6.7,-2.7,0,0,0,0,0,0,0,0,0,0,-6.2,0,0,GO:0070848,response to growth factor,M1011110000000000100,6,0
1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.4,-3.7,-2.2,-2.1,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,GO:0030833,regulation of actin filament polymerization,M1111100000000000001,6,0
0,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,-3.2,-2.7,-2.1,0,0,0,-2.5,0,0,0,0,0,0,-2.8,0,-2,GO:0045576,mast cell activation,M0001110001000000101,6,0
1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.9,-3.1,-2.6,-2.3,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,GO:0008064,regulation of actin polymerization or depolymerization,M1111100000000000001,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.3,-2.7,0,-6,-2.2,0,0,0,0,0,0,0,0,0,0,0,-2.9,-3.2,0,M235,PID TCR CALCIUM PATHWAY,M1101100000000000110,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-8.6,-3.4,0,-12,-6.4,0,0,0,0,0,0,0,0,0,-3.2,0,-3.9,0,0,GO:0048514,blood vessel morphogenesis,M1101100000000010100,6,0
1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.6,-2.1,-3.3,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,-4.7,0,M34,PID TCR PATHWAY,M1111000000000000110,6,0
1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,-2.5,-2.9,0,-3.5,0,0,0,0,0,-2.1,0,0,0,0,0,0,-4.6,0,-2.6,GO:0050731,positive regulation of peptidyl-tyrosine phosphorylation,M1101000001000000101,6,0
1,1,0,0,0,1,0,0,0,1,1,0,0,0,0,0,0,0,1,-2.6,-3.3,0,0,0,-2,0,0,0,-2.5,-2.6,0,0,0,0,0,0,0,-4.1,GO:0032507,maintenance of protein location in cell,M1100010001100000001,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-3.8,-2.3,0,-4.2,-3.4,0,0,0,0,0,0,0,0,0,0,0,-5.5,0,-3.3,GO:0070661,leukocyte proliferation,M1101100000000000101,6,0
0,1,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,-2.2,0,-3.7,-2.3,0,0,0,0,0,-2.4,0,0,0,0,0,-2.9,-2,0,GO:0043299,leukocyte degranulation,M0101100000100000110,6,0
0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-3.4,-5.7,-5.4,-2.7,0,0,0,0,0,0,0,0,0,0,-8.2,0,-5,GO:0002366,leukocyte activation involved in immune response,M0011110000000000101,6,0
1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.1,-2.4,0,0,-2.1,-2.9,0,0,0,0,0,0,0,0,0,0,-2.5,-2.4,0,GO:1903305,regulation of regulated secretory pathway,M1100110000000000110,6,0
0,0,1,0,1,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,-3.3,0,-2.7,0,0,0,0,-3,-2.2,0,0,0,0,0,-2.4,0,-2.5,R-HSA-2424491,DAP12 signaling,M0010100001100000101,6,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,-5.5,-2.9,-2.6,0,0,0,0,0,0,0,0,0,0,-3.5,-2.3,-4.6,GO:0050864,regulation of B cell activation,M0001110000000000111,6,0
0,1,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,-3.2,-2.1,-3.8,-2.3,0,0,-2.1,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0022604,regulation of cell morphogenesis,M0111100100000000100,6,0
0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,-2,0,-3.5,0,0,0,-3,0,0,0,0,0,0,0,0,-5,-5.4,-2.1,WP75,Toll like receptor signaling pathway,M0101000100000000111,6,0
1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.2,-3.7,0,0,-3.2,-3.9,0,0,0,0,0,0,0,0,0,0,-2.5,-4.1,0,CORUM:2693,NFAT-JUN-FOS DNA-protein complex,M1100110000000000110,6,0
1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-8.3,-3.1,-2.3,0,-5.4,0,0,0,0,0,0,0,0,0,0,0,-5.1,-2.2,0,GO:0007167,enzyme-linked receptor protein signaling pathway,M1110100000000000110,6,0
0,0,1,0,0,1,0,1,0,1,0,0,0,0,0,0,0,1,1,0,0,-2.5,0,0,-2.5,0,-2,0,-2.7,0,0,0,0,0,0,0,-2.7,-2.1,R-HSA-9013423,RAC3 GTPase cycle,M0010010101000000011,6,0
1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.2,-3.7,0,0,-3.2,-3.9,0,0,0,0,0,0,0,0,0,0,-2.5,-4.1,0,CORUM:2695,ETS2-FOS-JUN complex,M1100110000000000110,6,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.4,0,0,-3.5,-3.3,-2.2,0,0,0,0,0,0,0,0,0,0,-5.5,-3.1,0,hsa05321,Inflammatory bowel disease,M1001110000000000110,6,0
0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,-2.3,-3.2,-2.5,0,-2.3,0,0,0,0,0,0,0,0,0,0,-3.4,0,-3,GO:0034341,response to type II interferon,M0111010000000000101,6,0
1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.7,0,-2.3,-5,-3.6,-2.3,0,0,0,0,0,0,0,0,0,0,-5.8,0,0,GO:0071560,cellular response to transforming growth factor beta stimulus,M1011110000000000100,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-4.4,-2.4,0,-9.7,-5.6,0,0,0,0,0,0,0,0,0,-2.4,0,-3.4,0,0,GO:0001525,angiogenesis,M1101100000000010100,6,0
1,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,1,-3.1,-3.6,-2.8,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,-3,0,-2.8,GO:0006897,endocytosis,M1110000000100000101,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-7.9,-2.9,0,-13,-7.6,0,0,0,0,0,0,0,0,0,-2.9,0,-5.4,0,0,GO:0001568,blood vessel development,M1101100000000010100,6,0
0,1,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,-2.1,0,-2.5,0,0,0,0,0,-2.3,-4.5,0,0,0,0,0,-2.5,0,-2.5,GO:0045055,regulated exocytosis,M0101000001100000101,6,0
1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,-3.7,0,-3.6,-4.8,0,0,0,-2.2,0,0,0,0,0,0,0,0,-2.7,0,-3.5,R-HSA-8980692,RHOA GTPase cycle,M1011000100000000101,6,0
0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,1,0,-3.5,0,-3.9,-2.7,0,0,0,0,-3.5,0,0,0,0,0,0,0,-4.5,-2.7,GO:0045088,regulation of innate immune response,M0101100001000000011,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.4,-2.7,0,-3.9,-2,0,0,0,0,0,0,0,0,0,0,0,-3,-4.7,0,hsa05417,Lipid and atherosclerosis,M1101100000000000110,6,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-4.2,0,0,-3.3,-4.1,-2.6,0,0,0,0,0,0,0,0,0,0,-4,-3.7,0,WP5373,Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy,M1001110000000000110,6,0
0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-3.4,-5.7,-5.4,-2.7,0,0,0,0,0,0,0,0,0,0,-8.2,0,-5,GO:0002263,cell activation involved in immune response,M0011110000000000101,6,0
0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,-3.2,-2,-2.1,0,0,-3.6,0,0,0,0,0,0,0,0,-4.8,0,-4.8,GO:2000516,"positive regulation of CD4-positive, alpha-beta T cell activation",M0011100100000000101,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.3,-2.2,0,-3,-2.5,0,0,0,0,0,0,0,0,0,0,0,-4.9,-2.7,0,WP4585,Cancer immunotherapy by PD 1 blockade,M1101100000000000110,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-8,-2.7,0,-12,-7.2,0,0,0,0,0,0,0,0,0,-2.8,0,-5.3,0,0,GO:0001944,vasculature development,M1101100000000010100,6,0
0,1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,-2,-2,-2,0,-3.9,0,0,0,0,0,0,0,0,0,0,-2.6,0,-3.3,hsa05152,Tuberculosis,M0111010000000000101,6,0
1,0,0,1,1,0,0,0,1,0,0,0,0,0,1,0,1,0,0,-4.3,0,0,-5.9,-3.1,0,0,0,-2.1,0,0,0,0,0,-3.9,0,-5.4,0,0,GO:0045444,fat cell differentiation,M1001100010000010100,6,0
0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,-2.8,-5.5,-2.9,0,0,0,0,0,0,0,0,0,0,0,-2.5,-2.7,-4.2,hsa04062,Chemokine signaling pathway,M0011100000000000111,6,0
1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.2,-3.7,0,0,-3.2,-3.9,0,0,0,0,0,0,0,0,0,0,-2.5,-4.1,0,CORUM:2694,ERG-JUN-FOS DNA-protein complex,M1100110000000000110,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.3,-3.3,0,-4.3,-2.3,0,0,0,0,0,0,0,0,0,0,0,-4.1,-2.8,0,M124,PID CXCR4 PATHWAY,M1101100000000000110,6,0
1,0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,-4.3,0,-2.1,-4.5,0,0,-2.4,0,0,0,0,0,0,0,0,0,-3.1,-2.9,0,GO:0042063,gliogenesis,M1011001000000000110,6,0
1,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.4,-3.4,-2.9,0,-2.9,-3.8,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,M1110110000000000010,6,0
1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-2.4,0,-2.4,-3.2,-3.2,0,0,0,0,0,0,0,0,0,0,0,-7.9,0,-3.8,GO:0002822,regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M1011100000000000101,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-10,-2.8,0,-11,-7.8,0,0,0,0,0,0,0,0,0,-2.5,0,-4.6,0,0,GO:0035239,tube morphogenesis,M1101100000000010100,6,0
1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-5.4,-2.5,-2.1,-8.8,0,0,0,0,0,0,0,0,0,0,0,0,-6.7,-3.9,0,hsa05166,Human T-cell leukemia virus 1 infection,M1111000000000000110,6,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,-2.3,0,-3.9,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-7,-2.1,M88,PID CD8 TCR PATHWAY,M1011000000000000111,6,0
0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,1,1,1,0,-3.5,0,0,0,-3.2,0,-2.4,0,0,0,0,0,0,0,0,-2.4,-3.5,-2.6,GO:0071621,granulocyte chemotaxis,M0100010100000000111,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.4,-2.5,0,-4.5,-6.1,0,0,0,0,0,0,0,0,0,0,0,-2.5,-2.4,0,WP3888,VEGFA VEGFR2 signaling,M1101100000000000110,6,0
0,0,1,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,-2.1,-2.3,0,0,0,0,0,-2.9,-2.1,0,0,0,0,0,-2.2,0,-4.9,R-HSA-114604,GPVI-mediated activation cascade,M0011000001100000101,6,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.7,-2.5,0,-6,-5.7,0,0,0,0,0,0,0,0,0,0,0,-4.9,-5.2,0,WP2374,Oncostatin M signaling pathway,M1101100000000000110,6,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.3,0,0,-6.3,-3.3,-3.9,0,0,0,0,0,0,0,0,0,0,-8.7,-2.7,0,GO:0030217,T cell differentiation,M1001110000000000110,6,0
0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-2.5,-2.3,-2.4,0,-2.2,0,0,0,0,0,0,0,0,-4.4,0,-3.3,GO:0030183,B cell differentiation,M0001110100000000101,6,0
0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.4,-5.8,-2.6,-3.3,0,0,0,0,0,0,0,0,0,0,-2.4,0,-4.5,GO:0002237,response to molecule of bacterial origin,M0011110000000000101,6,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,-3.4,0,0,-4.2,-3.6,-2.3,0,0,0,0,0,0,0,0,0,0,-3.9,0,-4.8,GO:0032663,regulation of interleukin-2 production,M1001110000000000101,6,0
1,0,0,1,1,1,0,0,0,1,0,0,0,0,0,0,1,0,0,-2.4,0,0,-7.2,-3.5,-2.9,0,0,0,-3,0,0,0,0,0,0,-3.5,0,0,GO:0050728,negative regulation of inflammatory response,M1001110001000000100,6,0
1,0,1,1,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,-3.4,0,-2.2,-4.1,0,-2.2,0,0,0,0,-3.8,0,0,0,0,0,-2.4,0,0,GO:1904888,cranial skeletal system development,M1011010000100000100,6,0
1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.6,0,-2.2,-6.4,0,-2.9,0,0,0,0,0,0,0,0,0,0,-4.9,-3.2,0,WP560,TGF beta receptor signaling,M1011010000000000110,6,0
1,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-6.7,0,-3.9,-8.5,-6.2,-2.3,0,0,0,0,0,0,0,0,0,0,-5.5,0,0,GO:0071363,cellular response to growth factor stimulus,M1011110000000000100,6,0
1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,1,-2.4,0,0,-5.4,-2.1,0,0,0,0,0,0,-2.3,0,0,0,0,-4.4,0,-2.5,hsa04148,Efferocytosis,M1001100000010000101,6,0
1,0,0,1,1,0,0,0,0,0,0,0,0,1,1,0,1,0,0,-4.5,0,0,-3.2,-3,0,0,0,0,0,0,0,0,-2.3,-2.8,0,-2.6,0,0,GO:0060485,mesenchyme development,M1001100000000110100,6,0
0,0,0,1,1,1,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-2.5,-2.3,-2.4,0,-2.2,0,0,0,0,0,0,0,0,-3.3,0,-2.6,GO:0032649,regulation of type II interferon production,M0001110100000000101,6,0
1,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,1,0,1,-5.1,0,-3.2,-4.3,0,0,0,-4.8,0,0,0,0,0,0,0,0,-4.8,0,-3.1,R-HSA-9013148,CDC42 GTPase cycle,M1011000100000000101,6,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-5.1,0,0,-4.3,-2.6,0,0,0,0,0,0,0,0,0,0,0,-5.5,0,-3.1,GO:0032943,mononuclear cell proliferation,M1001100000000000101,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,-2.9,-4,-2.9,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,WP3892,Development of pulmonary dendritic cells and macrophage subsets,M1001110000000000100,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-7,0,0,-7.5,-4.2,-2.4,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,GO:0140747,regulation of ncRNA transcription,M1001110000000000100,5,0
0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,-2.1,0,-2.9,0,0,0,0,0,0,0,0,0,0,-2.9,-2.1,-2.8,hsa04014,Ras signaling pathway,M0001010000000000111,5,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-5,-2.7,-2.2,0,0,0,0,0,0,0,0,0,0,-3,0,-3.6,GO:0050871,positive regulation of B cell activation,M0001110000000000101,5,0
1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3,-2.3,0,-4.1,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.1,0,WP2018,RANKL RANK signaling pathway,M1101000000000000110,5,0
1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.7,0,-3.1,0,0,-3.8,0,0,0,0,0,0,0,0,0,0,-2.1,-3.3,0,hsa05135,Yersinia infection,M1010010000000000110,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-5.1,-2.4,0,-3.4,-3.7,0,0,0,0,0,0,0,0,0,0,0,-4.4,0,0,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M1101100000000000100,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,-3.3,0,-3.3,-2.6,0,0,0,0,0,0,0,0,0,0,0,-4.5,0,0,hsa04310,Wnt signaling pathway,M1101100000000000100,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.8,0,0,-2.9,-3.6,-2.3,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0045664,regulation of neuron differentiation,M1001110000000000100,5,0
1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,-2.1,-3.4,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.4,-2.1,WP4341,Non genomic actions of 1 25 dihydroxyvitamin D3,M1101000000000000011,5,0
0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.4,-2.1,-3.3,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,-3.9,GO:0007264,small GTPase mediated signal transduction,M0011100000000000101,5,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-4.5,0,0,-3.2,-3.6,0,0,0,0,0,0,0,0,0,-2.8,0,-2.1,0,0,GO:0003007,heart morphogenesis,M1001100000000010100,5,0
0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.1,-5,-2.5,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,-2.4,M22,PID GMCSF PATHWAY,M0011100000000000101,5,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-4.8,0,0,-4.8,-3.2,0,0,0,0,0,0,0,0,0,0,0,-3.2,-2.2,0,GO:1904018,positive regulation of vasculature development,M1001100000000000110,5,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.8,0,-2.7,-4,0,0,0,0,0,0,0,0,0,0,0,0,-5.4,-2.6,0,hsa04218,Cellular senescence,M1011000000000000110,5,0
1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-5.2,0,-2.5,-2.7,-2.8,0,0,0,0,0,0,0,0,0,0,0,-4.3,0,0,GO:0021537,telencephalon development,M1011100000000000100,5,0
1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,-2.1,0,-3,0,0,0,0,0,0,-2.8,-3,0,0,0,0,0,0,0,-2.3,GO:0022030,telencephalon glial cell migration,M1010000001100000001,5,0
0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.6,0,0,-3.6,-2.1,0,0,0,0,0,0,0,0,0,0,-2.8,-5.4,0,GO:0045648,positive regulation of erythrocyte differentiation,M0100110000000000110,5,0
1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,-3,0,-3,0,-3.1,0,0,0,0,0,0,0,0,0,0,-4.5,0,0,GO:0002262,myeloid cell homeostasis,M1101010000000000100,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.8,-2.1,0,-5.5,-2.4,0,0,0,0,0,0,0,0,0,0,0,-6.8,0,0,M290,PID IL12 STAT4 PATHWAY,M1101100000000000100,5,0
1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,-3.2,0,0,-3.1,-2.5,0,0,0,0,0,0,-3.1,0,0,0,0,-3,0,0,GO:0001892,embryonic placenta development,M1001100000010000100,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.6,0,0,-4.8,-3.6,-3.1,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,WP4879,Overlap between signal transduction pathways contributing to LMNA laminopathies,M1001110000000000100,5,0
0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-3.2,-3.5,-3.1,0,0,0,0,0,0,0,0,0,0,0,-4.9,0,-3.2,GO:0002285,lymphocyte activation involved in immune response,M0011100000000000101,5,0
1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,-3.2,0,0,-2.2,0,0,0,0,0,-2.3,0,0,0,0,0,0,-2.7,0,-2.7,GO:0046640,regulation of alpha-beta T cell proliferation,M1001000001000000101,5,0
0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,1,0,0,-2.2,-2.6,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,-3.9,-2.2,0,R-HSA-9679506,SARS-CoV Infections,M0110000001000000110,5,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-3.9,-2.1,-3.3,0,0,0,0,0,0,0,0,0,0,-5.7,-3.6,0,WP5198,Inflammatory bowel disease signaling,M0001110000000000110,5,0
1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,-2.8,0,0,-2.6,0,0,0,0,0,-3,0,0,0,0,0,0,-2,0,-6.9,hsa04611,Platelet activation,M1001000001000000101,5,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,-2.6,0,-2.2,-3.8,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4540,Hippo signaling regulation pathways,M1101110000000000000,5,0
1,0,1,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,-6.9,0,-2.5,0,-2.7,0,0,0,-2.5,0,0,0,0,0,0,0,-2.6,0,0,GO:0048562,embryonic organ morphogenesis,M1010100010000000100,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-4,0,0,-4.2,-4,-2,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,WP5115,Network map of SARS CoV 2 signaling pathway,M1001110000000000100,5,0
0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-3.1,0,-4,-4.2,-2.4,0,0,0,0,0,0,0,0,0,0,-3,0,0,GO:0042330,taxis,M0101110000000000100,5,0
1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2,-2.1,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,-2.8,0,hsa04657,IL-17 signaling pathway,M1101000000000000110,5,0
0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,-2.1,-2,-2.5,0,0,0,0,0,0,-2,0,0,0,0,0,-2.5,0,0,GO:0048704,embryonic skeletal system morphogenesis,M0111000000100000100,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.7,-3.1,0,-2.6,-2.2,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0032330,regulation of chondrocyte differentiation,M1101100000000000100,5,0
1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,-2.2,-4.3,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-5.1,hsa04666,Fc gamma R-mediated phagocytosis,M1101000000000000011,5,0
0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,-6.3,-2.6,0,0,0,0,0,-2.6,0,0,0,0,0,-8.1,-2.4,0,GO:0002443,leukocyte mediated immunity,M0001100000100000110,5,0
0,0,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,-5.1,-2.9,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,GO:0032496,response to lipopolysaccharide,M0011110000000000001,5,0
1,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,-2.3,0,0,-2.1,0,0,0,-3.6,0,0,0,0,0,0,0,0,-6.4,-2.2,0,GO:0002706,regulation of lymphocyte mediated immunity,M1001000100000000110,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-6.4,-2.1,0,-4.2,-2.6,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,GO:0001654,eye development,M1101100000000000100,5,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-6.7,0,0,-5.4,-4.3,0,0,0,0,0,0,0,0,0,0,0,-3.7,-2.8,0,GO:2000630,positive regulation of miRNA metabolic process,M1001100000000000110,5,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,1,-3.3,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.1,-4,R-HSA-5607764,CLEC7A (Dectin-1) signaling,M1000100000000000111,5,0
0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.4,-2.1,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,-2.8,0,R-HSA-877300,Interferon gamma signaling,M0111000000000000110,5,0
0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-4.2,0,-3.8,-4.3,-3.3,0,0,0,0,0,0,0,0,0,0,-4.9,0,0,GO:0060326,cell chemotaxis,M0101110000000000100,5,0
1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.7,-2.6,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2.5,0,hsa04010,MAPK signaling pathway,M1100100000000000110,5,0
0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,-2.7,-3.4,0,0,0,0,-3.3,-2.1,0,0,0,0,0,0,0,-3.4,GO:0045089,positive regulation of innate immune response,M0001100001100000001,5,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,-4.5,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.2,-3,-3.2,GO:0010562,positive regulation of phosphorus metabolic process,M1100000000000000111,5,0
1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,1,0,0,-2.8,0,0,-2.3,0,0,0,0,0,0,0,0,0,-2,-3.2,0,-3,0,0,GO:0048762,mesenchymal cell differentiation,M1001000000000110100,5,0
0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,-2,0,-3,-3.3,0,0,0,0,-3.8,0,0,0,0,0,0,0,0,-3.1,GO:0002833,positive regulation of response to biotic stimulus,M0101100001000000001,5,0
1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,-3.5,0,-3.6,0,-4.2,0,0,0,0,0,0,0,0,0,0,-5.1,0,0,GO:0034101,erythrocyte homeostasis,M1101010000000000100,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.8,-2.3,0,-3.8,-2.1,0,0,0,0,0,0,0,0,0,0,0,-4,0,0,WP2877,Vitamin D receptor pathway,M1101100000000000100,5,0
1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.3,-2.7,0,0,-3.6,-3,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,GO:0043378,"positive regulation of CD8-positive, alpha-beta T cell differentiation",M1100110000000000010,5,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-5.1,0,0,-4.3,-2.6,0,0,0,0,0,0,0,0,0,0,0,-5.5,0,-3.1,GO:0046651,lymphocyte proliferation,M1001100000000000101,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,-3.3,-2.6,-2.3,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:2000629,negative regulation of miRNA metabolic process,M1001110000000000100,5,0
0,0,1,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.7,-4.2,-2.1,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,-2.2,R-HSA-416482,G alpha (12/13) signalling events,M0011100100000000001,5,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,-3.4,0,0,-6.2,0,0,0,0,0,0,0,0,0,0,0,0,-4.9,-2.3,-2,hsa04630,JAK-STAT signaling pathway,M1001000000000000111,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-7.7,-2.4,0,-7.2,-2.5,0,0,0,0,0,0,0,0,0,-4.1,0,0,0,0,GO:0048844,artery morphogenesis,M1101100000000010000,5,0
1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,-2.1,0,-3,0,0,0,0,0,0,-2.8,-3,0,0,0,0,0,0,0,-2.3,GO:0021801,cerebral cortex radial glia-guided migration,M1010000001100000001,5,0
1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,-3.2,0,0,-6.8,-4.6,0,0,0,0,0,0,-4,0,0,0,0,-3.8,0,0,WP236,Adipogenesis,M1001100000010000100,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,-3.3,-2.6,-2.3,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:1902894,negative regulation of miRNA transcription,M1001110000000000100,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.9,0,0,-10,-2.7,-3.4,0,0,0,0,0,0,0,0,0,0,-4,0,0,WP4149,White fat cell differentiation,M1001110000000000100,5,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,-2.5,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,-2.6,-2.3,GO:0071248,cellular response to metal ion,M1010000000000000111,5,0
0,0,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,-3.2,-2.8,0,0,0,0,-2.9,-2.1,0,0,0,0,0,0,0,-4.2,GO:0002218,activation of innate immune response,M0001100001100000001,5,0
1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.1,0,-3,-2.9,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,GO:0071219,cellular response to molecule of bacterial origin,M1011010000000000001,5,0
0,1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2,-2.7,0,-2.6,-2.3,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,R-HSA-4641265,Repression of WNT target genes,M0110110000000000100,5,0
1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,-3.4,0,0,-4.1,0,0,0,0,-2.4,0,0,0,0,0,-3.3,0,-2.4,0,0,GO:0048839,inner ear development,M1001000010000010100,5,0
0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,-3,-3.5,0,0,0,0,0,-2.7,0,0,0,0,0,-4.2,0,-3.2,GO:0002275,myeloid cell activation involved in immune response,M0001100000100000101,5,0
0,0,0,1,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,-5.5,-2.7,0,-2.7,0,0,-2.1,0,0,0,0,0,0,-5.1,0,0,GO:0030335,positive regulation of cell migration,M0001101001000000100,5,0
0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,-2.4,-2.2,-2.6,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,-3.7,R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,M0111000000100000001,5,0
0,0,1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.6,0,-2.1,0,0,-3.2,0,0,0,0,0,0,0,0,0,-2.1,-2.2,R-HSA-9013404,RAC2 GTPase cycle,M0010100100000000011,5,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.3,0,0,-3.9,-3.9,0,0,0,0,0,0,0,0,0,-3.1,0,-2.5,0,0,GO:0050679,positive regulation of epithelial cell proliferation,M1001100000000010100,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-7.4,0,0,-7.3,-4.4,-2.5,0,0,0,0,0,0,0,0,0,0,-4.8,0,0,GO:1902893,regulation of miRNA transcription,M1001110000000000100,5,0
0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,1,0,0,-2.6,0,0,0,0,-4,0,0,0,0,0,0,0,0,-4.2,-2.2,-3,GO:0043372,"positive regulation of CD4-positive, alpha-beta T cell differentiation",M0010000100000000111,5,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,-2.5,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,-2.9,-2.5,hsa04625,C-type lectin receptor signaling pathway,M1001000000000000111,5,0
1,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,1,-3.3,0,0,0,-2.2,0,0,0,0,-2.7,0,0,0,0,0,0,-2.5,0,-2.2,GO:0043304,regulation of mast cell degranulation,M1000100001000000101,5,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-3.6,0,0,-2.2,-2.7,0,0,0,0,0,0,0,0,0,0,0,-2,0,-4.6,R-HSA-5621481,C-type lectin receptors (CLRs),M1001100000000000101,5,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.5,0,0,-4.8,-4,0,0,0,0,0,0,0,0,0,0,0,-3.4,-2.1,0,R-HSA-157118,Signaling by NOTCH,M1001100000000000110,5,0
1,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.7,0,-2.4,-2.6,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05224,Breast cancer,M1101110000000000000,5,0
0,0,0,0,1,1,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,-2.5,-2,0,0,0,-2.4,0,0,0,0,0,0,-3.8,0,-3.4,GO:0032722,positive regulation of chemokine production,M0000110001000000101,5,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-2.3,-2.7,-2.1,0,0,0,0,0,0,0,0,0,0,-2.4,0,-2.8,hsa04072,Phospholipase D signaling pathway,M0001110000000000101,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-4,0,0,-4.5,-4.3,-3.9,0,0,0,0,0,0,0,0,0,0,-5.1,0,0,WP4844,Influence of laminopathies on Wnt signaling,M1001110000000000100,5,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-5,0,0,-4.5,-4.6,0,0,0,0,0,0,0,0,0,0,0,-4.2,-2.6,0,GO:0002064,epithelial cell development,M1001100000000000110,5,0
0,0,1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,1,0,0,-2.5,0,0,-3.6,0,0,0,0,0,-2.1,0,0,0,0,0,-3.2,-3.8,WP4223,Ras signaling,M0010010000010000011,5,0
1,1,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,-5.8,-2.9,-3.9,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030036,actin cytoskeleton organization,M1111100000000000000,5,0
1,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,-2.6,-2.6,0,0,0,-2.2,0,0,0,-2.9,0,0,0,0,0,0,0,-3.1,0,GO:0051051,negative regulation of transport,M1100010001000000010,5,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.7,0,0,-5.8,-5,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2.3,0,GO:0045765,regulation of angiogenesis,M1001100000000000110,5,0
0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,-2.1,0,0,0,0,0,-5.3,-2.8,0,0,0,0,0,-2.3,0,-3.2,GO:0002861,regulation of inflammatory response to antigenic stimulus,M0001000001100000101,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.7,0,0,-4.5,-2.2,-3.1,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,GO:0061351,neural precursor cell proliferation,M1001110000000000100,5,0
0,0,0,1,1,0,0,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-2.1,-2.6,0,0,-2.3,0,0,0,0,0,0,0,0,-5.1,0,-2.5,GO:0045622,regulation of T-helper cell differentiation,M0001100100000000101,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.9,-3.1,0,-4.6,-2,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:1902903,regulation of supramolecular fiber organization,M1101100000000000100,5,0
0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,-2.5,-2.4,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,-6.1,-3.4,0,GO:0001910,regulation of leukocyte mediated cytotoxicity,M0110000100000000110,5,0
1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,-3.8,0,-3.7,0,-4.5,0,0,0,0,0,0,0,0,0,0,-4.3,0,0,GO:0030218,erythrocyte differentiation,M1101010000000000100,5,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,-2.4,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,-2.4,-2.1,GO:0071241,cellular response to inorganic substance,M1010000000000000111,5,0
1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.3,0,-2.4,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,-3,-2.9,0,R-HSA-8878171,Transcriptional regulation by RUNX1,M1010100000000000110,5,0
0,0,1,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,-4.2,-2.7,-2.4,0,0,0,0,-4.1,0,0,0,0,0,0,0,0,-2.3,R-HSA-2172127,DAP12 interactions,M0011100001000000001,5,0
1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.6,0,0,-2.7,0,-2.3,0,0,0,0,0,0,0,0,0,0,-2.3,-6.4,0,WP5072,Modulators of TCR signaling and T cell activation,M1001010000000000110,5,0
0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,1,0,-2.7,0,0,0,-3.2,0,-2.4,0,0,0,0,0,0,0,0,0,-3.5,-2.6,GO:1990266,neutrophil migration,M0100010100000000011,5,0
0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-3.1,0,-4,-4.2,-2.4,0,0,0,0,0,0,0,0,0,0,-3,0,0,GO:0006935,chemotaxis,M0101110000000000100,5,0
1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.1,-3.2,0,-4.5,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,-3.5,0,hsa05169,Epstein-Barr virus infection,M1101000000000000110,5,0
1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,-2.1,0,0,0,0,0,0,0,0,-2.5,-2.7,0,0,0,0,0,-2.8,0,-2,GO:0032753,positive regulation of interleukin-4 production,M1000000001100000101,5,0
0,0,0,1,0,1,0,0,0,0,1,0,0,0,0,0,1,1,0,0,0,0,-2.9,0,-2.4,0,0,0,0,-2.2,0,0,0,0,0,-3.1,-2.6,0,GO:0002444,myeloid leukocyte mediated immunity,M0001010000100000110,5,0
0,1,0,1,1,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,-2.8,0,-3.1,-2.2,0,0,0,0,-4,-2.9,0,0,0,0,0,0,0,0,GO:0046456,icosanoid biosynthetic process,M0101100001100000000,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-3.7,-2.4,0,-2.3,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,WP382,MAPK signaling pathway,M1101100000000000010,5,0
1,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-6.4,0,0,-5.9,-4.2,-2.2,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,GO:1902895,positive regulation of miRNA transcription,M1001110000000000100,5,0
0,1,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,-2.2,-3.2,-3,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,-3.6,R-HSA-9674555,Signaling by CSF3 (G-CSF),M0111000000100000001,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.6,-2.7,0,-2.4,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,WP399,Wnt signaling pathway and pluripotency,M1101100000000000010,5,0
0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-3,-2.8,-4.6,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,-5.8,0,hsa05170,Human immunodeficiency virus 1 infection,M0111000000000000110,5,0
0,1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.9,0,-4.3,-3.8,-2.6,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0040011,locomotion,M0101110000000000100,5,0
0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,-2.2,-2.2,0,0,0,0,0,-2.8,0,0,0,0,0,0,-2.4,0,-2.8,GO:0120032,regulation of plasma membrane bounded cell projection assembly,M0011000001000000101,5,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.8,0,0,-6.2,-4.8,0,0,0,0,0,0,0,0,0,0,0,-2.7,-2.2,0,GO:1901342,regulation of vasculature development,M1001100000000000110,5,0
1,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,-2.6,-3.4,0,0,0,0,0,0,0,-2.1,-2.1,0,0,0,0,0,0,0,-3.5,GO:0051651,maintenance of location in cell,M1100000001100000001,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.3,-2.7,0,-2.5,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,GO:0046643,regulation of gamma-delta T cell activation,M1101100000000000010,5,0
1,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-6.4,0,-2.9,0,-3.1,0,0,0,0,0,0,0,0,0,-2.4,0,-5.2,0,0,GO:0030900,forebrain development,M1010100000000010100,5,0
1,1,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2.9,-2.2,-2.6,-2.8,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9679191,Potential therapeutics for SARS,M1111000100000000000,5,0
0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,-2.2,-2.2,0,0,0,0,0,-2.8,0,0,0,0,0,0,-2.4,0,-2.8,GO:0060491,regulation of cell projection assembly,M0011000001000000101,5,0
0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-4.9,0,-2.3,0,-4.7,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2.4,GO:0061515,myeloid cell development,M0101010000000000011,5,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-4.7,0,0,-4.4,-3.4,0,0,0,0,0,0,0,0,0,0,0,-2.7,-2.3,0,GO:0045766,positive regulation of angiogenesis,M1001100000000000110,5,0
0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,0,0,-2.1,-3.9,0,0,0,0,0,-2.4,0,0,0,0,0,0,-2.8,0,-3.5,GO:0002720,positive regulation of cytokine production involved in immune response,M0011000001000000101,5,0
1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.5,0,-2.7,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,-3.9,-2,0,GO:0071417,cellular response to organonitrogen compound,M1010100000000000110,5,0
1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,1,-2.6,-2.8,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,-2.1,0,0,-2.5,GO:0051235,maintenance of location,M1100000000000101001,5,0
1,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,-3.1,-3.1,0,-2.4,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,GO:0046645,positive regulation of gamma-delta T cell activation,M1101010000000000010,5,0
1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2,0,-2.3,-2.2,0,-2.6,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:0002052,positive regulation of neuroblast proliferation,M1011010000000000100,5,0
1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.3,0,0,0,-4.7,-2.8,0,0,0,0,0,0,0,0,0,0,-3.8,-3,0,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M1000110000000000110,5,0
0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.6,-2,0,-2.1,0,0,0,0,0,0,0,0,0,0,-2.3,0,-2.9,GO:0002827,positive regulation of T-helper 1 type immune response,M0011010000000000101,5,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,-4.5,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.2,-3,-3.2,GO:0045937,positive regulation of phosphate metabolic process,M1100000000000000111,5,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.4,-2.2,0,-4,-3.7,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M1101100000000000100,5,0
1,1,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,-2.1,-2.2,0,-2.6,0,0,0,0,0,-3.4,0,0,0,0,0,0,-2.1,0,0,hsa05203,Viral carcinogenesis,M1101000001000000100,5,0
0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.1,0,-2.5,0,-2.6,0,0,0,0,0,0,0,0,0,0,-2.1,-2.2,0,hsa04613,Neutrophil extracellular trap formation,M0101010000000000110,5,0
1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,1,-3.4,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,-4.9,0,-3.2,GO:0001934,positive regulation of protein phosphorylation,M1000000001000000101,4,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.1,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,-2.4,0,WP3612,Photodynamic therapy induced NFE2L2 NRF2 survival signaling,M1100000000000000110,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-3.7,0,0,-3.6,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,GO:0018212,peptidyl-tyrosine modification,M1001100000000000001,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.5,0,0,-2.3,-3,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0021954,central nervous system neuron development,M1001100000000000100,4,0
1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,-3.3,0,0,0,-3.1,-2.3,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,WP4205,MET in type 1 papillary renal cell carcinoma,M1000110000000000010,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.7,0,0,-5,-3,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,GO:0071772,response to BMP,M1001100000000000100,4,0
1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,1,0,-2.5,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,-2.5,-2.2,0,hsa04066,HIF-1 signaling pathway,M1000000000010000110,4,0
1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-4.3,-2.8,-4.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,GO:0098657,import into cell,M1110000000000000001,4,0
0,1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.1,-2.5,0,0,-5.1,0,0,0,0,0,0,0,0,0,0,0,0,-4,GO:0042116,macrophage activation,M0110010000000000001,4,0
1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-3,-2.3,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-4,0,WP2873,Aryl hydrocarbon receptor pathway,M1100100000000000010,4,0
0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.3,-2.7,-3.3,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,R-HSA-166520,Signaling by NTRKs,M0011100000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.1,0,0,-2.6,-4.8,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0001936,regulation of endothelial cell proliferation,M1001100000000000100,4,0
1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-5.3,0,-2,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,GO:0060322,head development,M1010100000000000100,4,0
0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,-2.4,0,-4.2,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,WP481,Insulin signaling,M0110100000000000010,4,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-5.2,0,0,0,-4.1,0,0,0,0,0,0,0,0,0,-3,0,-3.3,0,0,GO:0030855,epithelial cell differentiation,M1000100000000010100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.7,0,0,-2.8,-3.1,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M1001100000000000100,4,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,-6,-4.8,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,-2.6,R-HSA-388396,GPCR downstream signalling,M0001100000000000011,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-3.8,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,-2.1,GO:0097028,dendritic cell differentiation,M1001000000000000101,4,0
0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.6,-2.8,-3.8,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,R-HSA-187037,Signaling by NTRK1 (TRKA),M0011100000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.7,0,0,-5,-3,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,GO:0071773,cellular response to BMP stimulus,M1001100000000000100,4,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,-2.1,-2.7,0,0,0,0,0,0,0,0,0,0,-2.3,-2.2,0,GO:0043030,regulation of macrophage activation,M0000110000000000110,4,0
1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,-2.7,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,WP3,Transcriptional activation by NRF2 in response to phytochemicals,M1100100000000000100,4,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.9,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,-6.3,-2.9,0,GO:0002763,positive regulation of myeloid leukocyte differentiation,M0101000000000000110,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.1,0,0,-2.5,-2.4,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,WP3995,Prion disease pathway,M1001100000000000100,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-4.4,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,-4.3,GO:0032743,positive regulation of interleukin-2 production,M1001000000000000101,4,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-3.9,-2.1,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,GO:0045577,regulation of B cell differentiation,M0001110000000000001,4,0
0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,-2.1,0,0,0,0,0,-2.2,0,0,0,0,0,-2,0,-2.7,GO:0032945,negative regulation of mononuclear cell proliferation,M0000100000100000101,4,0
0,0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.6,0,-2.4,-2.1,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,M206,PID PDGFRA PATHWAY,M0010110000000000010,4,0
1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.9,0,0,-2.8,0,-2.1,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0007405,neuroblast proliferation,M1001010000000000100,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.9,0,0,-5.6,0,0,0,0,0,0,0,0,0,0,0,0,-5.4,-3.6,0,WP5130,Th17 cell differentiation pathway,M1001000000000000110,4,0
1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,-2.8,0,0,-3.6,-2,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,GO:0003018,vascular process in circulatory system,M1001100000010000000,4,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,-2.2,-3,0,0,0,0,0,0,0,0,0,0,-2.9,-2.1,0,M175,PID ERBB2 ERBB3 PATHWAY,M0000110000000000110,4,0
1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.4,0,0,-4,0,-2.1,0,0,0,0,0,0,0,0,0,0,-5.1,0,0,GO:0048469,cell maturation,M1001010000000000100,4,0
1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,-3.5,0,-2.2,0,0,0,0,0,0,-2.1,-2.2,0,0,0,0,0,0,0,0,GO:0021795,cerebral cortex cell migration,M1010000001100000000,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.7,0,0,-4.9,-2.1,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,WP4331,Neovascularisation processes,M1001100000000000100,4,0
1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-3,0,0,-3.4,0,-2.8,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:0050680,negative regulation of epithelial cell proliferation,M1001010000000000100,4,0
1,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,-4.4,-2,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050878,regulation of body fluid levels,M1001101000000000000,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-6,0,0,-7.1,-2.2,0,0,0,0,0,0,0,0,0,0,0,-6.3,0,0,GO:0045596,negative regulation of cell differentiation,M1001100000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,-4.9,0,0,-4,-3.8,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,GO:0001701,in utero embryonic development,M1001100000010000000,4,0
0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-3.5,0,-2.1,0,0,0,0,0,0,0,0,0,0,-2.2,-2.3,0,WP2858,Ectoderm differentiation,M0001010000000000110,4,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.4,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-3.2,0,R-HSA-913531,Interferon Signaling,M0101000000000000110,4,0
1,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,-2.6,0,-2.6,0,0,0,0,0,0,-2.5,-2.6,0,0,0,0,0,0,0,0,GO:0021799,cerebral cortex radially oriented cell migration,M1010000001100000000,4,0
0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,-2.2,-2.1,0,0,0,0,-3,0,0,0,0,0,0,0,-2.1,R-HSA-166058,MyD88:MAL(TIRAP) cascade initiated on plasma membrane,M0000110000100000001,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-3,-2.7,0,WP2324,AGE RAGE pathway,M1001000000000000110,4,0
0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-3,0,-2.2,-2,0,0,0,0,0,0,0,0,0,0,0,-6,0,0,R-HSA-198933,Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell,M0101100000000000100,4,0
0,0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.5,0,0,-2,0,0,0,0,0,0,0,0,0,-2.7,-2.1,R-HSA-194138,Signaling by VEGF,M0000100100000000011,4,0
0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,-2.9,0,0,0,0,0,0,-2.7,-2.9,0,0,0,0,0,0,0,-3.3,GO:1902991,regulation of amyloid precursor protein catabolic process,M0010000001100000001,4,0
1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-3.4,-2.4,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,M63,PID AVB3 OPN PATHWAY,M1100100000000000010,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.6,0,0,-4.5,-2.5,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0001503,ossification,M1001100000000000100,4,0
1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-5.7,-3.2,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,WP2064,Neural crest differentiation,M1101000000000000100,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,-2.9,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,-5,GO:0030100,regulation of endocytosis,M1001000000000000011,4,0
0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.7,0,-2.5,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,WP1528,Physiological and pathological hypertrophy of the heart,M0101100000000000010,4,0
1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.7,-3.1,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,WP428,Wnt signaling,M1101000000000000100,4,0
0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,-2.2,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,-2.7,-2.1,0,GO:0002707,negative regulation of lymphocyte mediated immunity,M0100000100000000110,4,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.4,-2.2,-2.3,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0002448,mast cell mediated immunity,M0001110000000000100,4,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,-2.1,-2.7,GO:0060142,regulation of syncytium formation by plasma membrane fusion,M0010000000000000111,4,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,-3.4,0,-5.6,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032956,regulation of actin cytoskeleton organization,M1101100000000000000,4,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,-2.4,-3.7,GO:0032479,regulation of type I interferon production,M0001000000000000111,4,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.2,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,-3.1,0,hsa05145,Toxoplasmosis,M0101000000000000110,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.4,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,-4.8,-3.3,0,hsa04936,Alcoholic liver disease,M1001000000000000110,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-3.7,0,0,-3.6,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,GO:0018108,peptidyl-tyrosine phosphorylation,M1001100000000000001,4,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.7,-2.6,-3.8,GO:0042327,positive regulation of phosphorylation,M0100000000000000111,4,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.8,-2.7,0,0,0,0,0,0,0,0,0,0,0,-2.7,-2.1,0,GO:0021872,forebrain generation of neurons,M0001100000000000110,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,-2.4,-2.6,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0002381,immunoglobulin production involved in immunoglobulin-mediated immune response,M1001100000000000100,4,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.4,-2.6,-2.3,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,WP3630,NAD metabolism sirtuins and aging,M0001110000000000100,4,0
0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,-4,-2.1,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,-4.8,GO:0002758,innate immune response-activating signaling pathway,M0001100001000000001,4,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-3.2,-2.1,0,0,0,0,0,0,0,0,0,0,0,-2,-2.4,0,hsa04935,"Growth hormone synthesis, secretion and action",M0001100000000000110,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.5,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-2,-2.3,0,M5493,WNT SIGNALING,M1001000000000000110,4,0
0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.1,0,-2.1,0,0,0,0,0,0,0,0,0,0,-2.4,-2.3,0,hsa05133,Pertussis,M0001010000000000110,4,0
1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,-3.8,0,0,-2.8,0,0,0,0,0,0,0,0,-2.3,0,0,0,-2.3,0,0,GO:0044409,entry into host,M1001000000001000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.8,0,0,-3.1,-2.4,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,GO:0010634,positive regulation of epithelial cell migration,M1001100000000000100,4,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.3,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,-3.2,0,WP2435,Quercetin and Nf kB AP 1 induced apoptosis,M1100000000000000110,4,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.9,-3.1,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,GO:0019722,calcium-mediated signaling,M0001110000000000001,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.4,0,0,-2.6,-3.3,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,WP4239,Epithelial to mesenchymal transition in colorectal cancer,M1001100000000010000,4,0
0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-3.7,-2.4,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,GO:0008360,regulation of cell shape,M0111000000000000100,4,0
0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,-2.1,0,-3.1,0,0,0,0,0,0,-2.8,0,-2.1,GO:0002685,regulation of leukocyte migration,M0000000101000000101,4,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-6.7,-4.8,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,-2.3,R-HSA-372790,Signaling by GPCR,M0001100000000000101,4,0
0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,-2.2,-2.1,0,0,0,0,-3,0,0,0,0,0,0,0,-2.1,R-HSA-181438,Toll Like Receptor 2 (TLR2) Cascade,M0000110000100000001,4,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-4.9,-2.2,-2.3,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,M122,PID IL2 1PATHWAY,M0001110000000000010,4,0
1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4,0,-2.2,-2.1,-5.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035050,embryonic heart tube development,M1011100000000000000,4,0
0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.8,0,-2.2,0,0,0,0,0,0,0,0,0,0,-2.3,-3.3,0,WP585,Interferon type I signaling pathways,M0001010000000000110,4,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,-2,-2.7,0,0,0,0,0,0,0,0,0,0,-2.3,-4.3,0,M190,PID TCR JNK PATHWAY,M0000110000000000110,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.4,0,0,-3.6,-2.8,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,GO:0042060,wound healing,M1001100000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,-3.9,-2.5,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0035306,positive regulation of dephosphorylation,M1001100000000000100,4,0
0,1,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,1,0,0,-3.6,0,0,0,-2.1,0,0,0,-3.4,0,0,0,0,0,0,0,-3.8,0,GO:0045824,negative regulation of innate immune response,M0100010001000000010,4,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2,-3.4,-2.1,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,GO:0097154,GABAergic neuron differentiation,M0001110000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.8,0,0,-5.5,-2.8,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,WP2840,Hair follicle development cytodifferentiation part 3 of 3,M1001100000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.7,0,0,-2.6,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,WP289,Myometrial relaxation and contraction pathways,M1001100000000000010,4,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-3.7,-3.2,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,-2.4,M28,PID IL4 2PATHWAY,M0001100000000000101,4,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.5,0,-4.5,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,-3.1,0,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M0101000000000000110,4,0
0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,-2.2,-2,0,0,0,0,0,-2.5,0,0,0,0,0,-2,0,0,R-HSA-975155,MyD88 dependent cascade initiated on endosome,M0001100000100000100,4,0
0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,-2.9,-2.5,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,GO:0043376,"regulation of CD8-positive, alpha-beta T cell differentiation",M0100110000000000010,4,0
1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3,0,-2.3,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,hsa05225,Hepatocellular carcinoma,M1010100000000000100,4,0
0,0,0,0,1,0,1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.7,0,-2.7,0,0,-2,0,0,0,0,0,0,-4.9,0,0,GO:2000147,positive regulation of cell motility,M0000101001000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3.4,0,0,-2.4,-3.9,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,GO:0003206,cardiac chamber morphogenesis,M1001100000000010000,4,0
1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,-2.6,0,0,0,-2.6,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,-2,GO:0044089,positive regulation of cellular component biogenesis,M1000101000000000001,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.5,0,0,-4.9,-2.6,0,0,0,0,0,0,0,0,0,0,0,-4.8,0,0,GO:0009611,response to wounding,M1001100000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-6.7,0,0,-5.2,-2.4,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,GO:0010594,regulation of endothelial cell migration,M1001100000000000100,4,0
1,0,0,1,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,-2.7,0,0,-3.4,0,0,0,0,-3,0,0,0,0,0,-3.1,0,0,0,0,GO:0043583,ear development,M1001000010000010000,4,0
1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.1,0,0,-2.4,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,M1100110000000000000,4,0
0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.9,0,-2.3,-2.1,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,R-HSA-9031628,NGF-stimulated transcription,M0101100000000000100,4,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-3.4,-2.2,0,0,0,0,0,0,0,0,0,0,0,-5.1,-3.2,0,WP5422,IL 19 signaling pathway map,M0001100000000000110,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3.3,0,0,-2.1,-3.1,0,0,0,0,0,0,0,0,0,-3.9,0,0,0,0,GO:0060411,cardiac septum morphogenesis,M1001100000000010000,4,0
1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-7,-2.1,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,GO:0043010,camera-type eye development,M1100100000000000100,4,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.4,0,-2.2,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,-5.4,0,0,GO:0002705,positive regulation of leukocyte mediated immunity,M1011000000000000100,4,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-5.2,-2.2,0,0,0,0,0,0,0,0,0,0,0,-4.4,-2.3,0,WP3646,Hepatitis C and hepatocellular carcinoma,M0001100000000000110,4,0
0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,-2.2,-2.1,0,0,0,0,-3,0,0,0,0,0,0,0,-2.1,R-HSA-168179,Toll Like Receptor TLR1:TLR2 Cascade,M0000110000100000001,4,0
0,0,0,1,1,0,0,0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,-4.9,-2.3,0,0,0,0,0,0,-2,0,0,0,0,-2.6,0,0,WP3932,Focal adhesion PI3K Akt mTOR signaling pathway,M0001100000010000100,4,0
0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,-3.2,0,-2.4,-2,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,GO:0060759,regulation of response to cytokine stimulus,M0101100001000000000,4,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.5,-2.5,0,0,0,0,0,0,0,0,0,0,0,-3.9,-2.5,0,WP710,DNA damage response only ATM dependent,M0001100000000000110,4,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,-3.4,-2.6,0,0,0,0,0,0,0,0,0,-2.7,0,-2.1,0,0,GO:0048638,regulation of developmental growth,M0001100000000010100,4,0
1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,-3.8,0,0,-2.8,0,0,0,0,0,0,0,0,-2.3,0,0,0,-2.3,0,0,GO:0046718,viral entry into host cell,M1001000000001000100,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-3.5,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,-7.2,-4.6,0,WP5098,T cell activation SARS CoV 2,M1001000000000000110,4,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.8,0,-2.4,-6,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,GO:0048705,skeletal system morphogenesis,M1011000000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3.3,0,0,-4.3,-5,0,0,0,0,0,0,0,0,0,-3.9,0,0,0,0,GO:0003151,outflow tract morphogenesis,M1001100000000010000,4,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.2,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,-2.4,-3.1,0,R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,M1000100000000000110,4,0
0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,1,0,0,0,0,-2.1,0,0,0,0,0,-2.2,0,0,0,0,0,-2,0,-2.7,GO:0050672,negative regulation of lymphocyte proliferation,M0000100000100000101,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-3.5,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,-4,0,-3.1,GO:0042098,T cell proliferation,M1001000000000000101,4,0
1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.5,0,-3.3,0,-2,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,GO:0043434,response to peptide hormone,M1010100000000000100,4,0
1,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.8,0,-2.1,-3.3,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072132,mesenchyme morphogenesis,M1011100000000000000,4,0
1,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-3.3,0,-5.7,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032970,regulation of actin filament-based process,M1101100000000000000,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-6.7,0,0,-4.4,-2.5,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,GO:0150063,visual system development,M1001100000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,-3.2,-2.7,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,GO:0042100,B cell proliferation,M1001100000000000100,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-2.8,0,0,-4.5,0,0,0,0,0,0,0,0,0,0,0,0,-5.4,0,-2.1,GO:0002821,positive regulation of adaptive immune response,M1001000000000000101,4,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-3.7,0,-2.5,-4.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,GO:0071396,cellular response to lipid,M1011000000000000001,4,0
1,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,-2.9,0,0,-3.4,0,0,0,0,0,0,-2.8,0,0,0,0,0,-2.6,0,0,GO:0048701,embryonic cranial skeleton morphogenesis,M1001000000100000100,4,0
1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.3,-3.8,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,GO:0048821,erythrocyte development,M1100100000000000010,4,0
0,1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,-3.2,0,0,0,-3.7,0,-2.6,0,0,0,0,0,0,0,0,0,-3,0,GO:0030593,neutrophil chemotaxis,M0100010100000000010,4,0
0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.3,0,-2.5,-2.6,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M0101100000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-6.1,0,0,-6.3,-2.6,0,0,0,0,0,0,0,0,0,-3.8,0,0,0,0,GO:0060840,artery development,M1001100000000010000,4,0
0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,-2.2,-2,0,0,0,0,0,-2.5,0,0,0,0,0,-2,0,0,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,M0001100000100000100,4,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.1,0,-2.3,-5.2,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,GO:0060348,bone development,M1011000000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.7,0,0,-2.2,-3.5,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0021953,central nervous system neuron differentiation,M1001100000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.2,0,0,-2.3,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,hsa04928,"Parathyroid hormone synthesis, secretion and action",M1001100000000000001,4,0
1,0,0,0,1,0,0,0,0,0,0,1,1,0,0,0,0,0,0,-3.7,0,0,0,-2.5,0,0,0,0,0,0,-3.7,-2.5,0,0,0,0,0,0,WP4018,Clear cell renal cell carcinoma pathways,M1000100000011000000,4,0
0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-3.1,0,-3,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,GO:0038093,Fc receptor signaling pathway,M0101100000000000001,4,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,-2.2,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,-2.1,GO:0032755,positive regulation of interleukin-6 production,M0101000000000000101,4,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,-4.1,-2.2,0,0,0,0,0,0,0,0,0,0,-2.6,-3.1,0,hsa05418,Fluid shear stress and atherosclerosis,M0000110000000000110,4,0
1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-3.2,-4.7,0,0,0,0,0,0,0,0,0,0,0,-2,0,-2.6,0,0,0,GO:0007015,actin filament organization,M1100000000000101000,4,0
1,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,-2.1,-2.8,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000179,positive regulation of neural precursor cell proliferation,M1011010000000000000,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-8,0,0,-5,-2.3,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0010632,regulation of epithelial cell migration,M1001100000000000100,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-2.6,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,-5.8,0,-2.2,GO:0002824,positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M1001000000000000101,4,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.9,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-7.7,GO:0050764,regulation of phagocytosis,M0011000000000000011,4,0
0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.5,-2.2,-3.5,0,0,0,0,0,0,0,0,0,0,0,-3.1,GO:0031334,positive regulation of protein-containing complex assembly,M0000111000000000001,4,0
0,0,0,1,1,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,-2.2,-2,0,0,0,0,0,0,0,0,-2.7,0,-2.5,0,0,0,GO:0034764,positive regulation of transmembrane transport,M0001100000000101000,4,0
0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,-2.1,-2.2,0,0,0,0,0,-4.6,0,-3.4,GO:0031401,positive regulation of protein modification process,M0000000001100000101,4,0
0,1,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,-2.9,0,-2.1,-2.2,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,GO:0001959,regulation of cytokine-mediated signaling pathway,M0101100001000000000,4,0
1,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,-2.3,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,M223,PID BETA CATENIN NUC PATHWAY,M1010010000000000100,4,0
1,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,-5.9,-3.2,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030029,actin filament-based process,M1110100000000000000,4,0
0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.1,-2.3,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,M0110100000000000100,4,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.3,0,0,-5.1,0,0,0,0,0,0,0,0,0,0,0,0,-4.1,-2.4,0,WP4666,Hepatitis B infection,M1001000000000000110,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.4,0,0,-4.8,-2.5,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M1001100000000000100,4,0
0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.9,0,-2.9,0,-2.7,0,0,0,0,0,0,0,0,0,0,-5.4,GO:0032735,positive regulation of interleukin-12 production,M0001010100000000001,4,0
0,0,0,0,1,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,-2.4,0,0,0,0,-3.4,-2.6,0,0,0,0,0,0,0,-2.9,GO:0002532,production of molecular mediator involved in inflammatory response,M0000100001100000001,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,-3.3,-2.4,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,GO:0010595,positive regulation of endothelial cell migration,M1001100000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.9,0,0,-2.3,-2,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,GO:0002887,negative regulation of myeloid leukocyte mediated immunity,M1001100000000000100,4,0
0,0,0,0,1,1,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,-2.2,-2.1,0,0,0,0,-3,0,0,0,0,0,0,0,-2.1,R-HSA-168188,Toll Like Receptor TLR6:TLR2 Cascade,M0000110000100000001,4,0
1,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,-2.6,0,0,-2.5,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4262,Breast cancer pathway,M1100110000000000000,4,0
0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.4,0,0,-2.7,-2.8,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,GO:0051046,regulation of secretion,M0100110000000000010,4,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-3.5,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,-3.9,R-HSA-9006335,Signaling by Erythropoietin,M0011000000000000011,4,0
1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.5,0,0,-4.2,0,-2.4,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,M2,PID SMAD2 3NUCLEAR PATHWAY,M1001010000000000100,4,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-6.5,0,0,-4.2,-2.4,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,GO:0048880,sensory system development,M1001100000000000100,4,0
0,1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.1,0,0,-3.1,0,-2.7,0,0,0,0,0,0,0,0,0,-4.6,0,0,GO:0040017,positive regulation of locomotion,M0100101000000000100,4,0
0,1,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,-2.5,-2.3,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,-2.6,0,0,GO:0019883,antigen processing and presentation of endogenous antigen,M0110000001000000100,4,0
0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.1,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,-4.6,0,0,GO:0002709,regulation of T cell mediated immunity,M0010000100000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0046532,regulation of photoreceptor cell differentiation,M1001000000000000100,3,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,-2.2,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035265,organ growth,M1011000000000000000,3,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,-2.1,-2.3,0,R-HSA-1433557,Signaling by SCF-KIT,M0000010000000000110,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,-3.6,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061138,morphogenesis of a branching epithelium,M1001100000000000000,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,-3.8,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05206,MicroRNAs in cancer,M1001100000000000000,3,0
0,0,1,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,-3.9,-2.9,0,0,0,0,0,0,GO:0006869,lipid transport,M0010000000011000000,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,-3.8,0,WP4630,Measles virus infection,M1000000000000000110,3,0
1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,-2.1,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060041,retina development in camera-type eye,M1101000000000000000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.5,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,WP4336,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,M1001000000000000100,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,-2.3,0,WP3611,Photodynamic therapy induced AP 1 survival signaling,M1000000000000000110,3,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,-3.9,-2.4,0,GO:0031342,negative regulation of cell killing,M0000100000000000110,3,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.7,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,-4,0,0,GO:0007420,brain development,M1000100000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.3,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0031100,animal organ regeneration,M1001000000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.4,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,-5.1,0,0,GO:0002520,immune system development,M1001000000000000100,3,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,-2.7,GO:0032642,regulation of chemokine production,M0000100000000000101,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,-2.6,0,WP408,Oxidative stress response,M1000000000000000110,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.9,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0048663,neuron fate commitment,M1001000000000000100,3,0
1,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,-2.8,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,GO:1902074,response to salt,M1000101000000000000,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-5.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,-2.4,0,WP395,IL 4 signaling pathway,M0001000000000000110,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.7,-2.7,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0003158,endothelium development,M0001100000000000100,3,0
1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,-2.1,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,-2.3,GO:0097581,lamellipodium organization,M1000000001000000001,3,0
0,0,0,1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4,-2.1,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061041,regulation of wound healing,M0001101000000000000,3,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2,-2.7,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,GO:0032817,regulation of natural killer cell proliferation,M0000110000000000100,3,0
0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,-2.4,0,0,0,0,0,0,-3.4,0,0,0,0,0,-2.3,0,0,GO:0006887,exocytosis,M0001000000100000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,GO:0035023,regulation of Rho protein signal transduction,M1001000000000000100,3,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.8,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,GO:0003279,cardiac septum development,M1000100000000010000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,GO:0030851,granulocyte differentiation,M1001000000000000100,3,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.5,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,GO:0010639,negative regulation of organelle organization,M1100000000000000100,3,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3.5,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,GO:0040007,growth,M1010000000000010000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0044403,biological process involved in symbiotic interaction,M1001000000000000100,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,-2.9,0,0,GO:0048863,stem cell differentiation,M1000000000000010100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.8,0,0,-5,0,0,0,0,0,0,0,0,0,0,0,0,-6.1,0,0,M54,PID IL12 2PATHWAY,M1001000000000000100,3,0
0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.9,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,GO:0051090,regulation of DNA-binding transcription factor activity,M0100100000000000001,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.5,-2.5,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0048660,regulation of smooth muscle cell proliferation,M0001100000000000100,3,0
0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,WP364,IL6 signaling pathway,M0100100000000000010,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,-2.7,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3527,Pre implantation embryo,M1001100000000000000,3,0
0,0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,-2,0,0,0,0,-2.2,0,0,0,0,0,0,-3.5,0,0,GO:2000106,regulation of leukocyte apoptotic process,M0000100001000000100,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.6,-3.4,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,M91,PID TCPTP PATHWAY,M0001100000000000100,3,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,-2.7,0,GO:0002716,negative regulation of natural killer cell mediated immunity,M0100000000000000110,3,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.4,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,R-HSA-4086398,Ca2+ pathway,M0010100000000000010,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,-2.4,GO:0043123,positive regulation of canonical NF-kappaB signal transduction,M0001000000000000101,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,-2.2,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1901888,regulation of cell junction assembly,M1001100000000000000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:0032231,regulation of actin filament bundle assembly,M1001000000000000100,3,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-5.2,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,GO:0051897,positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M1000100000000000100,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,-2.2,-5.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032835,glomerulus development,M1001100000000000000,3,0
0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,-2.5,0,-2.4,0,0,0,R-HSA-8951664,Neddylation,M0000000000010101000,3,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,-3.2,GO:0002828,regulation of type 2 immune response,M0010000000000000101,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,-6.7,0,-3.2,0,0,GO:0030216,keratinocyte differentiation,M1000000000000010100,3,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.8,0,-2.2,-6.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009725,response to hormone,M1011000000000000000,3,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3.5,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,GO:0048589,developmental growth,M1010000000000010000,3,0
0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.7,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,GO:0016310,phosphorylation,M0100100000000000001,3,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,R-HSA-8939245,RUNX1 regulates transcription of genes involved in BCR signaling,M1100000000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.3,0,0,-4.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,GO:0030509,BMP signaling pathway,M1001000000000000100,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,-2.3,WP4559,Interactions between immune cells and microRNAs in tumor microenvironment,M1000000000000000101,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,-3.7,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061440,kidney vasculature development,M1001100000000000000,3,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,-4.2,-2.5,0,GO:0001911,negative regulation of leukocyte mediated cytotoxicity,M0000100000000000110,3,0
1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,-3.7,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032271,regulation of protein polymerization,M1100100000000000000,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-4.9,-2.4,0,0,0,0,0,0,0,0,0,0,0,-5.7,0,0,GO:0046631,alpha-beta T cell activation,M0001100000000000100,3,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,-4.1,-4.8,GO:1901741,positive regulation of myoblast fusion,M0000000000000000111,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.5,-2.3,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0048639,positive regulation of developmental growth,M0001100000000000100,3,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2.4,0,GO:0001914,regulation of T cell mediated cytotoxicity,M0100000000000000110,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.5,-2.4,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0070670,response to interleukin-4,M0001100000000000100,3,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3,-2,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:0071375,cellular response to peptide hormone stimulus,M0011000000000000100,3,0
1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,-4.6,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0051896,regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M1000001000000000100,3,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,-2.4,0,GO:0071346,cellular response to type II interferon,M0100000000000000110,3,0
0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.1,0,0,0,0,0,-2.3,GO:0046486,glycerolipid metabolic process,M0000000000011000001,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0046533,negative regulation of photoreceptor cell differentiation,M1001000000000000100,3,0
0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,WP3877,MYD88 distinct input output pathway,M0100010000000000010,3,0
0,1,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,-2,-2.1,0,0,0,0,0,0,0,0,GO:0033559,unsaturated fatty acid metabolic process,M0100000001100000000,3,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,-4.6,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,M164,PID ERBB1 DOWNSTREAM PATHWAY,M0001110000000000000,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.2,-2.1,0,0,0,0,0,0,0,0,0,0,0,-4.3,0,0,GO:0019724,B cell mediated immunity,M0001100000000000100,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,-2.1,0,0,0,hsa05205,Proteoglycans in cancer,M1000000000000101000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.7,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,R-HSA-1980143,Signaling by NOTCH1,M1001000000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0030879,mammary gland development,M1001000000000000100,3,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,-2.8,0,GO:0002715,regulation of natural killer cell mediated immunity,M0100000000000000110,3,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,WP2884,NRF2 pathway,M1100000000000000100,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-4.1,-2.3,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,GO:0045058,T cell selection,M0001100000000000100,3,0
0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.2,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,R-HSA-2029485,Role of phospholipids in phagocytosis,M0100100000000000001,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,-4.4,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,WP5102,Familial partial lipodystrophy,M1001000000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3.3,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,-4.9,0,0,0,0,M236,PID DELTA NP63 PATHWAY,M1001000000000010000,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,-3.7,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061437,renal system vasculature development,M1001100000000000000,3,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.9,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,R-HSA-2029481,FCGR activation,M0101000000000000001,3,0
0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,-2,0,0,0,0,0,-2.2,0,0,0,0,0,0,-2.6,0,0,GO:1990868,response to chemokine,M0001000001000000100,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-6.8,-4.5,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,GO:0008285,negative regulation of cell population proliferation,M0001100000000000100,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,-2.2,GO:0043122,regulation of canonical NF-kappaB signal transduction,M0001000000000000101,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.4,-2.2,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0035307,positive regulation of protein dephosphorylation,M0001100000000000100,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-5.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,-4.1,M141,PID PI3KCI PATHWAY,M0001000000000000101,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,-3.4,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0019932,second-messenger-mediated signaling,M1001100000000000000,3,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,-2.2,GO:0007159,leukocyte cell-cell adhesion,M0100000000000000101,3,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.1,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0033077,T cell differentiation in thymus,M0011000000000000100,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2.5,0,GO:0071356,cellular response to tumor necrosis factor,M0001000000000000110,3,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.7,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,GO:0002335,mature B cell differentiation,M0010100000000000001,3,0
0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,-2.5,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061035,regulation of cartilage development,M0101100000000000000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-4.1,0,0,-2.5,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,GO:0051701,biological process involved in interaction with host,M1001000000001000000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.5,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,M99,PID TXA2PATHWAY,M1001000000000000001,3,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2,-2.7,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0021892,cerebral cortex GABAergic interneuron differentiation,M0000110000000000100,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,-2.2,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051282,regulation of sequestering of calcium ion,M1001100000000000000,3,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,-3.2,GO:1901739,regulation of myoblast fusion,M0010000000000000011,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-4,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,R-HSA-418594,G alpha (i) signalling events,M0001100000000000001,3,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-4.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,-3.1,GO:0002830,positive regulation of type 2 immune response,M0010000000000000101,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.5,0,hsa05171,Coronavirus disease - COVID-19,M0001000000000000110,3,0
1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-3,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0021895,cerebral cortex neuron differentiation,M1000010000000000100,3,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,-3.6,GO:0001562,response to protozoan,M0010000000000000101,3,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3.2,-4.2,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:1901652,response to peptide,M0011000000000000100,3,0
0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,-4.3,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032715,negative regulation of interleukin-6 production,M0100110000000000000,3,0
1,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,-2.3,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032645,regulation of granulocyte macrophage colony-stimulating factor production,M1000110000000000000,3,0
0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.1,0,0,0,0,0,-3.8,0,0,WP2328,Allograft rejection,M0000000001100000100,3,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.2,0,-4.1,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,R-HSA-3858494,Beta-catenin independent WNT signaling,M0010100000000000010,3,0
0,1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,-2,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,M285,PID HNF3A PATHWAY,M0101010000000000000,3,0
0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2.2,-3.3,0,0,0,0,0,-2.5,GO:0046474,glycerophospholipid biosynthetic process,M0000000000011000001,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.5,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,R-HSA-2122947,NOTCH1 Intracellular Domain Regulates Transcription,M1001000000000000100,3,0
0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,-3,0,-2.8,0,0,0,GO:0062013,positive regulation of small molecule metabolic process,M0100000000000101000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.4,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0007179,transforming growth factor beta receptor signaling pathway,M1001000000000000100,3,0
0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2.2,-2.2,0,0,0,0,0,-2.4,GO:0006644,phospholipid metabolic process,M0000000000011000001,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.9,0,0,-4,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,M65,PID FRA PATHWAY,M1001000000000000100,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,-2.1,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003231,cardiac ventricle development,M1001100000000000000,3,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-4.1,GO:0060099,"regulation of phagocytosis, engulfment",M0010000000000000011,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,1,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,-2.1,0,0,GO:0048864,stem cell development,M1000000000000100100,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-5.8,-2.4,0,WP2795,Cardiac hypertrophic response,M0001000000000000110,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:2000177,regulation of neural precursor cell proliferation,M1001000000000000100,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,-4.9,0,0,0,0,0,0,0,0,0,-4,0,-3.7,0,0,0,GO:0062012,regulation of small molecule metabolic process,M0001000000000101000,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,-2.5,0,0,GO:0007389,pattern specification process,M1000000000000010100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,hsa04022,cGMP-PKG signaling pathway,M1001000000000000100,3,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.7,-3,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,GO:1901653,cellular response to peptide,M0011000000000000100,3,0
0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,-2.2,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,-2.4,0,0,GO:0031343,positive regulation of cell killing,M0010000001000000100,3,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,-4.6,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M0000100000000000011,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-4.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.7,0,GO:0034612,response to tumor necrosis factor,M0001000000000000110,3,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0042509,regulation of tyrosine phosphorylation of STAT protein,M1100000000000000100,3,0
1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,-2.2,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP313,Hepatocyte growth factor receptor signaling,M1010100000000000000,3,0
1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,0,0,0,0,-4.6,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0051133,regulation of NK T cell activation,M1000000100000000100,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,-4.1,-3.2,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,GO:0060537,muscle tissue development,M0001100000000010000,3,0
0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,-2.9,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,-2.6,GO:1900027,regulation of ruffle assembly,M0001000001000000001,3,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.8,-3.8,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,GO:0072089,stem cell proliferation,M0000110000000000100,3,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,-2.1,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098868,bone growth,M1011000000000000000,3,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,-3.2,-2,0,R-HSA-195721,Signaling by WNT,M0000100000000000110,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.6,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,WP4871,Kisspeptin kisspeptin receptor system in the ovary,M0001100000000000010,3,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,-2.8,-3.5,GO:0060143,positive regulation of syncytium formation by plasma membrane fusion,M0000000000000000111,3,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,-3.2,-2.3,0,R-HSA-2559583,Cellular Senescence,M0000010000000000110,3,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,-4.3,GO:0045628,regulation of T-helper 2 cell differentiation,M0010000000000000101,3,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-5.8,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0007169,transmembrane receptor protein tyrosine kinase signaling pathway,M1000100000000000100,3,0
0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,-3.3,0,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,0,-3.7,0,GO:0002832,negative regulation of response to biotic stimulus,M0100000001000000010,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,-2.4,hsa04061,Viral protein interaction with cytokine and cytokine receptor,M0001000000000000101,3,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,GO:0090287,regulation of cellular response to growth factor stimulus,M1000100000000010000,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,-3,0,WP4565,Neural crest cell migration in cancer,M0001000000000000110,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.2,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,GO:0014015,positive regulation of gliogenesis,M1001000000000000010,3,0
1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,1,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,-2.1,0,0,WP4241,Type 2 papillary renal cell carcinoma,M1000000000010000100,3,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,-2.7,GO:0045624,positive regulation of T-helper cell differentiation,M0010000000000000101,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.4,-4.8,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,WP3972,PDGFR beta pathway,M0001100000000000100,3,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,WP4808,Endochondral ossification with skeletal dysplasias,M0011000000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-2,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,GO:0007599,hemostasis,M1001000000000000001,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.3,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0016032,viral process,M1001000000000000100,3,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2,R-HSA-9607240,FLT3 Signaling,M0000010000000000011,3,0
0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,-2.8,0,0,0,0,0,0,0,0,0,0,-2,GO:0050858,negative regulation of antigen receptor-mediated signaling pathway,M0000010100000000001,3,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,-2.8,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000736,regulation of stem cell differentiation,M1011000000000000000,3,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.2,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,WP4217,Ebola virus infection in host,M0101000000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-5.2,0,0,-5.1,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0043535,regulation of blood vessel endothelial cell migration,M1001000000000000100,3,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.2,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,GO:0001782,B cell homeostasis,M0000110000000000001,3,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.3,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,-4.9,0,0,GO:0050730,regulation of peptidyl-tyrosine phosphorylation,M0101000000000000100,3,0
0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,-2.5,-2.7,0,0,0,0,0,0,0,-3.1,M33,PID GLYPICAN 1PATHWAY,M0000000001100000001,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,-4.1,-4.3,0,hsa04620,Toll-like receptor signaling pathway,M0001000000000000110,3,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-3.2,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,GO:0038094,Fc-gamma receptor signaling pathway,M0101000000000000001,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,-4.4,-2.2,0,WP5174,Ulcerative colitis signaling,M0001000000000000110,3,0
1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,-2.4,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M48,PID MET PATHWAY,M1010100000000000000,3,0
0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,-3.6,0,0,0,0,0,0,-2.3,0,0,0,0,0,-4.5,0,0,GO:0006959,humoral immune response,M0001000000100000100,3,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,-4,0,0,0,0,0,0,0,0,0,0,-2.4,-2,0,hsa04015,Rap1 signaling pathway,M0000010000000000110,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3,-2.1,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,GO:0032729,positive regulation of type II interferon production,M0001100000000000100,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,-3.4,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04371,Apelin signaling pathway,M1001100000000000000,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.8,-3,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0001961,positive regulation of cytokine-mediated signaling pathway,M0001100000000000100,3,0
1,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,-2.6,0,0,-3.5,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,GO:0031346,positive regulation of cell projection organization,M1001000001000000000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.1,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,GO:0031663,lipopolysaccharide-mediated signaling pathway,M1001000000000000001,3,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.1,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050807,regulation of synapse organization,M0001110000000000000,3,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.2,-3,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,R-HSA-909733,Interferon alpha/beta signaling,M0011000000000000100,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.2,-2.9,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,GO:0021879,forebrain neuron differentiation,M0001100000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,0,0,GO:0002711,positive regulation of T cell mediated immunity,M1001000000000000100,3,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.8,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,-6.7,GO:0050766,positive regulation of phagocytosis,M0010100000000000001,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-5.8,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,-3.5,0,GO:0009615,response to virus,M0001000000000000110,3,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,-3,-2.4,0,R-HSA-202403,TCR signaling,M0000100000000000110,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3,-2.5,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0071353,cellular response to interleukin-4,M0001100000000000100,3,0
0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,-7.6,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098609,cell-cell adhesion,M0101100000000000000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.4,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:0043536,positive regulation of blood vessel endothelial cell migration,M1001000000000000100,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,-2,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035303,regulation of dephosphorylation,M1001100000000000000,3,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.1,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050803,regulation of synapse structure or activity,M0001110000000000000,3,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-3.6,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,GO:0032695,negative regulation of interleukin-12 production,M1100000000000000010,3,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,WP231,TNF alpha signaling pathway,M1000100000000000010,3,0
1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,-3.2,0,-4.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0110053,regulation of actin filament organization,M1101000000000000000,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,-2.2,0,0,GO:0003002,regionalization,M1000000000000010100,3,0
0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,-4.4,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-186763,Downstream signal transduction,M0011100000000000000,3,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,-3.7,GO:0042832,defense response to protozoan,M0010000000000000101,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,-4,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001763,morphogenesis of a branching structure,M1001100000000000000,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,-6,-4.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007507,heart development,M1001100000000000000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:2000648,positive regulation of stem cell proliferation,M1001000000000000100,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.8,0,0,-3.5,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060562,epithelial tube morphogenesis,M1001100000000000000,3,0
0,0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,1,0,0,-3.2,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,-2.4,GO:1902003,regulation of amyloid-beta formation,M0010000000100000001,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.9,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,R-HSA-8951936,RUNX3 regulates p14-ARF,M1001000000000000100,3,0
0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,-3,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060760,positive regulation of response to cytokine stimulus,M0101100000000000000,3,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.4,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,GO:0030111,regulation of Wnt signaling pathway,M1100000000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,R-HSA-9006931,Signaling by Nuclear Receptors,M1001000000000000100,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,-3.3,-4.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072012,glomerulus vasculature development,M1001100000000000000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.8,0,0,-4,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,M68,PID RHOA REG PATHWAY,M1001000000000000100,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,-2.7,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04919,Thyroid hormone signaling pathway,M1001100000000000000,3,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.1,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,hsa04390,Hippo signaling pathway,M1100000000000000100,3,0
0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2.6,-2.6,0,0,0,0,0,-2.3,GO:0006650,glycerophospholipid metabolic process,M0000000000011000001,3,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.7,-3,0,0,0,0,0,0,0,0,0,0,-4.5,0,0,GO:0032814,regulation of natural killer cell activation,M0000110000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.4,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0051098,regulation of binding,M1001000000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,R-HSA-350054,Notch-HLH transcription pathway,M1001000000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,GO:0002244,hematopoietic progenitor cell differentiation,M1001000000000000100,3,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,-2.7,GO:0042092,type 2 immune response,M0000100000000000101,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,hsa05165,Human papillomavirus infection,M1001000000000000100,3,0
1,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,-2.2,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048339,paraxial mesoderm development,M1010100000000000000,3,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.4,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,WP516,Hypertrophy model,M0010100000000000100,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.3,-2.6,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,WP1544,MicroRNAs in cardiomyocyte hypertrophy,M0001100000000000100,3,0
0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,-2.1,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,-2.6,GO:0002862,negative regulation of inflammatory response to antigenic stimulus,M0001000001000000001,3,0
1,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2.7,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4928,MAPK pathway in congenital thyroid cancer,M1100100000000000000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.2,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,GO:0007249,canonical NF-kappaB signal transduction,M1001000000000000010,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.6,0,0,-4.8,0,0,0,0,0,0,0,0,0,0,0,0,-6.3,0,0,GO:0021700,developmental maturation,M1001000000000000100,3,0
0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.4,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,WP4357,NRF2 ARE regulation,M0100100000000000100,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,-2,0,GO:0007265,Ras protein signal transduction,M0001000000000000110,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.1,M233,PID EPO PATHWAY,M0001000000000000011,3,0
0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,-2.4,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,-5,R-HSA-9664433,Leishmania parasite growth and survival,M0001000001000000001,3,0
1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0032733,positive regulation of interleukin-10 production,M1000010000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,M36,PID IL27 PATHWAY,M1001000000000000100,3,0
0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,-3.1,-2.3,R-HSA-4420097,VEGFA-VEGFR2 Pathway,M0000000100000000011,3,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,-2.1,0,-2,GO:0046639,negative regulation of alpha-beta T cell differentiation,M0000010000000000101,3,0
0,1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,-2,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M8,PID ENDOTHELIN PATHWAY,M0101100000000000000,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,-2.7,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050886,endocrine process,M1001100000000000000,3,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.7,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,GO:0003205,cardiac chamber development,M1000100000000010000,3,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-3.1,-3,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0071425,hematopoietic stem cell proliferation,M0000110000000000100,3,0
1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.4,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,hsa04724,Glutamatergic synapse,M1000010000000000001,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M1001000000000000100,3,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-4.3,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,GO:0006468,protein phosphorylation,M0101000000000000001,3,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.5,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,R-HSA-195253,Degradation of beta-catenin by the destruction complex,M0010100000000000100,3,0
0,1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,-3.2,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,WP363,Wnt signaling pathway,M0100110000000000000,3,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,-2.2,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010976,positive regulation of neuron projection development,M1011000000000000000,3,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-4.1,GO:1905153,regulation of membrane invagination,M0010000000000000011,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,WP4211,Transcriptional cascade regulating adipogenesis,M1001000000000000100,3,0
0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,-2.4,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,-5,R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,M0001000001000000001,3,0
0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,-2.4,0,0,0,0,0,-4.3,0,0,0,0,0,-2.6,0,GO:0015908,fatty acid transport,M0000010000010000010,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-3.1,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,WP4337,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,M1001000000000000010,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.7,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,GO:0072091,regulation of stem cell proliferation,M1001000000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-5.4,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,-4.5,0,0,GO:0021543,pallium development,M1001000000000000100,3,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,-3.5,GO:0060333,type II interferon-mediated signaling pathway,M0100000000000000011,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,-4.9,0,0,GO:0002708,positive regulation of lymphocyte mediated immunity,M1001000000000000100,3,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,GO:0002312,B cell activation involved in immune response,M0010100000000000001,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,-4.6,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,-4.6,hsa04060,Cytokine-cytokine receptor interaction,M0001000000000000101,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-7.2,-3,0,0,0,0,0,0,0,0,0,0,0,-7.9,0,0,GO:0002460,adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M0001100000000000100,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,-3.2,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4659,Gastrin signaling pathway,M1001100000000000000,3,0
0,0,1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2.5,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,R-HSA-193648,NRAGE signals death through JNK,M0011000100000000000,3,0
0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.4,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0046847,filopodium assembly,M0110000000000000100,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.4,-2.2,0,0,0,0,0,0,0,0,0,0,0,-4.4,0,0,GO:0016064,immunoglobulin mediated immune response,M0001100000000000100,3,0
1,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.8,0,0,-7.7,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061061,muscle structure development,M1001100000000000000,3,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,-2.8,-2.3,0,R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),M0000100000000000110,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,-3,0,WP4564,Neural crest cell migration during development,M0001000000000000110,3,0
1,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,-5,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060021,roof of mouth development,M1011000000000000000,3,0
0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.4,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,-4.8,0,hsa05140,Leishmaniasis,M0100010000000000010,3,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.4,-2.4,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,GO:1903530,regulation of secretion by cell,M0000110000000000010,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,-2,GO:0045860,positive regulation of protein kinase activity,M1000000000000000101,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,-2.4,0,GO:0050729,positive regulation of inflammatory response,M0001000000000000110,3,0
0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,-2,0,0,0,0,0,-2.2,0,0,0,0,0,0,-2.6,0,0,GO:1990869,cellular response to chemokine,M0001000001000000100,3,0
0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.8,0,-2.8,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,M279,PID RB 1PATHWAY,M0001010000000000100,3,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,WP474,Endochondral ossification,M0011000000000000100,3,0
1,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.2,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045588,positive regulation of gamma-delta T cell differentiation,M1100010000000000000,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0007517,muscle organ development,M1001000000000000100,3,0
0,0,0,1,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,-2.4,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045586,regulation of gamma-delta T cell differentiation,M0001110000000000000,3,0
0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-3.2,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,GO:0030888,regulation of B cell proliferation,M0001010000000000001,3,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,-5.5,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,-2.1,0,hsa05161,Hepatitis B,M0001000000000000110,3,0
0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,-2.9,0,0,0,0,0,0,-2.1,0,0,0,0,0,-3.3,0,0,GO:0032940,secretion by cell,M0001000000100000100,3,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-3,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,GO:0009896,positive regulation of catabolic process,M1000100000000000010,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:1902692,regulation of neuroblast proliferation,M1001000000000000100,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,-2.5,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0046620,regulation of organ growth,M0001100000000000100,3,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0021781,glial cell fate commitment,M1100000000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.5,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,-5,0,0,GO:0010721,negative regulation of cell development,M1001000000000000100,3,0
1,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,-2.6,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010596,negative regulation of endothelial cell migration,M1001010000000000000,3,0
0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,-2.5,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,-2,GO:0061081,positive regulation of myeloid leukocyte cytokine production involved in immune response,M0001000001000000001,3,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.6,0,-4,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,GO:1901699,cellular response to nitrogen compound,M0010100000000000100,3,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.3,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,WP2431,Spinal cord injury,M1001000000000000100,3,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.9,0,0,0,-4.6,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0048340,paraxial mesoderm morphogenesis,M1000100000000000100,3,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,-3.2,GO:0002825,regulation of T-helper 1 type immune response,M0010000000000000101,3,0
1,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-4.3,0,0,-2.6,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,GO:0044000,movement in host,M1001000000001000000,3,0
0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.3,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,GO:0030890,positive regulation of B cell proliferation,M0001010000000000001,3,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,-2.5,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,WP4787,Osteoblast differentiation and related diseases,M0001100000000000100,3,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0042531,positive regulation of tyrosine phosphorylation of STAT protein,M1100000000000000100,3,0
1,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,-4,0,-4.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051493,regulation of cytoskeleton organization,M1101000000000000000,3,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,R-HSA-9018519,Estrogen-dependent gene expression,M1000000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,WP2857,Mesodermal commitment pathway,M1000000000000000100,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0003229,ventricular cardiac muscle tissue development,M0000100000000000100,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,M161,PID IFNG PATHWAY,M0000100000000000001,2,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0071402,cellular response to lipoprotein particle stimulus,M0000010000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071378,cellular response to growth hormone stimulus,M1001000000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,-2.5,0,GO:0043032,positive regulation of macrophage activation,M0000000000000000110,2,0
0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031646,positive regulation of nervous system process,M0010010000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,WP2037,Prolactin signaling pathway,M0001000000000000010,2,0
0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-202733,Cell surface interactions at the vascular wall,M0110000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0062042,regulation of cardiac epithelial to mesenchymal transition,M1001000000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,-2.4,0,GO:0005975,carbohydrate metabolic process,M0000000000010000010,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002347,response to tumor cell,M1001000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050768,negative regulation of neurogenesis,M1001000000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,-2.2,GO:0043371,"negative regulation of CD4-positive, alpha-beta T cell differentiation",M0000000000000000101,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04520,Adherens junction,M1010000000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0006366,transcription by RNA polymerase II,M0000100000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0010718,positive regulation of epithelial to mesenchymal transition,M1000000000000000100,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-6,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048598,embryonic morphogenesis,M1010000000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007188,adenylate cyclase-modulating G protein-coupled receptor signaling pathway,M0001100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,hsa04926,Relaxin signaling pathway,M0001000000000000010,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,R-HSA-201681,TCF dependent signaling in response to WNT,M0000100000000000100,2,0
0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032763,regulation of mast cell cytokine production,M0100010000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090257,regulation of muscle system process,M0001100000000000000,2,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:2000107,negative regulation of leukocyte apoptotic process,M0100000000000000100,2,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,R-HSA-5687128,MAPK6/MAPK4 signaling,M0100000000000000100,2,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032870,cellular response to hormone stimulus,M0010100000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0031099,regeneration,M1000000000000000100,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035051,cardiocyte differentiation,M0001100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0045191,regulation of isotype switching,M0001000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007596,blood coagulation,M1001000000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,-3.4,0,0,0,GO:0006984,ER-nucleus signaling pathway,M0000000000000101000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,hsa04917,Prolactin signaling pathway,M0001000000000000100,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,GO:1905155,positive regulation of membrane invagination,M0010000000000000001,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0032656,regulation of interleukin-13 production,M0010000000000000100,2,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,-2.2,GO:0048259,regulation of receptor-mediated endocytosis,M0000000001000000001,2,0
1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4541,Hippo Merlin signaling dysregulation,M1000010000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04330,Notch signaling pathway,M1001000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071496,cellular response to external stimulus,M1001000000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:1904035,regulation of epithelial cell apoptotic process,M1000000000000000100,2,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051495,positive regulation of cytoskeleton organization,M0011000000000000000,2,0
0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,R-HSA-2173791,TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition),M0100000000100000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,GO:1902532,negative regulation of intracellular signal transduction,M1000000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.5,0,0,-4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035909,aorta morphogenesis,M1001000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-4.9,0,0,0,0,0,0,0,0,0,0,0,0,-5.2,0,0,GO:0002449,lymphocyte mediated immunity,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,hsa04610,Complement and coagulation cascades,M0001000000000000100,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003416,endochondral bone growth,M1010000000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-6.7,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002009,morphogenesis of an epithelium,M1000100000000000000,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,GO:0045630,positive regulation of T-helper 2 cell differentiation,M0010000000000000001,2,0
1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007224,smoothened signaling pathway,M1000010000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,-2.5,0,0,0,R-HSA-556833,Metabolism of lipids,M0000000000000101000,2,0
0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030219,megakaryocyte differentiation,M0100010000000000000,2,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007163,establishment or maintenance of cell polarity,M1100000000000000000,2,0
0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071801,regulation of podosome assembly,M0100100000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-4.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0051129,negative regulation of cellular component organization,M1000000000000000100,2,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,-2.4,GO:0030032,lamellipodium assembly,M0000000001000000001,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP706,Sudden infant death syndrome SIDS susceptibility pathways,M1000100000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:2001199,negative regulation of dendritic cell differentiation,M1000000000000000100,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050869,negative regulation of B cell activation,M0001100000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,GO:0046578,regulation of Ras protein signal transduction,M1000000000000000100,2,0
0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030318,melanocyte differentiation,M0100010000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:0043410,positive regulation of MAPK cascade,M0000100000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0051347,positive regulation of transferase activity,M1000000000000000100,2,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098581,detection of external biotic stimulus,M0101000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04020,Calcium signaling pathway,M1001000000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032890,regulation of organic acid transport,M0001100000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,-4.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072109,glomerular mesangium development,M0001100000000000000,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070849,response to epidermal growth factor,M1010000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-4.8,0,0,WP3893,Development and heterogeneity of the ILC family,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,GO:0060216,definitive hemopoiesis,M0001000000000000100,2,0
0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,M0000100000100000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0022612,gland morphogenesis,M1000100000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007409,axonogenesis,M0001100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,WP4263,Pancreatic adenocarcinoma pathway,M0001000000000000100,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031344,regulation of cell projection organization,M1010000000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:2000741,positive regulation of mesenchymal stem cell differentiation,M1000000000000000100,2,0
1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009410,response to xenobiotic stimulus,M1000010000000000000,2,0
0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007611,learning or memory,M0001010000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0002208,somatic diversification of immunoglobulins involved in immune response,M1000000000000000100,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-3.3,hsa04750,Inflammatory mediator regulation of TRP channels,M0000000000000000011,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,R-HSA-418346,Platelet homeostasis,M0001000000000000001,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0055001,muscle cell development,M0001100000000000000,2,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,-2.1,0,0,R-HSA-2173789,TGF-beta receptor signaling activates SMADs,M0000000000100000100,2,0
1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1904936,interneuron migration,M1000010000000000000,2,0
0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060872,semicircular canal development,M0010010000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048505,regulation of timing of cell differentiation,M1001000000000000000,2,0
0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007160,cell-matrix adhesion,M0100010000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1904062,regulation of monoatomic cation transmembrane transport,M0001100000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,-3.1,0,0,0,GO:0042304,regulation of fatty acid biosynthetic process,M0000000000000101000,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,GO:0099024,plasma membrane invagination,M0010000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,hsa05416,Viral myocarditis,M0001000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,GO:0014033,neural crest cell differentiation,M1000000000000100000,2,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,-2.6,0,0,GO:0150146,cell junction disassembly,M0000000000100000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,-5.2,0,0,GO:0002286,T cell activation involved in immune response,M0001000000000000100,2,0
0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,GO:0042733,embryonic digit morphogenesis,M0010000010000000000,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021885,forebrain cell migration,M1010000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0045730,respiratory burst,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,WP4298,Acute viral myocarditis,M0001000000000000100,2,0
0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031644,regulation of nervous system process,M0010010000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0002069,columnar/cuboidal epithelial cell maturation,M1000000000000000100,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,R-HSA-199991,Membrane Trafficking,M0000100000000000010,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:2001198,regulation of dendritic cell differentiation,M1000000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,GO:0002293,alpha-beta T cell differentiation involved in immune response,M0001000000000000100,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,0,-4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003143,embryonic heart tube morphogenesis,M1000100000000000000,2,0
1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,R-HSA-3656532,TGFBR1 KD Mutants in Cancer,M1000000000100000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0001816,cytokine production,M0001000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050817,coagulation,M1001000000000000000,2,0
0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0097094,craniofacial suture morphogenesis,M0001010000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.5,GO:0002223,stimulatory C-type lectin receptor signaling pathway,M1000000000000000001,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0061072,iris morphogenesis,M1000000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,GO:0048534,hematopoietic or lymphoid organ development,M0001000000000000100,2,0
0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,-3.3,0,0,GO:0002687,positive regulation of leukocyte migration,M0000000100000000100,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0001912,positive regulation of leukocyte mediated cytotoxicity,M0010000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,WP5144,NRP1 triggered signaling pathways in pancreatic cancer,M1000000000000000100,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,GO:0002313,mature B cell differentiation involved in immune response,M0000100000000000001,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-5,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0045598,regulation of fat cell differentiation,M0001000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010633,negative regulation of epithelial cell migration,M1001000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,hsa04151,PI3K-Akt signaling pathway,M0001000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043011,myeloid dendritic cell differentiation,M1001000000000000000,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,GO:0010324,membrane invagination,M0010000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,WP5122,Prostaglandin and leukotriene metabolism in senescence,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,R-HSA-166166,MyD88-independent TLR4 cascade,M0001000000000000100,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.5,0,R-HSA-389356,CD28 co-stimulation,M0010000000000000010,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001947,heart looping,M1000100000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,-3.2,0,0,0,WP4718,Cholesterol metabolism with Bloch and Kandutsch Russell pathways,M0000000000000101000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,hsa04668,TNF signaling pathway,M0001000000000000010,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,-2.1,0,R-HSA-1168372,Downstream signaling events of B Cell Receptor (BCR),M0000000000000000110,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-4.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,M210,PID IL8 CXCR2 PATHWAY,M0001000000000000001,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M281,PID FAK PATHWAY,M1010000000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.4,-2,0,0,0,0,0,0,GO:0015718,monocarboxylic acid transport,M0000000000011000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090049,regulation of cell migration involved in sprouting angiogenesis,M1001000000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.3,GO:0009620,response to fungus,M0000100000000000001,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.6,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051960,regulation of nervous system development,M0001100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,GO:0008037,cell recognition,M0001000000000000001,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0022029,telencephalon cell migration,M1010000000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0002204,somatic recombination of immunoglobulin genes involved in immune response,M1000000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.5,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001649,osteoblast differentiation,M1001000000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,GO:0038095,Fc-epsilon receptor signaling pathway,M0000100000000000001,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9013695,NOTCH4 Intracellular Domain Regulates Transcription,M1001000000000000000,2,0
0,0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-4,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,GO:0006109,regulation of carbohydrate metabolic process,M0001000010000000000,2,0
0,0,1,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,R-HSA-204998,"Cell death signalling via NRAGE, NRIF and NADE",M0010000100000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-201556,Signaling by ALK,M1001000000000000000,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0045581,negative regulation of T cell differentiation,M0010000000000000100,2,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,-2.1,GO:0071675,regulation of mononuclear cell migration,M0000000001000000001,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,GO:0045649,regulation of macrophage differentiation,M0001000000000000100,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,GO:0070664,negative regulation of leukocyte proliferation,M0000100000000000001,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,-4.2,0,0,0,GO:0009991,response to extracellular stimulus,M0000000000000101000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0062043,positive regulation of cardiac epithelial to mesenchymal transition,M1001000000000000000,2,0
0,0,0,0,0,0,0,0,0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,-2,0,0,0,0,0,hsa04144,Endocytosis,M0000000001000100000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,GO:0045446,endothelial cell differentiation,M0001000000000000100,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,-2.2,R-HSA-9660826,Purinergic signaling in leishmaniasis infection,M0000000000000000101,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:0042093,T-helper cell differentiation,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,hsa05150,Staphylococcus aureus infection,M0001000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,-4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-8941856,RUNX3 regulates NOTCH signaling,M1001000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000563,"positive regulation of CD4-positive, alpha-beta T cell proliferation",M1001000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0002891,positive regulation of immunoglobulin mediated immune response,M0001000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,CORUM:642,CtBP complex,M1000000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,GO:0043368,positive T cell selection,M0001000000000000100,2,0
0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,GO:0010803,regulation of tumor necrosis factor-mediated signaling pathway,M0100000001000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0050673,epithelial cell proliferation,M1000000000000000100,2,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,M12,PID RHOA PATHWAY,M0100000000000000010,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-6,0,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009792,embryo development ending in birth or egg hatching,M1000100000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-416476,G alpha (q) signalling events,M0001100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,GO:0042742,defense response to bacterium,M0001000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,-4.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050769,positive regulation of neurogenesis,M1001000000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,GO:0051092,positive regulation of NF-kappaB transcription factor activity,M0000100000000000001,2,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051494,negative regulation of cytoskeleton organization,M1100000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:0051048,negative regulation of secretion,M0001000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:2000352,negative regulation of endothelial cell apoptotic process,M1000000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0035914,skeletal muscle cell differentiation,M0001000000000000100,2,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000191,regulation of fatty acid transport,M0101000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,0,0,GO:0008347,glial cell migration,M0001000000100000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0002562,somatic diversification of immune receptors via germline recombination within a single locus,M0000100000000000100,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,WP453,Inflammatory response pathway,M0010000000000000001,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001937,negative regulation of endothelial cell proliferation,M1001000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,GO:0002287,alpha-beta T cell activation involved in immune response,M0001000000000000100,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010612,regulation of cardiac muscle adaptation,M0001100000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,hsa05131,Shigellosis,M0000100000000000100,2,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000193,positive regulation of fatty acid transport,M0101000000000000000,2,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032535,regulation of cellular component size,M1100000000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051963,regulation of synapse assembly,M0001100000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001945,lymph vessel development,M1000100000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,-5.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3678,Amplification and expansion of oncogenic pathways as metastatic traits,M0001100000000000000,2,0
1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,GO:0042471,ear morphogenesis,M1000000010000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,GO:0043408,regulation of MAPK cascade,M0000100000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-4,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,WP4172,PI3K Akt signaling pathway,M0001000000000000100,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060836,lymphatic endothelial cell differentiation,M0001100000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045579,positive regulation of B cell differentiation,M0001100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:1903055,positive regulation of extracellular matrix organization,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:0002294,"CD4-positive, alpha-beta T cell differentiation involved in immune response",M0001000000000000100,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060412,ventricular septum morphogenesis,M1000100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-4.4,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,GO:2000146,negative regulation of cell motility,M0001000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,-4.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0019058,viral life cycle,M1001000000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002279,mast cell activation involved in immune response,M0001100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,GO:0002433,immune response-regulating cell surface receptor signaling pathway involved in phagocytosis,M0001000000000000001,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010001,glial cell differentiation,M1001000000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,WP4495,IL 10 anti inflammatory signaling pathway,M1000000000000000100,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0014706,striated muscle tissue development,M0001100000000000000,2,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1905563,negative regulation of vascular endothelial cell proliferation,M0000110000000000000,2,0
0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,-4.1,GO:0050854,regulation of antigen receptor-mediated signaling pathway,M0000000100000000001,2,0
0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,-2.8,GO:0008654,phospholipid biosynthetic process,M0000000000001000001,2,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043433,negative regulation of DNA-binding transcription factor activity,M0101000000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903242,regulation of cardiac muscle hypertrophy in response to stress,M0001100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,0,0,WP5039,SARS CoV 2 innate immunity evasion and cell specific immune response,M0001000000000000100,2,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000377,regulation of reactive oxygen species metabolic process,M0010100000000000000,2,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,-3.5,0,0,GO:0036230,granulocyte activation,M0000000000100000100,2,0
0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031641,regulation of myelination,M0010010000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,GO:0010883,regulation of lipid storage,M1000000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04621,NOD-like receptor signaling pathway,M1001000000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001822,kidney development,M1000100000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0014823,response to activity,M1000100000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,-4.5,0,0,0,GO:0031667,response to nutrient levels,M0000000000000101000,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,GO:0030838,positive regulation of actin filament polymerization,M0010000000000000001,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0002088,lens development in camera-type eye,M1000000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05207,Chemical carcinogenesis - receptor activation,M1001000000000000000,2,0
0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04216,Ferroptosis,M0100100000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04510,Focal adhesion,M1001000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048708,astrocyte differentiation,M1001000000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,GO:0040008,regulation of growth,M0000100000000010000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.5,GO:1990840,response to lectin,M1000000000000000001,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,GO:0050852,T cell receptor signaling pathway,M0001000000000000010,2,0
0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1901570,fatty acid derivative biosynthetic process,M0100100000000000000,2,0
0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,-3.6,0,0,0,0,0,0,0,0,GO:0042551,neuron maturation,M0000000001100000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0097485,neuron projection guidance,M0001100000000000000,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071364,cellular response to epidermal growth factor stimulus,M1010000000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0008015,blood circulation,M0001100000000000000,2,0
0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,hsa05231,Choline metabolism in cancer,M0000010000010000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,GO:0040013,negative regulation of locomotion,M0001000000000000100,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090066,regulation of anatomical structure size,M1000100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,WP581,EPO receptor signaling,M0001000000000000100,2,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,GO:0044272,sulfur compound biosynthetic process,M0100000000000001000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,-2.2,hsa04370,VEGF signaling pathway,M0000000000000000011,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0001885,endothelial cell development,M1000000000000000100,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,GO:0006911,"phagocytosis, engulfment",M0010000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0048771,tissue remodeling,M1000000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,GO:0001771,immunological synapse formation,M1000000000000000001,2,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,-4.4,0,0,hsa05323,Rheumatoid arthritis,M0000010000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP61,Notch signaling pathway,M1001000000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,-2.2,0,0,0,GO:0019217,regulation of fatty acid metabolic process,M0000000000000101000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,-2.5,0,GO:0046636,negative regulation of alpha-beta T cell activation,M0000000000000000110,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,R-HSA-392518,Signal amplification,M0001000000000000001,2,0
0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04810,Regulation of actin cytoskeleton,M0100010000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,M100,PID SHP2 PATHWAY,M1000000000000000010,2,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.4,R-HSA-9664323,FCGR3A-mediated IL10 synthesis,M0100000000000000001,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,-2.7,0,0,0,hsa03083,Polycomb repressive complex,M0000000000000101000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090100,positive regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M1001000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001570,vasculogenesis,M1001000000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,WP4304,Oligodendrocyte specification and differentiation leading to myelin components for CNS,M1000000000000000100,2,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030852,regulation of granulocyte differentiation,M1100000000000000000,2,0
0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030854,positive regulation of granulocyte differentiation,M0100010000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,-2.8,0,0,0,0,0,0,GO:0010876,lipid localization,M0000000000011000000,2,0
0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050890,cognition,M0001010000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031333,negative regulation of protein-containing complex assembly,M1001000000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003012,muscle system process,M1000100000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,-4.8,0,0,GO:0042088,T-helper 1 type immune response,M0000100000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0034110,regulation of homotypic cell-cell adhesion,M1001000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0072676,lymphocyte migration,M0001000000000000100,2,0
0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032703,negative regulation of interleukin-2 production,M0000110000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-2.2,0,WP2112,IL 17 signaling pathway,M0000000000000000110,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043303,mast cell degranulation,M0001100000000000000,2,0
1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,R-HSA-3656534,Loss of Function of TGFBR1 in Cancer,M1000000000100000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.5,GO:1990858,cellular response to lectin,M1000000000000000001,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0001837,epithelial to mesenchymal transition,M1000000000000000100,2,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007498,mesoderm development,M0010100000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050773,regulation of dendrite development,M1001000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,-4.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035904,aorta development,M1001000000000000000,2,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4538,Regulatory circuits of the STAT3 signaling pathway,M1100000000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.7,0,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0000902,cell morphogenesis,M1000100000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2355,Corticotropin releasing hormone signaling pathway,M1000100000000000000,2,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9671555,Signaling by PDGFR in disease,M0011000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0033003,regulation of mast cell activation,M1001000000000000000,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060070,canonical Wnt signaling pathway,M1010000000000000000,2,0
0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,-2.7,0,0,0,0,0,0,0,0,WP3668,Hypothesized pathways in pathogenesis of cardiovascular disease,M0000000001100000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,GO:0038096,Fc-gamma receptor signaling pathway involved in phagocytosis,M0001000000000000001,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,-4.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M17,PID NOTCH PATHWAY,M1001000000000000000,2,0
1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,R-HSA-3304356,SMAD2/3 Phosphorylation Motif Mutants in Cancer,M1000000000100000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048545,response to steroid hormone,M1001000000000000000,2,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,-2.3,GO:0033628,regulation of cell adhesion mediated by integrin,M0000000001000000001,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:1905953,negative regulation of lipid localization,M0001000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,-4.4,0,0,0,0,0,0,0,0,CORUM:5735,TGF-beta receptor-SMAD3 complex,M1000000000100000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M71,PID ILK PATHWAY,M1001000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0036336,dendritic cell migration,M0001000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043537,negative regulation of blood vessel endothelial cell migration,M1001000000000000000,2,0
0,1,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,GO:0006690,icosanoid metabolic process,M0100000001000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045667,regulation of osteoblast differentiation,M1001000000000000000,2,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0034616,response to laminar fluid shear stress,M1100000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060350,endochondral bone morphogenesis,M1001000000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0002200,somatic diversification of immune receptors,M0000100000000000100,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,-2.1,0,GO:0042269,regulation of natural killer cell mediated cytotoxicity,M0000000000000000110,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,GO:0050921,positive regulation of chemotaxis,M0001000000000000100,2,0
0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051147,regulation of muscle cell differentiation,M0001001000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003208,cardiac ventricle morphogenesis,M1001000000000000000,2,0
0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,-5.2,0,0,0,0,0,0,0,0,GO:0002576,platelet degranulation,M0000000001100000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,GO:0006991,response to sterol depletion,M0001000000000000001,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,WP536,Calcium regulation in cardiac cells,M0000100000000000010,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072001,renal system development,M1000100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-4.6,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,hsa05163,Human cytomegalovirus infection,M0001000000000000100,2,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,-3.4,0,0,WP4146,Macrophage markers,M0000000000100000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,GO:0042026,protein refolding,M1000000000000000010,2,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9818027,NFE2L2 regulating anti-oxidant/detoxification enzymes,M1100000000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007411,axon guidance,M0001100000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061438,renal system vasculature morphogenesis,M1000100000000000000,2,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,GO:0050860,negative regulation of T cell receptor signaling pathway,M0000010000000000001,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,-4.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060349,bone morphogenesis,M1001000000000000000,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,GO:0032660,regulation of interleukin-17 production,M0010000000000000001,2,0
0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,-2.1,GO:0045017,glycerolipid biosynthetic process,M0000000000001000001,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051592,response to calcium ion,M1000100000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.6,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003013,circulatory system process,M0001100000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0040034,"regulation of development, heterochronic",M1001000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,WP2895,Differentiation of white and brown adipocyte,M0001000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0048709,oligodendrocyte differentiation,M1000000000000000100,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007204,positive regulation of cytosolic calcium ion concentration,M0001100000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,-5.2,GO:0045807,positive regulation of endocytosis,M0000000000000000011,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.4,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP127,IL 5 signaling pathway,M0001100000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,CORUM:313,Cell cycle kinase complex CDK5,M1000000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,GO:0014032,neural crest cell development,M1000000000000100000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061043,regulation of vascular wound healing,M0001100000000000000,2,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,-2.9,0,0,GO:0098883,synapse pruning,M0000000000100000100,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021800,cerebral cortex tangential migration,M1000100000000000000,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,CORUM:2536,PLC-gamma-2-SLP-76-Lyn-Grb2 complex,M0010000000000000001,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,GO:0002431,Fc receptor mediated stimulatory signaling pathway,M0001000000000000001,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,GO:0046632,alpha-beta T cell differentiation,M0001000000000000100,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048738,cardiac muscle tissue development,M0001100000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0016444,somatic cell DNA recombination,M0000100000000000100,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0120035,regulation of plasma membrane bounded cell projection organization,M1010000000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,-2.2,0,0,0,GO:0046890,regulation of lipid biosynthetic process,M0000000000000101000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0048593,camera-type eye morphogenesis,M1000000000000000100,2,0
0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3931,Embryonic stem cell pluripotency pathways,M0100100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,GO:0017157,regulation of exocytosis,M0001000000000000010,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9012852,Signaling by NOTCH3,M1001000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,-4.8,0,0,R-HSA-6783783,Interleukin-10 signaling,M0001000000000000100,2,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,-2.6,0,0,WP5362,TAR syndrome,M0000000001000000100,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,-2,0,0,0,GO:0043161,proteasome-mediated ubiquitin-dependent protein catabolic process,M0000000000000101000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0019216,regulation of lipid metabolic process,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,GO:0030278,regulation of ossification,M0001000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0045786,negative regulation of cell cycle,M1000000000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0045190,isotype switching,M1000000000000000100,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061371,determination of heart left/right asymmetry,M1000100000000000000,2,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006898,receptor-mediated endocytosis,M0101000000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,GO:0021987,cerebral cortex development,M1000000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-5.4,0,0,GO:0030225,macrophage differentiation,M0001000000000000100,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-7.3,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048729,tissue morphogenesis,M1000100000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0032808,lacrimal gland development,M1000000000000000100,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:0032869,cellular response to insulin stimulus,M0010000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04064,NF-kappa B signaling pathway,M1001000000000000000,2,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-525793,Myogenesis,M0011000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0007266,Rho protein signal transduction,M0001000000000000100,2,0
0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045669,positive regulation of osteoblast differentiation,M0011000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-5.5,0,0,0,0,0,0,0,0,0,0,0,0,-5.1,0,0,GO:0030101,natural killer cell activation,M0001000000000000100,2,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071499,cellular response to laminar fluid shear stress,M1100000000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,GO:0048706,embryonic skeletal system development,M0000100000000000100,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,M26,PID NFKAPPAB ATYPICAL PATHWAY,M1000000000000000010,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4,0,0,WP4674,Head and neck squamous cell carcinoma,M1000000000000000100,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,-2.1,GO:0033674,positive regulation of kinase activity,M0000000000000000101,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030857,negative regulation of epithelial cell differentiation,M1001000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051961,negative regulation of nervous system development,M1001000000000000000,2,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1900274,regulation of phospholipase C activity,M0101000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0045830,positive regulation of isotype switching,M0001000000000000100,2,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043301,negative regulation of leukocyte degranulation,M1100000000000000000,2,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043068,positive regulation of programmed cell death,M1100000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:0090050,positive regulation of cell migration involved in sprouting angiogenesis,M0001000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3845,Canonical and non canonical Notch signaling,M1001000000000000000,2,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-5.7,0,0,0,0,GO:0002437,inflammatory response to antigenic stimulus,M0100000000000010000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,hsa05212,Pancreatic cancer,M0001000000000000100,2,0
0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,-2.8,GO:0050856,regulation of T cell receptor signaling pathway,M0000000100000000001,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,-3.9,0,hsa05162,Measles,M0000000000000000110,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1912420,Pre-NOTCH Processing in Golgi,M0001100000000000000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0042119,neutrophil activation,M0000100000000000100,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,GO:0060100,"positive regulation of phagocytosis, engulfment",M0010000000000000001,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1912408,Pre-NOTCH Transcription and Translation,M1001000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0002714,positive regulation of B cell mediated immunity,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-5,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,WP4255,Non small cell lung cancer,M0001000000000000100,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,GO:0032868,response to insulin,M0010000000000000010,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,GO:0001779,natural killer cell differentiation,M0001000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9013508,NOTCH3 Intracellular Domain Regulates Transcription,M1001000000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.4,0,0,0,0,GO:0008544,epidermis development,M1000000000000010000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.4,0,0,-4.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051145,smooth muscle cell differentiation,M1001000000000000000,2,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0071404,cellular response to low-density lipoprotein particle stimulus,M0000010000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,-5.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051962,positive regulation of nervous system development,M1001000000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003281,ventricular septum development,M1000100000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,-5.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050767,regulation of neurogenesis,M1001000000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072073,kidney epithelium development,M1000100000000000000,2,0
0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007229,integrin-mediated signaling pathway,M0101000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,M0001000000100000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,hsa05220,Chronic myeloid leukemia,M0001000000000000100,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,-2.2,0,0,0,GO:0046889,positive regulation of lipid biosynthetic process,M0000000000000101000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,hsa04217,Necroptosis,M1000000000000000100,2,0
1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M92,PID ANGIOPOIETIN RECEPTOR PATHWAY,M1010000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,M252,PID IL8 CXCR1 PATHWAY,M0001000000000000001,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,R-HSA-937061,TRIF(TICAM1)-mediated TLR4 signaling,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,GO:0002221,pattern recognition receptor signaling pathway,M0001000000000000001,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0045651,positive regulation of macrophage differentiation,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,GO:0035710,"CD4-positive, alpha-beta T cell activation",M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,GO:0002726,positive regulation of T cell cytokine production,M0001000000000000100,2,0
0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.1,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-5663213,RHO GTPases Activate WASPs and WAVEs,M0010100000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0014743,regulation of muscle hypertrophy,M0001100000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010543,regulation of platelet activation,M1001000000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-6,0,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043009,chordate embryonic development,M1000100000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0051135,positive regulation of NK T cell activation,M1000000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP5090,Complement system in neuronal development and plasticity,M1001000000000000000,2,0
0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043313,regulation of neutrophil degranulation,M0100010000000000000,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,R-HSA-9619665,EGR2 and SOX10-mediated initiation of Schwann cell myelination,M0010000000000100000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0070528,protein kinase C signaling,M0000100000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010922,positive regulation of phosphatase activity,M1001000000000000000,2,0
0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,GO:0002076,osteoblast development,M0001000000100000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,GO:0009895,negative regulation of catabolic process,M1000000000000100000,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,hsa04912,GnRH signaling pathway,M0000100000000000001,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035304,regulation of protein dephosphorylation,M0001100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0002295,T-helper cell lineage commitment,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,M145,PID P53 DOWNSTREAM PATHWAY,M0001000000000000100,2,0
0,1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098543,detection of other organism,M0100010000000000000,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043502,regulation of muscle adaptation,M0001100000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0021846,cell proliferation in forebrain,M1000000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002065,columnar/cuboidal epithelial cell differentiation,M1001000000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0034614,cellular response to reactive oxygen species,M1000100000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,-2.2,R-HSA-9664424,Cell recruitment (pro-inflammatory response),M0000000000000000101,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010611,regulation of cardiac muscle hypertrophy,M0001100000000000000,2,0
0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2263,Androgen receptor network in prostate cancer,M0010010000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,R-HSA-9675108,Nervous system development,M1000000000000100000,2,0
0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4313,Ferroptosis,M0100100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,GO:0032731,positive regulation of interleukin-1 beta production,M0001000000100000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,R-HSA-9013406,RHOQ GTPase cycle,M1000000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007219,Notch signaling pathway,M1001000000000000000,2,0
0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,-3.5,0,R-HSA-388841,Costimulation by the CD28 family,M0000000100000000010,2,0
0,0,1,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,GO:0002643,regulation of tolerance induction,M0010000001000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:0032653,regulation of interleukin-10 production,M1000000000000000100,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072006,nephron development,M1000100000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1912422,Pre-NOTCH Expression and Processing,M1001000000000000000,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006816,calcium ion transport,M1000100000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060396,growth hormone receptor signaling pathway,M1001000000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,GO:0090092,regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M1000000000000010000,2,0
0,0,0,1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-6.5,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903034,regulation of response to wounding,M0001001000000000000,2,0
0,0,0,0,0,0,0,0,0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.1,0,0,0,0,0,0,R-HSA-1483257,Phospholipid metabolism,M0000000000011000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0120161,regulation of cold-induced thermogenesis,M0001000000000000100,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010464,regulation of mesenchymal cell proliferation,M1001000000000000000,2,0
0,0,0,1,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,GO:0010935,regulation of macrophage cytokine production,M0001000001000000000,2,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,GO:2001185,"regulation of CD8-positive, alpha-beta T cell activation",M0100000000000000010,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,GO:0097696,receptor signaling pathway via STAT,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,-5.7,0,0,GO:0071674,mononuclear cell migration,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-4.5,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0030336,negative regulation of cell migration,M0001000000000000100,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0032652,regulation of interleukin-1 production,M0000100000000000100,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0034103,regulation of tissue remodeling,M0001100000000000000,2,0
1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1902904,negative regulation of supramolecular fiber organization,M1100000000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2586,Aryl hydrocarbon receptor pathway,M1001000000000000000,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.1,0,0,GO:0032816,positive regulation of natural killer cell activation,M0010000000000000100,2,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0055094,response to lipoprotein particle,M0000010000000000100,2,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,-2,GO:1900015,regulation of cytokine production involved in inflammatory response,M0000000000000000101,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0010458,exit from mitosis,M1000000000000000100,2,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:0046622,positive regulation of organ growth,M0000100000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0045647,negative regulation of erythrocyte differentiation,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,GO:0007259,receptor signaling pathway via JAK-STAT,M0001000000000000100,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,M115,PID REG GR PATHWAY,M0001000000000000100,2,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,GO:0150077,regulation of neuroinflammatory response,M0010000000000000001,2,0
1,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061439,kidney vasculature morphogenesis,M1000100000000000000,2,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,-4.6,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:1903053,regulation of extracellular matrix organization,M0001000000000000100,2,0
0,0,0,1,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0055006,cardiac cell development,M0001100000000000000,2,0
1,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048754,branching morphogenesis of an epithelial tube,M1001000000000000000,2,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090083,regulation of inclusion body assembly,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0002888,positive regulation of myeloid leukocyte mediated immunity,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,GO:0006259,DNA metabolic process,M0000000010000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-75876,Synthesis of very long-chain fatty acyl-CoAs,M0100000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0046928,regulation of neurotransmitter secretion,M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903036,positive regulation of response to wounding,M0001000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045060,negative thymic T cell selection,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0070102,interleukin-6-mediated signaling pathway,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2880,Glucocorticoid receptor pathway,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0042176,regulation of protein catabolic process,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0045638,negative regulation of myeloid cell differentiation,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098742,cell-cell adhesion via plasma-membrane adhesion molecules,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0099536,synaptic signaling,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1901873,regulation of post-translational protein modification,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1905331,negative regulation of morphogenesis of an epithelium,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,CORUM:443,BP-SMAD complex,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043281,regulation of cysteine-type endopeptidase activity involved in apoptotic process,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030859,polarized epithelial cell differentiation,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M72,PID NECTIN PATHWAY,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010616,negative regulation of cardiac muscle adaptation,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M23,PID WNT NONCANONICAL PATHWAY,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0045063,T-helper 1 cell differentiation,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,GO:0070723,response to cholesterol,M0000000000100000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0097746,blood vessel diameter maintenance,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035150,regulation of tube size,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006693,prostaglandin metabolic process,M0100000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032989,cellular anatomical entity morphogenesis,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,GO:0032819,positive regulation of natural killer cell proliferation,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070570,regulation of neuron projection regeneration,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,WP5088,Prostaglandin signaling,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0036438,maintenance of lens transparency,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010466,negative regulation of peptidase activity,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060252,positive regulation of glial cell proliferation,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043200,response to amino acid,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0055007,cardiac muscle cell differentiation,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,GO:0046434,organophosphate catabolic process,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,R-HSA-975871,MyD88 cascade initiated on plasma membrane,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090330,regulation of platelet aggregation,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP5205,Clock controlled autophagy in bone metabolism,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031214,biomineral tissue development,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0008306,associative learning,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,WP4206,Hereditary leiomyomatosis and renal cell carcinoma pathway,M0000000000000000010,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,M268,PID S1P S1P2 PATHWAY,M0000010000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000401,regulation of lymphocyte migration,M0100000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021761,limbic system development,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072576,liver morphogenesis,M0000100000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071901,negative regulation of protein serine/threonine kinase activity,M0000010000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04340,Hedgehog signaling pathway,M0010000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043086,negative regulation of catalytic activity,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006691,leukotriene metabolic process,M0100000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051258,protein polymerization,M0100000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-76009,Platelet Aggregation (Plug Formation),M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,GO:1902745,positive regulation of lamellipodium organization,M0000000000100000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021891,olfactory bulb interneuron development,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1059683,Interleukin-6 signaling,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:2000515,"negative regulation of CD4-positive, alpha-beta T cell activation",M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072103,glomerulus vasculature morphogenesis,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa00051,Fructose and mannose metabolism,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,R-HSA-8978868,Fatty acid metabolism,M0000000000000100000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071355,cellular response to interleukin-9,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.8,GO:0032667,regulation of interleukin-23 production,M0000000000000000001,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-3906995,Diseases associated with O-glycosylation of proteins,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,R-HSA-9694516,SARS-CoV-2 Infection,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP1545,miRNAs involved in DNA damage response,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072144,glomerular mesangial cell development,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090109,regulation of cell-substrate junction assembly,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003298,physiological muscle hypertrophy,M0000100000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003333,amino acid transmembrane transport,M0010000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010975,regulation of neuron projection development,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032305,positive regulation of icosanoid secretion,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9758941,Gastrulation,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-2894862,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,M1000000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP619,Type II interferon signaling,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,GO:0008645,hexose transmembrane transport,M0000000000010000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-6811438,Intra-Golgi traffic,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,WP5382,TGF Smad signaling pathway,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0045064,T-helper 2 cell differentiation,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003203,endocardial cushion morphogenesis,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035455,response to interferon-alpha,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0070167,regulation of biomineral tissue development,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2806,Complement system,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,R-HSA-8853884,Transcriptional Regulation by VENTX,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0010828,positive regulation of glucose transmembrane transport,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,GO:0106056,regulation of calcineurin-mediated signaling,M0000000000000000001,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009595,detection of biotic stimulus,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060211,regulation of nuclear-transcribed mRNA poly(A) tail shortening,M1000000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-425407,SLC-mediated transmembrane transport,M0010000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP5113,Antiviral and anti inflammatory effects of Nrf2 on SARS CoV 2 pathway,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050792,regulation of viral process,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0035272,exocrine system development,M0000000000000000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0008542,visual learning,M0000010000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032273,positive regulation of protein polymerization,M0010000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003197,endocardial cushion development,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001773,myeloid dendritic cell activation,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0045859,regulation of protein kinase activity,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0046850,regulation of bone remodeling,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP5381,Smith Magenis and Potocki Lupski syndrome copy number variation,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1904064,positive regulation of cation transmembrane transport,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072575,epithelial cell proliferation involved in liver morphogenesis,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP1559,Transcription factors regulate miRNAs related to cardiac hypertrophy,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,GO:0070830,bicellular tight junction assembly,M0000000000010000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1902882,regulation of response to oxidative stress,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,WP4329,miRNA role in immune response in sepsis,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M5887,NABA BASEMENT MEMBRANES,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,GO:0120193,tight junction organization,M0000000000010000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05222,Small cell lung cancer,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04270,Vascular smooth muscle contraction,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,GO:0051180,vitamin transport,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,GO:0002639,positive regulation of immunoglobulin production,M0000000000000000100,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4155,Endometrial cancer,M0010000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035589,G protein-coupled purinergic nucleotide receptor signaling pathway,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032928,regulation of superoxide anion generation,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021952,central nervous system projection neuron axonogenesis,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045124,regulation of bone resorption,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0055123,digestive system development,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035329,hippo signaling,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0038113,interleukin-9-mediated signaling pathway,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,GO:1903052,positive regulation of proteolysis involved in protein catabolic process,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP5036,Angiotensin II receptor type 1 pathway,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.1,0,0,0,0,0,0,0,GO:0015711,organic anion transport,M0000000000010000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070555,response to interleukin-1,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060037,pharyngeal system development,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,WP5402,10q22q23 copy number variation,M0000000000000000100,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060592,mammary gland formation,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0045591,positive regulation of regulatory T cell differentiation,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M18,PID INTEGRIN1 PATHWAY,M0001000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04612,Antigen processing and presentation,M0010000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.6,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-112316,Neuronal System,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,R-HSA-2142688,Synthesis of 5-eicosatetraenoic acids,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002228,natural killer cell mediated immunity,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,WP4494,Selective expression of chemokine receptors during T cell polarization,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061919,process utilizing autophagic mechanism,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,M257,PID EPHRINB REV PATHWAY,M0000000000000000001,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000977,regulation of forebrain neuron differentiation,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0062197,cellular response to chemical stress,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,GO:0031295,T cell costimulation,M0000000000000000001,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP5063,FOXP3 in COVID 19,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9707587,Regulation of HMOX1 expression and activity,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,GO:0140888,interferon-mediated signaling pathway,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,WP1772,Apoptosis modulation and signaling,M0000000000000000010,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0060828,regulation of canonical Wnt signaling pathway,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0097421,liver regeneration,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,R-HSA-8848021,Signaling by PTK6,M0000000000010000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4658,Small cell lung cancer,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,R-HSA-202424,Downstream TCR signaling,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,GO:0019941,modification-dependent protein catabolic process,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0106014,regulation of inflammatory response to wounding,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,WP3915,Angiopoietin like protein 8 regulatory pathway,M0000000000000000010,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035337,fatty-acyl-CoA metabolic process,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,hsa05208,Chemical carcinogenesis - reactive oxygen species,M0000000000000000010,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,GO:0016322,neuron remodeling,M0000000000100000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1904994,regulation of leukocyte adhesion to vascular endothelial cell,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,M295,SIG PIP3 SIGNALING IN CARDIAC MYOCTES,M0000000000000000010,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4496,Signal transduction through IL1R,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3298,Melatonin metabolism and effects,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001974,blood vessel remodeling,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072010,glomerular epithelium development,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,GO:0032091,negative regulation of protein binding,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060509,type I pneumocyte differentiation,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071104,response to interleukin-9,M0001000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0034030,ribonucleoside bisphosphate biosynthetic process,M0100000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1296071,Potassium Channels,M0000010000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006636,unsaturated fatty acid biosynthetic process,M0100000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0019082,viral protein processing,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051966,"regulation of synaptic transmission, glutamatergic",M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-186797,Signaling by PDGF,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0042307,positive regulation of protein import into nucleus,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,R-HSA-418597,G alpha (z) signalling events,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,R-HSA-114608,Platelet degranulation,M0000000000100000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006939,smooth muscle contraction,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1902905,positive regulation of supramolecular fiber organization,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,GO:1903050,regulation of proteolysis involved in protein catabolic process,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9673767,"Signaling by PDGFRA transmembrane, juxtamembrane and kinase domain mutants",M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1904951,positive regulation of establishment of protein localization,M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP5353,A network map of Macrophage stimulating protein MSP signaling,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903307,positive regulation of regulated secretory pathway,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP51,Regulation of actin cytoskeleton,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1912399,Pre-NOTCH Processing in the Endoplasmic Reticulum,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-3928662,EPHB-mediated forward signaling,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006914,autophagy,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-977606,Regulation of Complement cascade,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,M275,PID ALPHA SYNUCLEIN PATHWAY,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,GO:0045834,positive regulation of lipid metabolic process,M0000000000000100000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M5193,SIG CHEMOTAXIS,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903531,negative regulation of secretion by cell,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071466,cellular response to xenobiotic stimulus,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002767,immune response-inhibiting cell surface receptor signaling pathway,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-8939247,RUNX1 regulates transcription of genes involved in interleukin signaling,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,GO:0019882,antigen processing and presentation,M0000000001000000000,1,0
0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,GO:0030866,cortical actin cytoskeleton organization,M0000000100000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0150116,regulation of cell-substrate junction organization,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3967,miR 509 3p alteration of YAP1 ECM axis,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,GO:0001666,response to hypoxia,M0000000000010000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060576,intestinal epithelial cell development,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0032825,positive regulation of natural killer cell differentiation,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9700645,ALK mutants bind TKIs,M0000100000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009593,detection of chemical stimulus,M0000010000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031000,response to caffeine,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0032720,negative regulation of tumor necrosis factor production,M0000000000000000100,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031589,cell-substrate adhesion,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0019884,antigen processing and presentation of exogenous antigen,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M166,PID ATF2 PATHWAY,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4790,FGF23 signaling in hypophosphatemic rickets and related disorders,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051775,response to redox state,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9725371,Nuclear events stimulated by ALK signaling in cancer,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,GO:0016042,lipid catabolic process,M0000000000010000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045198,establishment of epithelial cell apical/basal polarity,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M196,PID IL23 PATHWAY,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007610,behavior,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0002548,monocyte chemotaxis,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051965,positive regulation of synapse assembly,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,GO:0036293,response to decreased oxygen levels,M0000000000010000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1904996,positive regulation of leukocyte adhesion to vascular endothelial cell,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,WP530,Cytokines and inflammatory response,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0070372,regulation of ERK1 and ERK2 cascade,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060839,endothelial cell fate commitment,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-400253,Circadian Clock,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045930,negative regulation of mitotic cell cycle,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-397014,Muscle contraction,M1000000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0099537,trans-synaptic signaling,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0045655,regulation of monocyte differentiation,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072011,glomerular endothelium development,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070527,platelet aggregation,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0042472,inner ear morphogenesis,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9796292,Formation of axial mesoderm,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,GO:0051770,positive regulation of nitric-oxide synthase biosynthetic process,M0000000000000000010,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001764,neuron migration,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0033047,regulation of mitotic sister chromatid segregation,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0046835,carbohydrate phosphorylation,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043255,regulation of carbohydrate biosynthetic process,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,GO:0007422,peripheral nervous system development,M0000000000000100000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP49,IL 2 signaling pathway,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-2682334,EPH-Ephrin signaling,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010565,regulation of cellular ketone metabolic process,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,GO:0009395,phospholipid catabolic process,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,GO:0120034,positive regulation of plasma membrane bounded cell projection assembly,M0000000001000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070673,response to interleukin-18,M0001000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060443,mammary gland morphogenesis,M0010000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-373760,L1CAM interactions,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0042267,natural killer cell mediated cytotoxicity,M0001000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP1992,Genes targeted by miRNAs in adipocytes,M0100000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003014,renal system process,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003184,pulmonary valve morphogenesis,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04512,ECM-receptor interaction,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043523,regulation of neuron apoptotic process,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,GO:0032774,RNA biosynthetic process,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M135,PID IL5 PATHWAY,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,GO:0062207,regulation of pattern recognition receptor signaling pathway,M0000000000000000001,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4549,Fragile X syndrome,M0000010000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072595,maintenance of protein localization in organelle,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009266,response to temperature stimulus,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,0,0,GO:0002292,T cell differentiation involved in immune response,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,GO:0032924,activin receptor signaling pathway,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,R-HSA-3304349,Loss of Function of SMAD2/3 in Cancer,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:1903902,positive regulation of viral life cycle,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072102,glomerulus morphogenesis,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060323,head morphogenesis,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0045670,regulation of osteoclast differentiation,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032370,positive regulation of lipid transport,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:1901722,regulation of cell proliferation involved in kidney development,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,GO:0033630,positive regulation of cell adhesion mediated by integrin,M0000000000000000001,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M276,PID FGF PATHWAY,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1901568,fatty acid derivative metabolic process,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021988,olfactory lobe development,M1000000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-8940973,RUNX2 regulates osteoblast differentiation,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070301,cellular response to hydrogen peroxide,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1900047,negative regulation of hemostasis,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:0060998,regulation of dendritic spine development,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007368,determination of left/right symmetry,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048008,platelet-derived growth factor receptor signaling pathway,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1904407,positive regulation of nitric oxide metabolic process,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP306,Focal adhesion,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,GO:0061384,heart trabecula morphogenesis,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903351,cellular response to dopamine,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0032736,positive regulation of interleukin-13 production,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035924,cellular response to vascular endothelial growth factor stimulus,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,GO:0043491,phosphatidylinositol 3-kinase/protein kinase B signal transduction,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071501,cellular response to sterol depletion,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M151,PID AR TF PATHWAY,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4685,Melanoma,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030048,actin filament-based movement,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2001235,positive regulation of apoptotic signaling pathway,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007173,epidermal growth factor receptor signaling pathway,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045600,positive regulation of fat cell differentiation,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070542,response to fatty acid,M0001000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045061,thymic T cell selection,M0010000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098916,anterograde trans-synaptic signaling,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060575,intestinal epithelial cell differentiation,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071229,cellular response to acid chemical,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-2586552,Signaling by Leptin,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0030500,regulation of bone mineralization,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071214,cellular response to abiotic stimulus,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,GO:2000060,positive regulation of ubiquitin-dependent protein catabolic process,M0000000000000000010,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4136,Fibrin complement receptor 3 signaling pathway,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030513,positive regulation of BMP signaling pathway,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP1455,Serotonin transporter activity,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,R-HSA-9013106,RHOC GTPase cycle,M0000000000000000001,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903243,negative regulation of cardiac muscle hypertrophy in response to stress,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-381042,PERK regulates gene expression,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,WP53,ID signaling pathway,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,GO:2000379,positive regulation of reactive oxygen species metabolic process,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,GO:0010884,positive regulation of lipid storage,M0000000000000000001,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043305,negative regulation of mast cell degranulation,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032677,regulation of interleukin-8 production,M0100000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0062014,negative regulation of small molecule metabolic process,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,GO:0009988,cell-cell recognition,M0000000000000000001,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1990849,vacuolar localization,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071260,cellular response to mechanical stimulus,M1000000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9682385,FLT3 signaling in disease,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,GO:0006351,DNA-templated transcription,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M213,PID AR NONGENOMIC PATHWAY,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,WP545,Complement activation,M0000000000100000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0150078,positive regulation of neuroinflammatory response,M0010000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048814,regulation of dendrite morphogenesis,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070669,response to interleukin-2,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0043388,positive regulation of DNA binding,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0061383,trabecula morphogenesis,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,GO:1902176,negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway,M0000000000000000010,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010863,positive regulation of phospholipase C activity,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,M0000000000000000010,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0002363,alpha-beta T cell lineage commitment,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021575,hindbrain morphogenesis,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,GO:0030307,positive regulation of cell growth,M0000000000100000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060351,cartilage development involved in endochondral bone morphogenesis,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045661,regulation of myoblast differentiation,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:2000679,positive regulation of transcription regulatory region DNA binding,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021772,olfactory bulb development,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050920,regulation of chemotaxis,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035296,regulation of tube diameter,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0034762,regulation of transmembrane transport,M0000100000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1901137,carbohydrate derivative biosynthetic process,M0100000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-8939211,ESR-mediated signaling,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.8,GO:0032747,positive regulation of interleukin-23 production,M0000000000000000001,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002224,toll-like receptor signaling pathway,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1990410,adrenomedullin receptor signaling pathway,M1000000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043383,negative T cell selection,M0010000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001946,lymphangiogenesis,M0000100000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05213,Endometrial cancer,M0010000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-383280,Nuclear Receptor transcription pathway,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-354194,GRB2:SOS provides linkage to MAPK signaling for Integrins,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-2894858,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,GO:0071715,icosanoid transport,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060325,face morphogenesis,M0001000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-73887,Death Receptor Signaling,M0010000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05033,Nicotine addiction,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0002360,T cell lineage commitment,M0000000000000000100,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043586,tongue development,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,GO:0001755,neural crest cell migration,M0000000000000100000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1839124,FGFR1 mutant receptor activation,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,hsa05164,Influenza A,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0036376,sodium ion export across plasma membrane,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060074,synapse maturation,M0100000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M16,PID INSULIN PATHWAY,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,GO:0046903,secretion,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003044,regulation of systemic arterial blood pressure mediated by a chemical signal,M0000100000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4159,GABA receptor signaling,M0000010000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,M0000010000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-6803157,Antimicrobial peptides,M0000010000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032691,negative regulation of interleukin-1 beta production,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0002232,leukocyte chemotaxis involved in inflammatory response,M0000000000000000100,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0120033,negative regulation of plasma membrane bounded cell projection assembly,M0010000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032368,regulation of lipid transport,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1990830,cellular response to leukemia inhibitory factor,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:0002712,regulation of B cell mediated immunity,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0071322,cellular response to carbohydrate stimulus,M0000000000000000100,1,0
0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,GO:1901224,positive regulation of non-canonical NF-kappaB signal transduction,M0000000100000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,GO:0090407,organophosphate biosynthetic process,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,GO:0072666,establishment of protein localization to vacuole,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0070741,response to interleukin-6,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1901201,regulation of extracellular matrix assembly,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,0,0,0,0,0,GO:0044242,cellular lipid catabolic process,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,GO:0002220,innate immune response activating cell surface receptor signaling pathway,M0000000000000000001,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002067,glandular epithelial cell differentiation,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045656,negative regulation of monocyte differentiation,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4723,Omega 3 omega 6 fatty acid synthesis,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,hsa05230,Central carbon metabolism in cancer,M0000000000010000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0014742,positive regulation of muscle hypertrophy,M0000100000000000000,1,0
0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,GO:0030865,cortical cytoskeleton organization,M0000000100000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,GO:0043353,enucleate erythrocyte differentiation,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0104004,cellular response to environmental stimulus,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051893,regulation of focal adhesion assembly,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,GO:0071407,cellular response to organic cyclic compound,M0000000000000100000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4481,Resistin as a regulator of inflammation,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2583,T cell receptor and co stimulatory signaling,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0045620,negative regulation of lymphocyte differentiation,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M41,PID ER NONGENOMIC PATHWAY,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003222,ventricular trabecula myocardium morphogenesis,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007406,negative regulation of neuroblast proliferation,M0001000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4884,Pathogenesis of SARS CoV 2 mediated by nsp9 nsp10 complex,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,R-HSA-5621480,Dectin-2 family,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:0045445,myoblast differentiation,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0090207,regulation of triglyceride metabolic process,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010614,negative regulation of cardiac muscle hypertrophy,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,M12705,SIG CD40PATHWAYMAP,M0000010000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0120162,positive regulation of cold-induced thermogenesis,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,GO:0070884,regulation of calcineurin-NFAT signaling cascade,M0000000000000000001,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006516,glycoprotein catabolic process,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,WP5368,Sulfatase and aromatase pathway,M0000000000000000010,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP5033,Genes associated with the development of rheumatoid arthritis,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,GO:0006623,protein targeting to vacuole,M0000000000100000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1905809,negative regulation of synapse organization,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:1903054,negative regulation of extracellular matrix organization,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032727,positive regulation of interferon-alpha production,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071868,cellular response to monoamine stimulus,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,GO:0002281,macrophage activation involved in immune response,M0000000000000000001,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1902930,regulation of alcohol biosynthetic process,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0016447,somatic recombination of immunoglobulin gene segments,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002675,positive regulation of acute inflammatory response,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,GO:1902115,regulation of organelle assembly,M0000000000000000010,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009743,response to carbohydrate,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,WP5355,Metabolic Epileptic Disorders,M0000000000010000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043380,regulation of memory T cell differentiation,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035090,maintenance of apical/basal cell polarity,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031623,receptor internalization,M0100000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001958,endochondral ossification,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0048010,vascular endothelial growth factor receptor signaling pathway,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0072672,neutrophil extravasation,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903350,response to dopamine,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,hsa04725,Cholinergic synapse,M0000000000000000010,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,0,hsa04210,Apoptosis,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032418,lysosome localization,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1990823,response to leukemia inhibitory factor,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-5173214,O-glycosylation of TSR domain-containing proteins,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010951,negative regulation of endopeptidase activity,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M271,PID PI3K PLC TRK PATHWAY,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0036075,replacement ossification,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003272,endocardial cushion formation,M0000100000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04530,Tight junction,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0032823,regulation of natural killer cell differentiation,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,M254,PID MYC REPRESS PATHWAY,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903035,negative regulation of response to wounding,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,WP3874,Canonical and non canonical TGF B signaling,M0000000000100000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4535,Envelope proteins and their potential roles in EDMD physiopathology,M0010000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010563,negative regulation of phosphorus metabolic process,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.7,0,0,0,0,GO:0043588,skin development,M0000000000000010000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,GO:0060541,respiratory system development,M0000000000000010000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,R-HSA-76005,Response to elevated platelet cytosolic Ca2+,M0000000000100000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903670,regulation of sprouting angiogenesis,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0052547,regulation of peptidase activity,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,R-HSA-5683057,MAPK family signaling cascades,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070672,response to interleukin-15,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP304,Kit receptor signaling pathway,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000772,regulation of cellular senescence,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051964,negative regulation of synapse assembly,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045199,maintenance of epithelial cell apical/basal polarity,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002634,regulation of germinal center formation,M0000100000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098655,monoatomic cation transmembrane transport,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0006826,iron ion transport,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001909,leukocyte mediated cytotoxicity,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0034599,cellular response to oxidative stress,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051384,response to glucocorticoid,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1904238,pericyte cell differentiation,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0110011,regulation of basement membrane organization,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071870,cellular response to catecholamine stimulus,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,GO:0007043,cell-cell junction assembly,M0000000000010000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072223,metanephric glomerular mesangium development,M0000100000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035855,megakaryocyte development,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,GO:0030705,cytoskeleton-dependent intracellular transport,M0000000000000000010,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04392,Hippo signaling pathway - multiple species,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090077,foam cell differentiation,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072008,glomerular mesangial cell differentiation,M0000100000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-112315,Transmission across Chemical Synapses,M0000010000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009855,determination of bilateral symmetry,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9020558,Interleukin-2 signaling,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045912,negative regulation of carbohydrate metabolic process,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0034765,regulation of monoatomic ion transmembrane transport,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M118,PID INTEGRIN A9B1 PATHWAY,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048048,embryonic eye morphogenesis,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0035655,interleukin-18-mediated signaling pathway,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0070098,chemokine-mediated signaling pathway,M0000000000000000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0044331,cell-cell adhesion mediated by cadherin,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,R-HSA-5684264,MAP3K8 (TPL2)-dependent MAPK1/3 activation,M0000000000000000010,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003179,heart valve morphogenesis,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0150118,negative regulation of cell-substrate junction organization,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006936,muscle contraction,M0000100000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1900407,regulation of cellular response to oxidative stress,M0100000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04916,Melanogenesis,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031329,regulation of cellular catabolic process,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,hsa04920,Adipocytokine signaling pathway,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,GO:0006631,fatty acid metabolic process,M0000000001000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0010885,regulation of cholesterol storage,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045936,negative regulation of phosphate metabolic process,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4829,mBDNF and proBDNF regulation of GABA neurotransmission,M0001000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-389359,CD28 dependent Vav1 pathway,M0010000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071805,potassium ion transmembrane transport,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006509,membrane protein ectodomain proteolysis,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001906,cell killing,M0001000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032757,positive regulation of interleukin-8 production,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,WP5358,JAK STAT signaling in the regulation of Beta cells,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1295596,Spry regulation of FGF signaling,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032332,positive regulation of chondrocyte differentiation,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,GO:0007584,response to nutrient,M0000000000000001000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072574,hepatocyte proliferation,M0000100000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0008356,asymmetric cell division,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021955,central nervous system neuron axonogenesis,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0001916,positive regulation of T cell mediated cytotoxicity,M0000000000000000100,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1902992,negative regulation of amyloid precursor protein catabolic process,M0010000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030166,proteoglycan biosynthetic process,M0100000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043242,negative regulation of protein-containing complex disassembly,M0100000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0042989,sequestering of actin monomers,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031668,cellular response to extracellular stimulus,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0019370,leukotriene biosynthetic process,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,GO:0060249,anatomical structure homeostasis,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,CORUM:5233,TNF-alpha/NF-kappa B signaling complex 5,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030856,regulation of epithelial cell differentiation,M1000000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1902475,L-alpha-amino acid transmembrane transport,M0010000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9707564,Cytoprotection by HMOX1,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M234,PID IL2 STAT5 PATHWAY,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,hsa04940,Type I diabetes mellitus,M0000000001000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4312,Rett syndrome causing genes,M0000010000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048167,regulation of synaptic plasticity,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,GO:0046394,carboxylic acid biosynthetic process,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,GO:0010952,positive regulation of peptidase activity,M0000000001000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0055013,cardiac muscle cell development,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,GO:2001243,negative regulation of intrinsic apoptotic signaling pathway,M0000000000000000010,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031643,positive regulation of myelination,M0010000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010906,regulation of glucose metabolic process,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061298,retina vasculature development in camera-type eye,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098727,maintenance of cell number,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4698,Vitamin D sensitive calcium signaling in depression,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05120,Epithelial cell signaling in Helicobacter pylori infection,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006929,substrate-dependent cell migration,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001938,positive regulation of endothelial cell proliferation,M0000100000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903825,organic acid transmembrane transport,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,GO:0043632,modification-dependent macromolecule catabolic process,M0000000000000000010,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050804,modulation of chemical synaptic transmission,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4971,Phosphoinositides metabolism,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,hsa00565,Ether lipid metabolism,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,GO:0002478,antigen processing and presentation of exogenous peptide antigen,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,GO:0061462,protein localization to lysosome,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,GO:0030162,regulation of proteolysis,M0000000000100000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0046879,hormone secretion,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,WP558,Complement and coagulation cascades,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,R-HSA-389357,CD28 dependent PI3K/Akt signaling,M0000000000000000010,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001502,cartilage condensation,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,WP4582,Cancer immunotherapy by CTLA4 blockade,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3651,Pathways affected in adenoid cystic carcinoma,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,GO:0140352,export from cell,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,R-HSA-196849,Metabolism of water-soluble vitamins and cofactors,M0000000000010000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045787,positive regulation of cell cycle,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9670439,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050808,synapse organization,M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05223,Non-small cell lung cancer,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1902869,regulation of amacrine cell differentiation,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032088,negative regulation of NF-kappaB transcription factor activity,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0052548,regulation of endopeptidase activity,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043280,positive regulation of cysteine-type endopeptidase activity involved in apoptotic process,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,GO:0010232,vascular transport,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,GO:0002526,acute inflammatory response,M0000000000001000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071415,cellular response to purine-containing compound,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,GO:0002637,regulation of immunoglobulin production,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0055012,ventricular cardiac muscle cell differentiation,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035264,multicellular organism growth,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,GO:0010970,transport along microtubule,M0000000000000000010,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035338,long-chain fatty-acyl-CoA biosynthetic process,M0100000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048680,positive regulation of axon regeneration,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006658,phosphatidylserine metabolic process,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098660,inorganic ion transmembrane transport,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0051656,establishment of organelle localization,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051952,regulation of amine transport,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:2000319,regulation of T-helper 17 cell differentiation,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,0,0,0,0,0,WP3614,Photodynamic therapy induced HIF 1 survival signaling,M0000000000010000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0000302,response to reactive oxygen species,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0002495,antigen processing and presentation of peptide antigen via MHC class II,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010919,regulation of inositol phosphate biosynthetic process,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090596,sensory organ morphogenesis,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0033500,carbohydrate homeostasis,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071107,response to parathyroid hormone,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-5083630,Defective LFNG causes SCDO3,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0097205,renal filtration,M0000100000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001516,prostaglandin biosynthetic process,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,GO:0070374,positive regulation of ERK1 and ERK2 cascade,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0140546,defense response to symbiont,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0023061,signal release,M0000100000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030041,actin filament polymerization,M0100000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M229,PID P38 ALPHA BETA DOWNSTREAM PATHWAY,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0016445,somatic diversification of immunoglobulins,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0048661,positive regulation of smooth muscle cell proliferation,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05134,Legionellosis,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,R-HSA-166663,Initial triggering of complement,M0000000000100000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035249,"synaptic transmission, glutamatergic",M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003177,pulmonary valve development,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1855204,Synthesis of IP3 and IP4 in the cytosol,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0120039,plasma membrane bounded cell projection morphogenesis,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035850,epithelial cell differentiation involved in kidney development,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060416,response to growth hormone,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,hsa04350,TGF-beta signaling pathway,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,R-HSA-446652,Interleukin-1 family signaling,M0000000000100000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002820,negative regulation of adaptive immune response,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,R-HSA-1483206,Glycerophospholipid biosynthesis,M0000000000010000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-446353,Cell-extracellular matrix interactions,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048341,paraxial mesoderm formation,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0097191,extrinsic apoptotic signaling pathway,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05160,Hepatitis C,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,R-HSA-948021,Transport to the Golgi and subsequent modification,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2034,Leptin signaling pathway,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0046686,response to cadmium ion,M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060419,heart growth,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa00650,Butanoate metabolism,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-2644602,Signaling by NOTCH1 PEST Domain Mutants in Cancer,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,R-HSA-5653656,Vesicle-mediated transport,M0000000000000000010,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,GO:1904659,glucose transmembrane transport,M0000000000010000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0015824,proline transport,M1000000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090314,positive regulation of protein targeting to membrane,M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1482801,Acyl chain remodelling of PS,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035723,interleukin-15-mediated signaling pathway,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,GO:0006958,"complement activation, classical pathway",M0000000000100000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061045,negative regulation of wound healing,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001738,morphogenesis of a polarized epithelium,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001569,branching involved in blood vessel morphogenesis,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0007088,regulation of mitotic nuclear division,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0086064,cell communication by electrical coupling involved in cardiac conduction,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1630316,Glycosaminoglycan metabolism,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0033673,negative regulation of kinase activity,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0071351,cellular response to interleukin-18,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4,0,0,0,0,0,0,0,WP534,Glycolysis and gluconeogenesis,M0000000000010000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045599,negative regulation of fat cell differentiation,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0033032,regulation of myeloid cell apoptotic process,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006111,regulation of gluconeogenesis,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,GO:0001894,tissue homeostasis,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,WP4806,EGFR tyrosine kinase inhibitor resistance,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4141,PI3K AKT mTOR vitamin D3 signaling,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-2644603,Signaling by NOTCH1 in Cancer,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4142,Metabolism of sphingolipids in ER and Golgi apparatus,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0034405,response to fluid shear stress,M1000000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098662,inorganic cation transmembrane transport,M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1500931,Cell-Cell communication,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003301,physiological cardiac muscle hypertrophy,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,GO:0035633,maintenance of blood-brain barrier,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,R-HSA-202433,Generation of second messenger molecules,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061049,cell growth involved in cardiac muscle cell development,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0038083,peptidyl-tyrosine autophosphorylation,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,GO:1990748,cellular detoxification,M0000000000010000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010818,T cell chemotaxis,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,GO:0010743,regulation of macrophage derived foam cell differentiation,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,WP254,Apoptosis,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,R-HSA-9012546,Interleukin-18 signaling,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,hsa01521,EGFR tyrosine kinase inhibitor resistance,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3676,BDNF TrkB signaling,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0141087,positive regulation of inflammasome-mediated signaling pathway,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1905005,regulation of epithelial to mesenchymal transition involved in endocardial cushion formation,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060972,left/right pattern formation,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0014850,response to muscle activity,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,GO:0034330,cell junction organization,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,GO:0048193,Golgi vesicle transport,M0000000000000000001,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-3371568,Attenuation phase,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0042984,regulation of amyloid precursor protein biosynthetic process,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,GO:0007272,ensheathment of neurons,M0000000000000000010,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9818749,Regulation of NFE2L2 gene expression,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1901880,negative regulation of protein depolymerization,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1905314,semi-lunar valve development,M1000000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001893,maternal placenta development,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3958,GPR40 pathway,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1905007,positive regulation of epithelial to mesenchymal transition involved in endocardial cushion formation,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,GO:0072330,monocarboxylic acid biosynthetic process,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,GO:0032787,monocarboxylic acid metabolic process,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,GO:0061760,antifungal innate immune response,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,R-HSA-425397,"Transport of vitamins, nucleosides, and related molecules",M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9703465,Signaling by FLT3 fusion proteins,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048858,cell projection morphogenesis,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.4,0,0,GO:0043367,"CD4-positive, alpha-beta T cell differentiation",M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,R-HSA-448424,Interleukin-17 signaling,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002679,respiratory burst involved in defense response,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-8983432,Interleukin-15 signaling,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,hsa04670,Leukocyte transendothelial migration,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0097305,response to alcohol,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2380,Brain derived neurotrophic factor BDNF signaling pathway,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05226,Gastric cancer,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,GO:0140029,exocytic process,M0000000000100000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,CORUM:1519,IL6ST-PRKCD-STAT3 complex,M0000100000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0046457,prostanoid biosynthetic process,M0100000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045662,negative regulation of myoblast differentiation,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,GO:0098754,detoxification,M0000000000010000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP5224,2q37 copy number variation syndrome,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-5083635,Defective B3GALTL causes PpS,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3599,Transcription factor regulation in adipogenesis,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,GO:0046580,negative regulation of Ras protein signal transduction,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009612,response to mechanical stimulus,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,R-HSA-111885,Opioid Signalling,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,GO:0002724,regulation of T cell cytokine production,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,GO:1905523,positive regulation of macrophage migration,M0000000000000000001,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051402,neuron apoptotic process,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP5087,Pleural mesothelioma,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:0019933,cAMP-mediated signaling,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010460,positive regulation of heart rate,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M50,PID PTP1B PATHWAY,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1902256,regulation of apoptotic process involved in outflow tract morphogenesis,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002774,Fc receptor mediated inhibitory signaling pathway,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,GO:0031669,cellular response to nutrient levels,M0000000000000001000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,GO:0006892,post-Golgi vesicle-mediated transport,M0000000000000000001,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3935,Leptin insulin signaling overlap,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903320,regulation of protein modification by small protein conjugation or removal,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0072538,T-helper 17 type immune response,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0043373,"CD4-positive, alpha-beta T cell lineage commitment",M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,hsa05330,Allograft rejection,M0000000001000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4542,Leukocyte intrinsic Hippo pathway functions,M1000000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007632,visual behavior,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,WP2637,Interleukin 1 IL 1 structural pathway,M0000000000000000010,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04145,Phagosome,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0062009,secondary palate development,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-912526,Interleukin receptor SHC signaling,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,R-HSA-933542,TRAF6 mediated NF-kB activation,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-432142,Platelet sensitization by LDL,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-982772,Growth hormone receptor signaling,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,GO:0032291,axon ensheathment in central nervous system,M0000000000000000010,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032651,regulation of interleukin-1 beta production,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1483249,Inositol phosphate metabolism,M0001000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043065,positive regulation of apoptotic process,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,GO:0072384,organelle transport along microtubule,M0000000000000000010,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0008589,regulation of smoothened signaling pathway,M0000010000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1904705,regulation of vascular associated smooth muscle cell proliferation,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903587,regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021780,glial cell fate specification,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,GO:0050848,regulation of calcium-mediated signaling,M0000000000100000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-2197563,NOTCH2 intracellular domain regulates transcription,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060213,positive regulation of nuclear-transcribed mRNA poly(A) tail shortening,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,GO:0042130,negative regulation of T cell proliferation,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0045589,regulation of regulatory T cell differentiation,M0000000000000000100,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0034033,purine nucleoside bisphosphate biosynthetic process,M0100000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009914,hormone transport,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070424,regulation of nucleotide-binding oligomerization domain containing signaling pathway,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,GO:0006364,rRNA processing,M0000000000100000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M55,PID S1P S1P3 PATHWAY,M0001000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-193704,p75 NTR receptor-mediated signalling,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,GO:0045747,positive regulation of Notch signaling pathway,M0000000000100000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0042692,muscle cell differentiation,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,R-HSA-1257604,PIP3 activates AKT signaling,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-397795,G-protein beta:gamma signalling,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,WP4838,Regucalcin in proximal tubule epithelial kidney cells,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031960,response to corticosteroid,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,GO:0002455,humoral immune response mediated by circulating immunoglobulin,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,GO:0046942,carboxylic acid transport,M0000000000010000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070588,calcium ion transmembrane transport,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,CORUM:725,P2X7 receptor signalling complex,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006029,proteoglycan metabolic process,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9664420,Killing mechanisms,M0000100000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0099177,regulation of trans-synaptic signaling,M0000010000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048667,cell morphogenesis involved in neuron differentiation,M0000100000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-888590,"GABA synthesis, release, reuptake and degradation",M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9669938,Signaling by KIT in disease,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032892,positive regulation of organic acid transport,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072678,T cell migration,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035235,ionotropic glutamate receptor signaling pathway,M0000010000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009449,gamma-aminobutyric acid biosynthetic process,M0000010000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-354192,Integrin signaling,M0000100000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009448,gamma-aminobutyric acid metabolic process,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,R-HSA-382551,Transport of small molecules,M0000000000010000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010742,macrophage derived foam cell differentiation,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-3781865,Diseases of glycosylation,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,hsa04976,Bile secretion,M0000000000010000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4823,Genes controlling nephrogenesis,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045666,positive regulation of neuron differentiation,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,R-HSA-8854691,Interleukin-20 family signaling,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0097398,cellular response to interleukin-17,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060986,endocrine hormone secretion,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,M193,PID NEPHRIN NEPH1 PATHWAY,M0000000000000000010,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072239,metanephric glomerulus vasculature development,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0042593,glucose homeostasis,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051412,response to corticosterone,M0001000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051150,regulation of smooth muscle cell differentiation,M0100000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000178,negative regulation of neural precursor cell proliferation,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP5356,Disturbed pathways in Duchenne Muscular Dystrophy,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04672,Intestinal immune network for IgA production,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072148,epithelial cell fate commitment,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003094,glomerular filtration,M0000100000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070432,regulation of nucleotide-binding oligomerization domain containing 2 signaling pathway,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,GO:0045773,positive regulation of axon extension,M0000000000100000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000136,regulation of cell proliferation involved in heart morphogenesis,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031331,positive regulation of cellular catabolic process,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0019886,antigen processing and presentation of exogenous peptide antigen via MHC class II,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-4085001,Sialic acid metabolism,M1000000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9013420,RHOU GTPase cycle,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,WP5321,Prostaglandin and leukotriene metabolism in senescence,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903903,regulation of establishment of T cell polarity,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0046629,gamma-delta T cell activation,M0100000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060402,calcium ion transport into cytosol,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,GO:0007585,respiratory gaseous exchange by respiratory system,M0000000010000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051152,positive regulation of smooth muscle cell differentiation,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090102,cochlea development,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060711,labyrinthine layer development,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003176,aortic valve development,M1000000000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1905039,carboxylic acid transmembrane transport,M0010000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006692,prostanoid metabolic process,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,R-HSA-9006925,Intracellular signaling by second messengers,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-8985947,Interleukin-9 signaling,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,R-HSA-879518,Transport of organic anions,M0000000000000000010,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04929,GnRH secretion,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032732,positive regulation of interleukin-1 production,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048565,digestive tract development,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,R-HSA-9683701,Translation of Structural Proteins,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,GO:0002690,positive regulation of leukocyte chemotaxis,M0000000000000000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-112310,Neurotransmitter release cycle,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,GO:0070482,response to oxygen levels,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,GO:1903707,negative regulation of hemopoiesis,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,R-HSA-8957322,Metabolism of steroids,M0000000000000001000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061036,positive regulation of cartilage development,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-2644606,Constitutive Signaling by NOTCH1 PEST Domain Mutants,M1000000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048168,regulation of neuronal synaptic plasticity,M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-500792,GPCR ligand binding,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010171,body morphogenesis,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,GO:0005996,monosaccharide metabolic process,M0000000000010000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0044321,response to leptin,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.6,0,0,0,0,0,0,0,M44,PID HIF2PATHWAY,M0000000000010000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001709,cell fate determination,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,GO:0031294,lymphocyte costimulation,M0000000000000000001,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001933,negative regulation of protein phosphorylation,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,GO:0043252,sodium-independent organic anion transport,M0000000000000000010,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0044770,cell cycle phase transition,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072189,ureter development,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,M177,PID EPHA FWDPATHWAY,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,GO:0045806,negative regulation of endocytosis,M0000000000000000010,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007268,chemical synaptic transmission,M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2864,Apoptosis related network due to altered Notch3 in ovarian cancer,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031664,regulation of lipopolysaccharide-mediated signaling pathway,M0001000000000000000,1,0
0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.2,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051148,negative regulation of muscle cell differentiation,M0000001000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,GO:2000058,regulation of ubiquitin-dependent protein catabolic process,M0000000000000000010,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,GO:0015849,organic acid transport,M0000000000010000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071383,cellular response to steroid hormone stimulus,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,GO:1902253,regulation of intrinsic apoptotic signaling pathway by p53 class mediator,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,WP195,IL 1 signaling pathway,M0000000000000000010,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0044772,mitotic cell cycle phase transition,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003170,heart valve development,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M278,PID RAC1 PATHWAY,M0000100000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007612,learning,M0000010000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-8986944,Transcriptional Regulation by MECP2,M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9020958,Interleukin-21 signaling,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,R-HSA-9706369,Negative regulation of FLT3,M0000000000000000010,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-8934593,Regulation of RUNX1 Expression and Activity,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0033866,nucleoside bisphosphate biosynthetic process,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,GO:0090497,mesenchymal cell migration,M0000000000000100000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0002519,natural killer cell tolerance induction,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030522,intracellular receptor signaling pathway,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0060586,multicellular organismal-level iron ion homeostasis,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,WP384,Apoptosis modulation by HSP70,M0000000000000000010,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0051101,regulation of DNA binding,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001708,cell fate specification,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,WP5284,Cell interactions of the pancreatic cancer microenvironment,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0031666,positive regulation of lipopolysaccharide-mediated signaling pathway,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021766,hippocampus development,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0046949,fatty-acyl-CoA biosynthetic process,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070302,regulation of stress-activated protein kinase signaling cascade,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032233,positive regulation of actin filament bundle assembly,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0042326,negative regulation of phosphorylation,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051146,striated muscle cell differentiation,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000737,negative regulation of stem cell differentiation,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001676,long-chain fatty acid metabolic process,M0100000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001774,microglial cell activation,M0000010000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060078,regulation of postsynaptic membrane potential,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,GO:0043297,apical junction assembly,M0000000000010000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1901889,negative regulation of cell junction assembly,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,R-HSA-450294,MAP kinase activation,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048806,genitalia development,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0008217,regulation of blood pressure,M0001000000000000000,1,0
0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,GO:0006310,DNA recombination,M0000000100000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,R-HSA-168928,DDX58/IFIH1-mediated induction of interferon-alpha/beta,M0000000000000000100,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072007,mesangial cell differentiation,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071350,cellular response to interleukin-15,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,WP3617,Photodynamic therapy induced NF kB survival signaling,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.5,0,0,0,0,GO:0009913,epidermal cell differentiation,M0000000000000010000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,GO:0051603,proteolysis involved in protein catabolic process,M0000000000000000010,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0016045,detection of bacterium,M0100000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1900227,positive regulation of NLRP3 inflammasome complex assembly,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,GO:0030326,embryonic limb morphogenesis,M0000000010000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-5173105,O-linked glycosylation,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003180,aortic valve morphogenesis,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,R-HSA-9637628,Modulation by Mtb of host immune system,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035590,purinergic nucleotide receptor signaling pathway,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0042391,regulation of membrane potential,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-5576891,Cardiac conduction,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0097396,response to interleukin-17,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP22,IL 9 signaling pathway,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,0,0,GO:0021814,cell motility involved in cerebral cortex radial glia guided migration,M0000000000100000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0110020,regulation of actomyosin structure organization,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0009799,specification of symmetry,M0000100000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006813,potassium ion transport,M0000010000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010613,positive regulation of cardiac muscle hypertrophy,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-8941284,RUNX2 regulates chondrocyte maturation,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010566,regulation of ketone biosynthetic process,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090184,positive regulation of kidney development,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035994,response to muscle stretch,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0046633,alpha-beta T cell proliferation,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007097,nuclear migration,M1000000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0015698,inorganic anion transport,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,hsa05320,Autoimmune thyroid disease,M0000000001000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:0043409,negative regulation of MAPK cascade,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,GO:0022010,central nervous system myelination,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051607,defense response to virus,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035088,establishment or maintenance of apical/basal cell polarity,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061005,cell differentiation involved in kidney development,M0000100000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04713,Circadian entrainment,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0033365,protein localization to organelle,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,R-HSA-6811442,Intra-Golgi and retrograde Golgi-to-ER traffic,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0060397,growth hormone receptor signaling pathway via JAK-STAT,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,R-HSA-3304351,Signaling by TGF-beta Receptor Complex in Cancer,M0000000000100000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001667,ameboidal-type cell migration,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0055017,cardiac muscle tissue growth,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045927,positive regulation of growth,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045879,negative regulation of smoothened signaling pathway,M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1900182,positive regulation of protein localization to nucleus,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051588,regulation of neurotransmitter transport,M0000010000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002066,columnar/cuboidal epithelial cell development,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007156,homophilic cell adhesion via plasma membrane adhesion molecules,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,WP2023,Cell differentiation expanded index,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032933,SREBP signaling pathway,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0097152,mesenchymal cell apoptotic process,M0000000000000000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0002269,leukocyte activation involved in inflammatory response,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,R-HSA-1221632,Meiotic synapsis,M0000000000100000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2876,Pregnane X receptor pathway,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,R-HSA-9006927,Signaling by Non-Receptor Tyrosine Kinases,M0000000000010000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,CORUM:2692,SMAD3-SMAD4-cJun-cFos complex,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,GO:0150104,transport across blood-brain barrier,M0000000000010000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032303,regulation of icosanoid secretion,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0007200,phospholipase C-activating G protein-coupled receptor signaling pathway,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP268,Notch signaling,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0048535,lymph node development,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070371,ERK1 and ERK2 cascade,M0001000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010765,positive regulation of sodium ion transport,M0100000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9673324,WNT5:FZD7-mediated leishmania damping,M0000100000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061900,glial cell activation,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:0002483,antigen processing and presentation of endogenous peptide antigen,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0045657,positive regulation of monocyte differentiation,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0045197,establishment or maintenance of epithelial cell apical/basal polarity,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1905954,positive regulation of lipid localization,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,CORUM:6084,AFF4 super elongation complex (SEC),M1000000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043266,regulation of potassium ion transport,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,GO:0051646,mitochondrion localization,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP138,Androgen receptor signaling pathway,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M113,PID NFAT 3PATHWAY,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0043549,regulation of kinase activity,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,GO:0015749,monosaccharide transmembrane transport,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,GO:0035113,embryonic appendage morphogenesis,M0000000010000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP170,Nuclear receptors,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.3,0,0,0,0,0,0,0,GO:0034219,carbohydrate transmembrane transport,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,GO:0006622,protein targeting to lysosome,M0000000000100000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-6.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-451927,Interleukin-2 family signaling,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021542,dentate gyrus development,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.8,0,0,0,0,0,0,0,0,GO:0021815,modulation of microtubule cytoskeleton involved in cerebral cortex radial glia guided migration,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,GO:0002889,regulation of immunoglobulin mediated immune response,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0008038,neuron recognition,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1839117,Signaling by cytosolic FGFR1 fusion mutants,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,WP524,G13 signaling pathway,M0000010000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0070572,positive regulation of neuron projection regeneration,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0060561,apoptotic process involved in morphogenesis,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,GO:0071354,cellular response to interleukin-6,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-5578775,Ion homeostasis,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1905952,regulation of lipid localization,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,GO:0010744,positive regulation of macrophage derived foam cell differentiation,M0000000000000000001,1,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,GO:0010950,positive regulation of endopeptidase activity,M0000000001000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,R-HSA-164938,Nef-mediates down modulation of cell surface receptors by recruiting them to clathrin adapters,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,WP2848,Pluripotent stem cell differentiation pathway,M0000000000000000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0016339,calcium-dependent cell-cell adhesion via plasma membrane cell adhesion molecules,M0000010000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0150076,neuroinflammatory response,M0000010000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010959,regulation of metal ion transport,M0000100000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032490,detection of molecule of bacterial origin,M0100000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0019827,stem cell population maintenance,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP98,Prostaglandin synthesis and regulation,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0014013,regulation of gliogenesis,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,GO:0048002,antigen processing and presentation of peptide antigen,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030510,regulation of BMP signaling pathway,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,GO:0030323,respiratory tube development,M0000000000000010000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,WP3624,Lung fibrosis,M0000000000000000100,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,GO:0097237,cellular response to toxic substance,M0000000000010000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,GO:0006633,fatty acid biosynthetic process,M0000000000100000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05017,Spinocerebellar ataxia,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0003417,growth plate cartilage development,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9673770,Signaling by PDGFRA extracellular domain mutants,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,R-HSA-446203,Asparagine N-linked glycosylation,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050995,negative regulation of lipid catabolic process,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071230,cellular response to amino acid stimulus,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,R-HSA-9035034,RHOF GTPase cycle,M0000000000100000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030168,platelet activation,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0034109,homotypic cell-cell adhesion,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2911,miRNA targets in ECM and membrane receptors,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,hsa05332,Graft-versus-host disease,M0000000001000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010717,regulation of epithelial to mesenchymal transition,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000116,regulation of cysteine-type endopeptidase activity,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071639,positive regulation of monocyte chemotactic protein-1 production,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,GO:0030163,protein catabolic process,M0000000000000000010,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05217,Basal cell carcinoma,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,WP3596,miR 517 relationship with ARCN1 and USP1,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-8878166,Transcriptional regulation by RUNX2,M1000000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0050931,pigment cell differentiation,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,GO:0051100,negative regulation of binding,M0000000000000000010,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,CORUM:2529,"LAT-PLC-gamma-1-p85-GRB2-CBL-VAV-SLP-76 signaling complex, C305 activated",M0010000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0097435,supramolecular fiber organization,M0100000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0008154,actin polymerization or depolymerization,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,hsa05322,Systemic lupus erythematosus,M0000000000100000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,GO:0051769,regulation of nitric-oxide synthase biosynthetic process,M0000000000000000010,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4874,CAMKK2 pathway,M0100000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP167,Eicosanoid synthesis,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032060,bleb assembly,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:2000573,positive regulation of DNA biosynthetic process,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,M162,PID RXR VDR PATHWAY,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,0,0,GO:0030324,lung development,M0000000000000010000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0071313,cellular response to caffeine,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051895,negative regulation of focal adhesion assembly,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0010518,positive regulation of phospholipase activity,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,GO:0008366,axon ensheathment,M0000000000000000010,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0016331,morphogenesis of embryonic epithelium,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,hsa05020,Prion disease,M0000000000000000010,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0021889,olfactory bulb interneuron differentiation,M0000100000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098743,cell aggregation,M0100000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061564,axon development,M0000100000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-177929,Signaling by EGFR,M0010000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP4746,Thyroid hormones production and peripheral downstream signaling effects,M0000100000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.6,0,WP4880,Host pathogen interaction of human coronaviruses interferon induction,M0000000000000000010,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0072104,glomerular capillary formation,M0000100000000000000,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0098739,import across plasma membrane,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,GO:2000351,regulation of endothelial cell apoptotic process,M0000000000000000100,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032930,positive regulation of superoxide anion generation,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,R-HSA-2173788,Downregulation of TGF-beta receptor signaling,M0000000000100000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0051099,positive regulation of binding,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.6,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043124,negative regulation of canonical NF-kappaB signal transduction,M0001000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9725370,Signaling by ALK fusions and activated point mutants,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-913709,O-linked glycosylation of mucins,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,GO:0051058,negative regulation of small GTPase mediated signal transduction,M0000000000000000100,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0008593,regulation of Notch signaling pathway,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,GO:1902106,negative regulation of leukocyte differentiation,M0000000000000000100,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9027284,Erythropoietin activates RAS,M0010000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,M0000000000000000010,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP3679,Cell type dependent selectivity of CCK2R signaling,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.8,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0001101,response to acid chemical,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa04932,Non-alcoholic fatty liver disease,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0014902,myotube differentiation,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048592,eye morphogenesis,M1000000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0090322,regulation of superoxide metabolic process,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.2,0,0,GO:0045953,negative regulation of natural killer cell mediated cytotoxicity,M0000000000000000100,1,0
0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.7,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1902430,negative regulation of amyloid-beta formation,M0010000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0030195,negative regulation of blood coagulation,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0061245,establishment or maintenance of bipolar cell polarity,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,R-HSA-450531,Regulation of mRNA stability by proteins that bind AU-rich elements,M0000000000000000010,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0051783,regulation of nuclear division,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2203,Thymic stromal lymphopoietin TSLP signaling pathway,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,GO:0006997,nucleus organization,M0000000000100000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0097084,vascular associated smooth muscle cell development,M0001000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0055057,neuroblast division,M0100000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0006930,"substrate-dependent cell migration, cell extension",M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032456,endocytic recycling,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9709957,Sensory Perception,M1000000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0032494,response to peptidoglycan,M0001000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa05146,Amoebiasis,M0001000000000000000,1,0
0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-1296072,Voltage gated Potassium channels,M0000010000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,GO:0043369,"CD4-positive or CD8-positive, alpha-beta T cell lineage commitment",M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-5655302,Signaling by FGFR1 in disease,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0034775,glutathione transmembrane transport,M0000000000000000100,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-6783589,Interleukin-6 family signaling,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3,0,0,0,0,0,0,0,GO:0008643,carbohydrate transport,M0000000000010000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,hsa00532,Glycosaminoglycan biosynthesis - chondroitin sulfate / dermatan sulfate,M0100000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-5.9,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9700206,Signaling by ALK in cancer,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-9614085,FOXO-mediated transcription,M1000000000000000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0043405,regulation of MAP kinase activity,M0000100000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,WP2513,Nanoparticle triggered regulated necrosis,M0100000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-166658,Complement cascade,M0001000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-3371571,HSF1-dependent transactivation,M1000000000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.3,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,R-HSA-210744,Regulation of gene expression in late stage (branching morphogenesis) pancreatic bud precursor cells,M1000000000000000000,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0035336,long-chain fatty-acyl-CoA metabolic process,M0100000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-3.4,0,0,0,0,0,0,0,GO:0120192,tight junction assembly,M0000000000010000000,1,0
0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.2,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048812,neuron projection morphogenesis,M0000100000000000000,1,0
1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0042542,response to hydrogen peroxide,M1000000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,GO:0002504,antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,M0000000000000000100,1,0
0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.4,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:1903671,negative regulation of sprouting angiogenesis,M0100000000000000000,1,0
0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-2.5,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,GO:0048679,regulation of axon regeneration,M0001000000000000000,1,0
0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,1,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,0,-4.3,GO:0050832,defense response to fungus,M0000000000000000001,1,0
